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 Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum 
Disorder (ASD) are highly comorbid and share deficits in working memory, motor 
inhibition and cognitive flexibility. Serotonin modulates these functions and 
Fluoxetine has positive clinical effects in these disorders.  
 Functional magnetic resonance imaging was used to scan 22 ADHD and 22 
ASD boys, under placebo or an acute dose of Fluoxetine, in a double-blind, placebo-
controlled, randomised design, while they performed N-Back, Stop and reversal 
learning tasks. Repeated measures analyses within patients assessed drug effects. 
Patients under each drug condition were compared to 20 controls to test for 
normalisation effects.  
 During the N-Back, under placebo, relative to controls, ADHD and ASD 
groups shared underactivation in right dorsolateral prefrontal cortex (DLPFC). ASD 
boys showed disorder-specific deactivation of posterior cingulate (PCC). Under 
Fluoxetine, DLPFC underactivation in ASD was significantly normalised and PCC 
deactivation was increased in ADHD, relative to controls.  
During the Stop task, under placebo, relative to controls, ASD boys showed 
disorder-specific overactivation in bilateral inferior frontal cortex while ADHD boys 
showed disorder-specific underactivation in ventrolateral prefrontal cortex. Under 
Fluoxetine, prefrontal dysfunctions were significantly normalised in both disorders, 
due to inverse up and downregulation effects of Fluoxetine in these regions, in each 
disorder.  
During reversal learning, under placebo, ASD boys exhibited disorder-specific 
underactivation in medial prefrontal cortex (mPFC), compared to controls and 
ADHD, while patients shared decreased activation in precuneus. Under Fluoxetine, 
mPFC activation was upregulated and normalised in ASD boys, but down-regulated 
in ADHD boys. 
 Fluoxetine had disorder-dissociated, inverse effects on frontal brain function 
in ADHD and ASD during inhibition and reversal learning. During working memory 
Fluoxetine improved task-positive frontal activation in ASD and task-negative 
activation in ADHD. These inverse effects of Fluoxetine on frontal brain activation in 
the two disorders potentially reflect inverse baseline serotonin levels and may 
underlie its clinical effect. 
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Chapter 1 – Executive Dysfunction in ADHD and 
ASD 
 
1.1 – Introduction 
 
According to the Diagnostic and Statistical Manual of Mental Disorders – IV 
(DSM-IV) (American et al., 1994), Attention Deficit Hyperactive Disorder (ADHD) 
is a neurodevelopmental disorder defined by levels of inattention, impulsivity and 
hyperactivity which are inappropriate for the age of the individual (American et al., 
1994). In order for a clinical diagnosis to be made, a team of clinicians will conduct a 
semi-structured interview with the primary care-giver of the child and, depending on 
his or her age, the child, to ascertain whether the symptoms of inattention, impulsivity 
and hyperactivity have been present before the age of seven, have persisted for a 
number of years, and significantly impair home life, social life and school/work life 
(American et al., 1994). School observations, as well as interviews and reports from 
teachers, are used in conjunction with the information from the parent in order to 
obtain a holistic view of the child’s behaviour. Clinicians use scores on two different 
domains focusing on inattention and hyperactivity/impulsivity to decide whether the 
individual has predominantly hyperactive/impulsive, inattentive or combined 
symptoms of ADHD and these three groupings are known as the three subtypes of 
ADHD (American et al., 1994).  ADHD has a gender ratio of 3:1 and a current 
prevalence of 3-8% (American et al., 1994, Polanczyk et al., 2007, Ramtekkar et al., 
2010). It is one of the most frequently diagnosed childhood disorders and often 
persists into adulthood, with recent research reporting persistence levels of 66-78% 
(Barkley et al., 1992, Biederman et al., 2010). It is a debilitating disorder, associated 
with poor academic performance, increased risk taking, addictive behaviours and 
increased levels of crime (Biederman et al., 2004, Ohlmeier et al., 2008, Fletcher and 
Wolfe, 2009). It is also highly comorbid with externalising behavioural disorders such 
as Conduct Disorder (CD) and Oppositional Defiant Disorder (ODD) ((Jensen et al., 
1997, Willcutt et al., 1999, Connor and Doerfler, 2008).  
Another neurodevelopmental disorder, which may initially appear very different 
from ADHD, is Autism Spectrum Disorder (ASD). ASD is an umbrella term for a 
group of neurodevelopmental disorders which all have impairments in communication 
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and social interaction, and the presence of restricted and repetitive, otherwise known 
as stereotyped, behaviours (American et al., 1994). These three components which are 
vital for ASD diagnosis are often called ‘the ASD triad’ and all three must be present 
for an ASD diagnosis to be made. The triad start to become evident between the ages 
of 3-5 when children begin to talk and interact with their peers, but they are often 
present from the first year of life. Two of the most widely used diagnostic instruments 
for ASD are the Autism Diagnostic Interview – Revised (ADI) and the Autism 
Diagnostic Observation Schedule (ADOS). The ADI is a detailed interview with the 
primary care giver of the individual which assesses symptoms of the triad and their 
current and past prevalence (Lord et al., 1994). The ADOS is a selection of tasks that 
are performed with the individual to assess their current autistic characteristics based 
on the triad and the tasks vary dependent on the verbal ability of the person 
undergoing the ADOS (Lord et al., 2000). Much like ADHD, ASD has a higher 
prevalence in boys than girls with a gender ratio of 4.3:1 (Rivet and Matson, 2011).  
The global prevalence of ASD is 20 in 10,000 (Williams et al., 2006c) and the 
disorder has a high rate of persistence into adulthood, with recent research reporting 
levels of up to 58% (Howlin et al., 2004). 
ADHD and ASD share many behavioural characteristics; it has been 
consistently reported that children with ASD have clinically significant levels of 
hyperactivity and inattention, with up to 30% meeting the clinical criteria for ADHD 
(Goldstein and Schwebach, 2004, Gadow et al., 2006, Gadow et al., 2005, Leyfer et 
al., 2006, de Bruin et al., 2007, Simonoff et al., 2008, Sinzig et al., 2009, Gargaro et 
al., 2011, St. Pourcain et al., 2011, Rommelse et al., 2011). Furthermore, it has been 
observed that children with ADHD also have traits of the ASD triad, namely poor 
social interaction (Clark et al., 1999, Reiersen et al., 2007, Mulligan et al., 2009, 
Kochhar et al., 2011). Several authors have also commented on the arbitrary 
distinctions that have been drawn between these two disorders and whether the 
diagnostic criteria for these conditions should be viewed together as a 
neurodevelopmental spectrum (Hattori et al., 2006, Funabiki et al., 2011, van der 
Meer et al., 2012). Currently , DSM-IV does not allow co-diagnosis of ADHD and 
ASD (American et al., 1994). In response to the overwhelming evidence for 
overlapping behaviours in these two disorders, the upcoming DSM-V will allow a co-
diagnosis of both ASD and ADHD to be given (http://www.dsm5.org). However, 
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relatively little is known about the shared and disorder-specific biological 
abnormalities present in these two overlapping disorders. Greater knowledge on the 
similarities and disorder-specific differences between ADHD and ASD, particularly in 
a biological measure such as neurofunctional activity, has the potential to aid 
diagnosis and shed light on treatment targets. 
 
However, before biological measures can be discussed, one must focus on 
neuropsychology, as this is the area which defined the cognitive impairments present 
in ADHD and ASD and suggested that brain based abnormalities may play a role in 
the deficits observed. Executive functions are defined as the higher processing aspects 
of our cognition that work together to allow goal directed behaviour to occur (Stuss 
and Alexander, 2000). Executive functions involve cognitive processes such as 
working memory (WM), inhibition, cognitive flexibility, attention, planning, temporal 
foresight and performance monitoring (Stuss and Alexander, 2000). Executive 
functions can be divided into “cool” and “hot” depending on whether they involve 
purely abstract or reward related tasks, respectively (Zelazo and Müller, 2002). Due to 
the cognitive performance deficits observed in ADHD and ASD it was hypothesised 
that both ADHD (Barkley, 1997, Willcutt et al., 2005) and ASD (Ozonoff et al., 1991, 
Pennington and Ozonoff, 1996, Corbett et al., 2009) may be disorders of executive 
dysfunction. Therefore, elucidating the executive function profiles of ADHD and 
ASD will enable one to ascertain which cognitive functions would be best to 
investigate at a neurofunctional level. Due to the focus of this PhD, research 
investigating the executive function domains of WM, inhibition and cognitive 
flexibility in children with ADHD and children with ASD will be reviewed in detail 
below. Other cognitive deficits pertaining to each of the disorders, but which are not 









1.2 – Working Memory 
 
1.2.1 – Working Memory in ADHD 
 
WM is defined as the ability to temporarily store and manipulate information in 
order to guide and direct behaviour (Baddeley, 1996). There are various WM models, 
however, Baddeley’s two component model is the most accepted and referenced due 
to the large amount of data which supports it (Baddeley, 2003). This model states that 
there are separate phonological and visuo-spatial storage components in WM which 
deal with verbal and visuo-spatial stimuli. These components are overseen by a 
central executive component which enables the manipulation of the data stored in the 
phonological and visuo-spatial components, as well as drawing on information from 
long term memory (Baddeley, 2003). 
 
Verbal storage and central executive function are often assessed by tasks such as 
the digit span forward and digit span backwards, respectively. These tasks involve 
repeating a string of numbers in the order they were presented, the forward condition, 
and then in the reverse, the backward condition. After each correct trial the number of 
digits in the sequence increases, with the largest sequence consisting of nine digits. A 
closely linked paradigm known as the spatial span forward and backwards is 
frequently used to assess visuo-spatial storage and central executive function, 
however, spatial information in the form of a sequence of squares on a screen is used 
instead of digits. The similarities between these tasks enable easy comparison 
between phonological and visuo-spatial working memory abilities (Baddeley, 2003).  
 
Another classic paradigm for measuring phonological WM is the N-Back task. 
In this task, a series of letters is presented to the participant one by one on the screen 
and the task is divided into different conditions. 0-Back requires the participant to 
make a response when a target letter appears, 1-Back requires a response when the 
letter is the same as one before it, 2-Back requires a response when the letter is the 
same as two before it and 3-Back requires a response when the letter is the same as 
three before it (Baddeley, 2003). This task is therefore parametric as it has three WM 
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loads of increasing difficulty. This makes the N-Back more sensitive than other WM 
tasks as it enables one to measure the effects of WM load on task performance.  
     
Deficits in WM may play a role in the absentmindedness that is often reported in 
children with ADHD (American et al., 1994). Furthermore, there is a 
neuropsychological hypothesis of ADHD which posits that deficits in WM are the key 
impairment in the disorder and that this deficit then leads to other symptoms such as 
poor inhibition and hyperactivity (Stevens et al., 2002, Klingberg et al., 2005, Rapport 
et al., 2009, Alderson et al., 2010). Although further evidence is needed to support a 
link between WM deficits and ADHD symptoms, there is a large body of data which 
supports the presence of WM deficits in children with ADHD compared to their 
typically developing peers. 
 
It has been repeatedly observed that children with ADHD, who have had a 24hr 
medication washout, perform worse than controls on tasks of phonological and 
visuospatial storage and central executive function, as is evidenced by the 
significantly lower scores and increased number of errors they make on both the 
forward and backwards component of the digit and spatial span tasks (Stevens et al., 
2002, Martinussen and Tannock, 2006, Rommelse et al., 2008, Rapport et al., 2008, 
Kofler et al., 2010, Toplak et al., 2009, Gau and Shang, 2010, Alderson et al., 2010, 
Wee et al., 2010). Lower WM scores have also been reported for children with 
ADHD relative to controls when performing verbal and spatial free-recall tasks 
(Gibson et al., 2009, Crocker et al., 2011) and maze memory tasks which assess 
visuo-spatial memory (Wee et al., 2010). These deficits are also present in medication 
naïve samples, as studies using this population have also reported lower scores and 
increased errors using spatial span and spatial WM tasks from the Cambridge 
Neuropsyhcological Test Automated Battery (CANTAB) (Kempton et al., 1999, 
Rhodes et al., 2005, Rhodes et al., 2012, Barnett et al., 2009). 
 
When focusing on studies that have employed the N-Back task,  an overall 
greater number of omission errors, greater intra-subject variability with increasing 
WM load and impaired task performance have been observed in children with ADHD 
compared to typically developing children (Klein et al., 2006, Pasini et al., 2007). 
This highlights the effectiveness of the N-Back at tapping into the phonological WM 
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deficits which have been consistently reported in children with ADHD (Willcutt et al., 
2005, Martinussen et al., 2005, Kasper et al., 2012). 
 
Meta-analyses investigating the full extent of the phonological and visuo-spatial 
WM deficit in ADHD have all supported the presence of deficits in both the storage 
and central executive components of both of these functions during WM tasks 
(Willcutt et al., 2005, Martinussen et al., 2005, Kasper et al., 2012). 
 
Moreover, a number of studies have shown that these WM deficits have been 
associated with symptoms of inattention (Martinussen and Tannock, 2006) and WM 
training can lead to improved response inhibition, and a decrease in inattentive 
symptoms, in children with ADHD (Klingberg et al., 2005). This suggests that if one 
gains an understanding of the biological basis of the WM impairment in ADHD, and 
aims to normalise it, this may have an ameliorative effect on ADHD behaviour. 
 
1.2.2 – Working Memory in ASD 
 
Research into WM has also been conducted in children with ASD to ascertain 
whether they exhibit deficits in this domain, as it would provide further evidence for 
the executive function hypothesis of ASD and may be linked to the deficits in 
planning that are often reported in this patient group (Ozonoff et al., 1991, Hughes et 
al., 1994, Hill, 2004, Zinke et al., 2010). 
 
Research into verbal WM has produced varied results with some studies finding 
deficits in the phonological loop and central executive component of WM in children 
and adolescents with ASD compared to their typically developing peers during 
forward and backward digit span, sentence span, free-recall, self-ordered pointing and 
N-Back tasks (Bennetto et al., 1996, Russell et al., 1996, Minshew and Goldstein, 
2001, Joseph et al., 2005b, Nakahachi et al., 2006, Cui et al., 2010, Yerys et al., 
2012). However, other studies have found no impairment in WM in children with 
ASD compared to controls during these same tasks (Ozonoff and Strayer, 2001). 
These conflicting findings may be due to the innate phenotypic heterogeneity of ASD, 
the inclusion of females and the high level of psychiatric comorbidities present in the 
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ASD groups. Furthermore, there is evidence in children with ASD that the parametric 
design of the N-Back task highlights the difficulties in phonological memory in this 
patient group, which may be missed in the commonly used digit and word recall tasks 
(Cui et al., 2010). This suggests that the N-Back may be more appropriate than other 
tasks for eliciting the phonological WM deficits that have been reported in ASD.    
 
Research into visuo-spatial WM has produced more consistent results, with most 
studies finding a deficit in the visuo-spatial sketch pad and central executive 
component of WM in children with ASD compared to controls during the spatial WM 
and spatial span tasks of the CANTAB, oculomotor delayed response tasks and the 
maze memory task (Minshew and Goldstein, 2001, Minshew et al., 1999, Joseph et 
al., 2005a, Landa and Goldberg, 2005, Williams et al., 2005, Williams et al., 2006b, 
Verte et al., 2005, Luna et al., 2007, Steele et al., 2007, Loveland et al., 2008, Cui et 
al., 2010, Zinke et al., 2010). There is, however, a small number of studies which fail 
to find visuo-spatial WM deficits (Griffith et al., 1999, Ozonoff and Strayer, 2001) 
but this may be due to the small sample sizes used in these studies, the heterogeneity 
of the groups and the particularly young age of the children used in Griffiths et al 
1999 who were aged between 3-5 years old. 
  
Current literature suggests that children and adolescents with ASD are impaired 
in WM and that this impairment is more severe in the visuo-spatial domain (Bennetto 
et al., 1996, Russell et al., 1996, Minshew et al., 1999, Minshew and Goldstein, 2001, 
Landa and Goldberg, 2005, Williams et al., 2005, Williams et al., 2006b, Joseph et al., 
2005a, Joseph et al., 2005b, Verte et al., 2005, Nakahachi et al., 2006, Luna et al., 
2007, Steele et al., 2007, Loveland et al., 2008, Cui et al., 2010, Zinke et al., 2010, 
Yerys et al., 2012). There is a small body of conflicting evidence (Griffith et al., 1999, 
Ozonoff and Strayer, 2001) and the contrasting data in this area may be due to the 
differing cognitive demands of the task, as it has been observed that children with 
ASD exhibit their WM deficits under higher WM loads as they begin to reach their 
storage capacity (Landa and Goldberg, 2005, Steele et al., 2007, Cui et al., 2010). 
Further research using homogenous groups and well defined, challenging paradigms 
with as little loading on other executive functions as possible should be conducted in 
order to clarify the conflicting evidence regarding verbal WM deficits in children with 
ASD. The aforementioned N-Back task would be the ideal paradigm to address this 
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issue, particularly as WM load can be manipulated to make the task demanding 
enough for potential group differences to be observed.  
 
1.2.3 – Summary of Working Memory in ADHD and ASD 
 
The current literature provides strong evidence for the presence of a WM deficit 
in both children with ADHD (Stevens et al., 2002, Rhodes et al., 2005, Rhodes et al., 
2012, Martinussen and Tannock, 2006, Klein et al., 2006, Rommelse et al., 2008, 
Rapport et al., 2008, Kofler et al., 2010, Toplak et al., 2009, Gibson et al., 2009, 
Barnett et al., 2009, Gau and Shang, 2010, Alderson et al., 2010, Wee et al., 2010, 
Crocker et al., 2011, Martinussen et al., 2005, Willcutt et al., 2005, Kasper et al., 
2012) and children with ASD (Bennetto et al., 1996, Minshew and Goldstein, 2001, 
Minshew et al., 1999, Landa and Goldberg, 2005, Williams et al., 2005, Williams et 
al., 2006b, Joseph et al., 2005a, Joseph et al., 2005b, Verte et al., 2005, Nakahachi et 
al., 2006, Luna et al., 2007, Steele et al., 2007, Loveland et al., 2008, Cui et al., 2010, 
Zinke et al., 2010, Yerys et al., 2012) compared to controls during tasks that assess 
both verbal and visuo-spatial storage, as well as the central executive component, of 
WM. Children and adolescents with ASD appear to be more impaired in visuo-spatial 
WM as oppose to verbal WM ((Minshew et al., 1999, Minshew and Goldstein, 2001, 
Landa and Goldberg, 2005, Williams et al., 2005, Williams et al., 2006b, Verte et al., 
2005, Joseph et al., 2005a, Luna et al., 2007, Steele et al., 2007, Loveland et al., 2008, 
Cui et al., 2010, Zinke et al., 2010) but there is evidence that the parametric aspect of 
the N-Back task is able to draw out subtle verbal memory difficulties in both ADHD 
(Klein et al., 2006, Pasini et al., 2007) and ASD (Cui et al., 2010). This makes it an 
ideal task to use in a study comparing the two disorders. 
 
However, the only studies to directly compare ADHD and ASD have used 
visual-spatial WM tasks. These studies have yielded differing results, with some 
reporting that ASD children use poorer strategies and make more errors on the spatial 
WM and spatial span task of the CANTAB compared to both ADHD and typically 
developing children. In these studies, the children with ADHD were also impaired on 
the tasks compared to controls, suggesting that the WM deficit was shared between 
the two disorders, but more severe in ASD (Goldberg et al., 2005, Corbett et al., 
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2009).  There is also evidence to suggest that the WM deficit is specific to ADHD as 
it has been observed that children with ADHD make significantly more errors on the 
spatial WM task of the CANTAB compared to controls, while children with ASD do 
not differ from the ADHD or control group. (Happe et al., 2006). A few studies have 
reported no significant differences between ADHD, ASD or typically developing 
children during the spatial WM task of the CANTAB or the self-ordered pointing task 
(Sinzig et al., 2008, Geurts et al., 2004). Therefore, it would be of great interest to 
investigate verbal WM in a task such as the N-Back which has been shown to be 
effective in both ADHD (Klein et al., 2006, Pasini et al., 2007) and ASD (Cui et al., 
2010) and which enables one to investigate the effect not only of WM, but of WM 
load as well. 
 
1.3 – Motor and Interference Inhibition  
 
1.3.1 – Motor Response Inhibition in ADHD 
 
Motor response inhibition is defined as the ability to suppress a prepotent motor 
response (Barkley, 1997).  
 
A task which is used to assess motor response inhibition is the Go/No-Go task. 
The Go/No-Go task requires a motor response to a Go signal and the inhibition of this 
response to a No-Go signal. The dependent measure is the probability of inhibition, 
which can also be expressed as commission errors (responses to the No-Go signal). 
Throughout the task, the percentage of Go signals is predominant and the No-Go 
signals are rare, ideally leading to a ratio of 70:30. Along with motor response 
inhibition, the Go/No-Go tasks also taps into response selection and decision making. 
 
The Stop Signal task can also be used to assess motor response inhibition. 
During this task, the participant is told to respond to the presentation of a ‘go’ 
stimulus as quickly as they can by making a motor response, such as a button press. 
Throughout the course of this task, the subject will be randomly presented with 
infrequent ‘stop trials’, in either visual or auditory form, which will appear shortly 
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after the presentation of the go stimulus. In the traditional Stop Signal task the delay 
between go signal and stop signal is fixed by several delays of 250ms or 350ms. 
However, in order to prevent subjects from waiting for the predictable stop signal 
delay, a tracking Stop Signal task was created.  The important aspect of the tracking 
Stop Signal task is that the delay between the presentation of the go stimulus and the 
presentation of the stop stimulus, which is initially set at 250ms, is individually 
altered after each stop trial to ensure that every subject inhibits in 50% of the trials. 
This makes the task equally difficult for every subject. The main performance 
measure of this task relies on the adjustable delay between the go stimulus and the 
stop stimulus. The Stop Signal Reaction Time (SSRT) is calculated by subtracting the 
mean stop signal delay time from the mean reaction time to go trials and a longer 
SSRT indicates poor inhibition (Logan et al., 1997). 
 
  The key difference between the Go/No-Go task and the Stop Signal task is that 
the Stop Signal task requires inhibition of an already triggered motor response and 
therefore contains a higher load on motor response inhibition. Logan, the creator of 
the Stop Signal task, described the process of motor response inhibition in the Stop 
Signal task as a race between two competing responses, one which aims to make a 
motor response, and the other which aims to prevent the already triggered motor 
response from occurring (Logan et al., 1997).   
 
Due to the key role that difficulties in inhibition play in the diagnosis of ADHD 
(American et al., 1994), there is a wealth of research that uses these two tasks to 
investigate motor response inhibition in children with this disorder.  
 
There is consistent evidence from neuropsychological studies that ADHD 
children have deficits in the Stop Signal task, as they have increased SSRTs (Rubia et 
al., 2001b, Rubia et al., 2007a, Martel et al., 2007, de Zeeuw et al., 2008, Lee et al., 
2008, Luman et al., 2009). In addition, studies have also found abnormal Go process 
measures, such as increased mean reaction times and increased reaction time 
variability to go trials, and this variability is thought to be due to poor response 
preparation and lapses in attention throughout the task (Scheres et al., 2001, de Zeeuw 




Recent meta-analyses of the Stop Signal task have confirmed the presence of an 
inhibitory deficit in children with ADHD, as they have much longer SSRTs, the key 
indicator of poor inhibition during the task, as well as longer mean reaction times to 
go trials, compared to typically developing controls (Oosterlaan et al., 1998, Willcutt 
et al., 2005, Lijffijt et al., 2005, Alderson et al., 2007, Lipsyzc and Schachar, 2010).  
 
There is also evidence for impaired performance in the Go/No-Go task in 
individuals with ADHD compared to controls (Oosterlaan et al., 1998, Overtoom et 
al., 2002, Rubia et al., 1998, Rubia et al., 2001b, Rubia et al., 2007a, Wodka et al., 
2007, Huang-Pollock et al., 2007). 
 
1.3.2 – Interference Inhibition in ADHD 
 
Another aspect of inhibition which has been investigated in ADHD is 
interference inhibition. Interference inhibition is described as the ability to suppress a 
dominant prepotent response in favour of a conflicting but correct response (Golden, 
1978, Simon, 1990, Eriksen and Schultz, 1979). Three of the most well used tasks to 
assess this cognitive function are the Stroop Colour and Word task (Golden, 1978), 
which assesses verbal interference inhibition, the Eriksen Flanker Task and the Simon 
task, which both assess visuospatial interference inhibition (Simon, 1990, Eriksen and 
Schultz, 1979). 
 
With regards to verbal interference inhibition, meta-analyses of the Stroop task 
in children with ADHD report mixed findings as poor colour naming and increased 
interference scores, relative to controls, have been previously reported (Homack and 
Riccio, 2004, Lansbergen et al., 2007). However, a meta-analysis of Stroop tasks in 
children and adults with ADHD found no evidence for impaired interference 
inhibition (Schwartz and Verhaeghen, 2008), and another meta-analysis in children 
with ADHD found that findings were dependent on the method used to calculate 
interference (Van Mourik et al., 2005). 
 
Research into visuo-spatial interference inhibition has produced similarly 
conflicting results. Recent studies in children with ADHD have reported no deficit in 
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interference inhibition compared to controls on the Eriksen Flanker task (Adolfsdottir 
et al., 2008, Booth et al., 2007, Yordanova et al., 2011) or the Stroop task (Brocki et 
al., 2008, van Mourik et al., 2009, van Mourik et al., 2011). However, a recent review 
investigating interference inhibition in children with ADHD, as assessed by the 
Eriksen Flanker task and the Simon task, supported the presence of deficits in this 
cognitive domain in children with ADHD compared to controls (Mullane et al., 2009). 
 
Thus, the current literature suggests that interference inhibition is not a key, 
consistent deficit in children with ADHD (Booth et al., 2007, Adolfsdottir et al., 2008, 
Brocki et al., 2008, van Mourik et al., 2009, van Mourik et al., 2011, Yordanova et al., 
2011, Van Mourik et al., 2005, Schwartz and Verhaeghen, 2008). 
 
1.3.3 – Motor Response and Interference Inhibition in ASD 
 
There have been a number of studies investigating inhibition in ASD as it has 
been noted, at both a neuropsychological and a neurobiological level, that repetitive 
and restrictive behaviours may be linked to problems with inhibitory control (Lopez et 
al., 2005, Langen et al., 2011). The studies that have assessed inhibition in ASD have 
produced relatively mixed results, but the findings in this field become slightly more 
consistent once motor response inhibition and interference inhibition are viewed 
separately. 
     
Studies focusing on motor response inhibition have found that children with 
ASD make more commission errors and have larger SSRTs than typical developing 
controls during Go/No-Go (Bishop and Norbury, 2005, Christ et al., 2007) and Stop 
Signal tasks (Verte et al., 2005, Lemon et al., 2011), respectively. Current reviews 
also support the presence of a deficit in prepotent response inhibition in ASD (Hill, 
2004, Sanders et al., 2008, O'Hearn et al., 2008). However, there is also some 
evidence to suggest that motor response inhibition is intact in children with ASD 
(Ozonoff and Strayer, 1997, Raymaekers et al., 2006). The use of small sample sizes, 
altered versions of the Stop Signal task and the fact that the ADOS was not used to 




Conflicting results have also been reported in interference inhibition. Research 
focusing on interference inhibition has produced evidence for task- specific deficits. 
Most studies report intact interference inhibition on Stroop tasks (Ozonoff and Jensen, 
1999, Russell et al., 1999, Christ et al., 2007, Adams and Jarrold, 2009, Christ et al., 
2011) apart from two studies reporting poor interference control in children with ASD 
compared to their typically developing peers (Verte et al., 2005, Robinson et al., 
2009). It has been suggested that due to the lower levels of reading comprehension 
and reading ability in children with ASD, the word-colour interference of the Stroop 
task is less of an interference for this population compared to typically developing 
children of the same age (Adams and Jarrold, 2009). This is supported by the finding 
that, studies using Eriksen Flanker tasks and Simon tasks have reported impaired 
performance in children with ASD compared to controls (Christ et al., 2007, Christ et 
al., 2011, Hughes, 1996, Solomon et al., 2008, Tsai et al., 2011).   
 
Hence, current research suggests that motor response inhibition (Bishop and 
Norbury, 2005, Verte et al., 2005, Christ et al., 2007, Lemon et al., 2011) and 
interference inhibition, as assessed using tasks with minimal reading or 
comprehension, is impaired in children with ASD compared to controls (Hughes, 
1996, Solomon et al., 2008, Robinson et al., 2009, Christ et al., 2011, Tsai et al., 
2011). However, the use of different paradigms, mixed sex groups and small sample 
sizes limit the reliability of these findings and all reviews in this area have commented 
on the need for more research to be conducted in order to elucidate the type of 
inhibitory deficit present in children with ASD (Hill, 2004, Sanders et al., 2008, 
O'Hearn et al., 2008). Therefore, research which investigates not only the cognitive 
aspect of inhibition, but also any underlying neurofunctional abnormalities, in a 
homogeneous sample of ASD individuals, may lead a clearer understanding of this 
deficit. 
 
1.3.4 – Summary of Inhibition in ADHD and ASD 
 
A number of studies have directly compared motor response inhibition between 
children with ADHD and children with ASD. These studies have reported mixed 
findings as some which have employed the Go/No-Go task have observed increased 
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omission and commission errors in children with ADHD, compared to children with 
ASD and typically developing children, while no difference in performance was 
observed between the ASD and control group (Happe et al., 2006, Sinzig et al., 2008). 
There have also been findings of no significant group differences between children 
with ADHD, children with ASD and controls using the Go/No-Go task (Raymaekers 
et al., 2007). However, using a Stop Signal task, it was observed that children with 
ADHD and ASD had significantly slower SSRTs compared to controls and that the 
two disorders were equally impaired (Geurts et al., 2004). 
 
Thus, although the current literature in ADHD and ASD supports the presence 
of poor motor response inhibition in children with ADHD (Rubia et al., 2001b, Rubia 
et al., 2007a, Martel et al., 2007, de Zeeuw et al., 2008, Lee et al., 2008, Luman et al., 
2009, Oosterlaan et al., 1998, Willcutt et al., 2005, Lijffijt et al., 2005, Alderson et al., 
2007, Lipsyzc and Schachar, 2010) and children with ASD (Bishop and Norbury, 
2005, Verte et al., 2005, Christ et al., 2007, Lemon et al., 2011), the extent to which 
these deficits are specific to ADHD, or are shared between the two disorders, has yet 
to be discerned. This is of vital importance as a greater understanding of the 
commonalities and disorder-specific differences in motor response inhibition between 
the two disorders has the potential to aid diagnosis. 
 
Interference inhibition has the same potential, however the findings in this field 
are also conflicting, with some Stroop studies reporting that children with ASD are 
more impaired than children with ADHD and that both clinical groups are impaired 
compared to typically developing controls (Corbett et al., 2009). However, others 
have observed that ADHD children are specifically impaired in interference inhibition 
compared to ASD and control children, who perform equally as well each other 
(Ozonoff and Jensen, 1999). Equal performance between the ADHD, ASD and 
control groups has also been reported (Goldberg et al., 2005). A study using the 
Eriksen Flanker task found that children with ADHD performed worse than children 
with ASD and controls (Geurts et al., 2008). Due to the potential difficulties of using 
the Stroop Word-Colour task in children with ASD (Adams and Jarrold, 2009), future 
research should aim to use the Erikson Flanker task in order to increase homogeneity 
in this field and produce more reliable results concerning the potential differential or 
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shared difficulties in interference inhibition in children with ADHD and children with 
ASD.  
 
Both motor response and interference inhibition are important aspects of 
executive function which potentially play a role in ADHD and ASD behaviours 
(American et al., 1994). Therefore research is needed to shed light on whether these 
cognitive domains are impaired in both disorders and if so whether the neural 
correlates of this dysfunction are similar or distinct. 
 
1.4 – Cognitive Flexibility 
 
1.4.1 – Cognitive Flexibility in ADHD 
 
Another executive which is thought to be impaired in both ADHD and ASD is 
cognitive flexibility. Cognitive flexibility is the ability of a person to change stimulus-
response associations and adapt them based on feedback. One of the most common 
tasks for assessing cognitive flexibility is the Wisconsin Card Sorting Task (WCST) 
which requires participants to sort cards based on colour, shape or number, and after 
obtaining a string of correct responses the sorting rule is changed, unbeknown to the 
participant. They then have to adapt their behaviour to ascertain the new sorting rule 
and errors associated with continued selection of the previously correct rule are 
known as perservative errors and are indicative of poor cognitive flexibility (Milner, 
1963). However, as the WCST also taps into other executive functions such as WM 
and inhibition, and is dependent on IQ, there are other paradigms which test cognitive 
flexibility with less reliance on other executive functions.  
 
There are other switching tasks that have lower demands on WM.  Versions of 
the Meiran Switch Task are commonly used visuo-spatial cognitive flexibility tasks 
that require participants to change their motor response between a horizontal and 
vertical dimension depending on an instruction stimulus. This is seen in the Rubia 
adaptation of the Merian Switch task (Rubia et al., 2007a) as there is an arrow in the 
centre of the grid; if this arrow points to the side the participant must make a button 
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press to indicate which side of the screen the dot is on. If the arrow is pointing up or 
down the participant must make a button press to indicate whether the dot is in the 
upper or lower quadrant of the screen. These two types of trial are alternated 
throughout the task and the subject is required to switch their response accordingly 
(Meiran, 1996). 
 
These types of tasks differ from reward reversal learning tasks, which also 
assess cognitive flexibility but require the participant to learn the stimulus-reward 
association and then reverse their response and select a previously non-rewarded 
stimulus that is now rewarded (Kehagia et al., 2010). The intra-dimensional/extra-
dimensional (ID/ED) task of the CANTAB is a nine staged set shifting task of 
increasing difficulty. The task starts with the intra-dimensional aspect and this 
requires the participant to learn a stimulus-reward contingency between two pictures 
of colour filled shapes by selecting them with a button press and seeing which one 
produces positive feedback. This rule then reverses and the participant has to begin to 
choose the other, previously non-rewarded image. The difficulty of the task increases 
and as the stages get more challenging white lines are added to the images, and these 
extra-dimensional white lines become relevant for the stimulus-reward association 
(Robbins et al., 1994). This increasing difficulty enables the researcher to better 
assess the level of cognitive flexibility the participant is impaired in.   
 
Increased perservative responses on the WCST have been observed in a group 
of 35 medication naïve, non-comorbid boys with ADHD compared to controls 
(Marzocchi et al., 2008). However, Shimoni et al found no evidence of impairment in 
children with ADHD compared to controls while using a child friendly version of the 
WCST (Shimoni et al., 2012). The latter study used only a small age range of 8-11 
years old and failed to comment on whether these children were medicated on the day 
of testing. Thus, these caveats may account for the lack of impairment observed.  
 
Impaired cognitive flexibility in ADHD has also been observed during 
switching tasks. A switching task with a sustained attention component reported that 
children with ADHD made more commission errors during switch trials compared to 
repeated trials, relative to controls (Inoue et al., 2008). It has also been shown that 
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children with ADHD who have undergone a 48hr medication washout have increased 
reaction time variability, relative to controls, during a switch task and this was 
associated with symptom severity (Oades and Christiansen, 2008). Furthermore, 
poorer switching ability has been observed in unmedicated children with ADHD 
compared to their typically developing peers (Cepeda et al., 2000). However, a 
switching task with an element of interference inhibition found no impairment in the 
ADHD group relative to controls (Rommelse et al., 2007). Also, a study using the 
Meiran switch task only found a trend of impairment (Rubia et al., 2007a). This null 
finding may be due to the age range of the participants used, as their ages ranged from 
8-19 years old. Furthermore, the fact that interference inhibition was intertwined with 
cognitive flexibility makes it difficult to state whether these null findings are truly 
reflective of intact cognitive flexibility in ADHD. 
 
More consistent results have been reported in studies using the ID/ED in 
unmedicated children with ADHD, finding that they failed to complete as many 
stages, and took more trials to reach the criterion for each stage, compared to 
medicated ADHD children and controls (Kempton et al., 1999). Reversal tasks have 
also reported that children with ADHD who have had a 24hr washout take more trials 
to reach the criterion for reversal compared to controls (Itami and Uno, 2002).  
 
Meta-analyses and reviews have also supported the presence of a deficit in 
cognitive flexibility in children with ADHD (Walshaw et al., 2010, Willcutt et al., 
2005, Chamberlain et al., 2011) and this may be linked to some of the comorbidities 
between ADHD and ASD, as there is evidence that children with ASD also have 
impairments in cognitive flexibility.  
 
1.4.2 – Cognitive Flexibility in ASD 
 
As restricted and repetitive behaviours are one of the key diagnostic features of 
ASD, a large amount of neuropsychological research has been conducted in order to 




Studies employing the WCST have reported increased perservative errors, and a 
lack of significant strategy change with time, in children with ASD compared to 
typically developing controls (Ozonoff, 1995, Ozonoff and McEvoy, 1994, Ozonoff et 
al., 1991, Bennetto et al., 1996, Verte et al., 2005, Van Eylen et al., 2011). 
 
Children with ASD also performed worse on the ID/ED task compared to their 
typically developing peers, as they completed fewer stages, took more trials to reach 
criterion in the later stages of the task and made more perservative errors (Hughes et 
al 1994). This finding of poorer performance in the extra-dimensional stages of the 
ID/ED task in children with Asperger’s and children with ASD, compared to controls, 
has been replicated (Ozonoff et al., 2000, Yerys et al., 2009). It has also been reported 
that this increase in errors was correlated with repetitive behaviour (Yerys et al., 
2009). 
 
A lower percentage of shifting in children with ASD, relative to controls, has 
also been observed in simple switching tasks (Yerys et al., 2012); however, some 
studies have found no difference in performance between children with ASD and 
controls in these tasks (Poljac et al., 2010). 
 
This cognitive inflexibility has also been observed during reversal learning tasks 
as studies using a spatial reversal task have reported increased perservative errors in 
children with ASD relative to typically developing controls (McEvoy et al., 1993, 
Coldren and Halloran, 2003, Yerys et al., 2007) as have studies using object 
discrimination reversal learning tasks (Loveland et al., 2008). There is also evidence 
to suggest that children with ASD have difficulties establishing stimulus-reward 
contingencies during reversal learning tasks (Zalla et al., 2009). Studies using young 
children, aged 3-4, have found no deficit in reversal learning in children with ASD, 
suggesting that this impairment becomes more evident with age (Lionello-DeNolf et 
al., 2008, Dawson et al., 2002). However, further research is needed to confirm this.  
 
There is a wealth of evidence to support the presence of cognitive inflexibility in 
children and adolescents with ASD and this impairment can be elicited using a variety 
of cognitive flexibility tasks (Ozonoff et al., 1991, Ozonoff and McEvoy, 1994, 
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Ozonoff, 1995, Ozonoff et al., 2000, McEvoy et al., 1993, Hughes et al., 1994, 
Bennetto et al., 1996, Coldren and Halloran, 2003, Verte et al., 2005, Yerys et al., 
2007, Yerys et al., 2009, Yerys et al., 2012, Robinson et al., 2009, Van Eylen et al., 
2011) alongside a number of negative findings (Geurts et al., 2009). However, the 
association between this cognitive deficit and ASD behaviours has yet to be fully 
explored. Future research should aim to investigate this potential association and try 
to shed light on the neural underpinnings of this cognitive deficit as this will help to 
increase our understanding about the link between brain dysfunction and behaviour in 
ASD.  
 
1.4.3 – Summary of Cognitive Flexibility in ADHD and ASD 
 
Studies using the WCST to directly compare cognitive flexibility in children 
with ADHD and children with ASD have found that children with ASD produce more 
perservative errors compared to both children with ADHD and controls, who do not 
differ from each other (Ozonoff and Jensen, 1999, Geurts et al., 2004). It has also 
been shown that children with ADHD and children with Pervasive Development 
Disorder – Not Otherwise Specified produce more total errors and achieved fewer 
categories compared to controls, and that the two patient groups did not differ from 
each other (Kado et al., 2012). A study by Tsuchiya et al showed that both the ADHD 
and ASD group produced more perservative responses compared to controls 
(Tsuchiya et al., 2005). However, the ADHD group produced more ‘Milner type’ 
perservative errors than both the control and ASD groups and these errors are 
described by the authors as responses which would have been correct in the preceding 
trial. They concluded that ADHD children had poorer cognitive flexibility than ASD 
children: however, as the WCST also taps in to inhibition processes the performance 
of ADHD children may be a combination of deficits in motor response inhibition and 
cognitive flexibility. 
 
In contrast, studies using the ID/ED in children with ADHD and children with 
ASD found no significant differences between the patients and controls (Goldberg et 
al., 2005, Happe et al., 2006, Corbett et al., 2009) and this may be due to the relatively 




Thus, although direct comparisons between ADHD and ASD have produced 
mixed results, there is strong evidence for cognitive inflexibility in children with 
ADHD (Kempton et al., 1999, Cepeda et al., 2000, Itami and Uno, 2002, Inoue et al., 
2008, Oades and Christiansen, 2008, Marzocchi et al., 2008, Walshaw et al., 2010, 
Willcutt et al., 2005, Chamberlain et al., 2011) and children with ASD (Ozonoff et al., 
1991, Ozonoff and McEvoy, 1994, Ozonoff, 1995, Ozonoff et al., 2000, McEvoy et 
al., 1993, Hughes et al., 1994, Bennetto et al., 1996, Coldren and Halloran, 2003, 
Verte et al., 2005, Yerys et al., 2007, Yerys et al., 2009, Yerys et al., 2012, Robinson 
et al., 2009, Van Eylen et al., 2011). However, studies using both children with 
ADHD and children with ASD have produced conflicting, and in the case of the 
ID/ED task null, results (Goldberg et al., 2005, Happe et al., 2006, Sinzig et al., 2008, 
Corbett et al., 2009). Future studies should focus on comparing these two 
neurodevelopmental disorders on reversal learning tasks as this paradigm has not been 
used to directly compare children with ADHD and children with ASD. It may produce 
clearer results, as it loads less onto other executive functions compared to the WCST 
and this may be the reason why unclear results have been obtained in studies using the 
WCST. Furthermore, the use of small, heterogeneous groups in the studies using the 
ID/ED may have led to the null findings observed. The use of larger, homogeneous 
groups will help to rectify these caveats and produce more reliable results.  
 
1.5 – Other Cognitive Domains 
 
1.5.1 – ADHD 
 
In order to understand the full psychological profile of both ADHD and ASD, 
and gain a holistic view of both complex disorders, the other main cognitive domains 
of impairment will be briefly discussed. 
 
 Children with ADHD also exhibit deficits in executive function domains other 
than those previously reviewed, particularly in sustained attention. Sustained attention 
is defined as the ability to voluntarily attend to a specific, infrequent stimuli 
(Parasuraman et al., 1998). It has been consistently reported that children with ADHD 
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make more omission and commission errors relative to controls during classic 
vigilance tasks such as the Continuous Performance Task (Willcutt et al., 2005, 
Gualtieri and Johnson, 2008, Klein et al., 2006, Rubia et al., 2007a).  
 
In addition, it has been reported that children with ADHD are impaired in tasks 
of temporal discounting. Temporal discounting refers to the relative value of a reward 
based upon the length of time the reward is delayed for (Sonuga-Barke et al., 2003). 
Children with ADHD have difficulty delaying reward and will choose small 
immediate rewards over larger delayed rewards significantly more than their aged 
matched peers (Solanto et al., 2001, Thorell, 2007, Bitsakou et al., 2009, Marco et al., 
2009, Scheres et al., 2010). It has been hypothesised that this ‘delay aversion’ may 
play a key role in the behaviours observed in ADHD (Sonuga-Barke, 2003). It has 
also been shown that children with ADHD exhibit difficulties in other hot executive 
functions because they have altered sensitivity to reward during tasks that involve 
reward and/or motivation, such as temporal discounting and gambling tasks (Solanto 
et al., 2001, Toplak et al., 2006, Thorell, 2007, Garon et al., 2006, Luman et al., 2010, 
Scheres et al., 2010). 
 
Furthermore, there is compelling evidence to support the presence of motor 
timing and time perception deficits in children with ADHD, as it has been repeatedly 
shown that children with ADHD have problems with fine temporal discrimination and 
time reproduction (Toplak et al., 2006, Rubia et al., 2009a, Noreika et al., 2013). 
 
1.5.2 – ASD 
 
While children with ASD show executive dysfunction, and there is evidence to 
suggest that this impairment plays a vital role in the aetiology of ASD (Hughes et al., 
1994, Ozonoff et al., 2004, Hill, 2004, Geurts et al., 2004, Corbett et al., 2009), 
individuals with ASD have more consistently been associated with deficits in other 
cognitive and social domains. There is evidence that ASD patients are impaired in 
Theory of Mind (ToM). ToM is described as the ability to understand, and empathise 
with, the mental state of others and it has been shown that individuals with ASD are 
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impaired in this skill (Baron-Cohen and Laraine Masters, 2000, Baron-Cohen et al., 
1985, Frith, 1994, Joseph and Tager-Flusberg, 2004, Tager-Flusberg, 2007).  
 
It has also been argued that differences in central coherence, the ability to assess 
information as a whole and focus less on the finer details in order to understand the 
general meaning, may play a part in the clinical symptoms of ASD (Happé, 1997, 
Pellicano et al., 2006, Booth and Happé, 2010). 
 
1.6 – Overall conclusions 
 
There is evidence that both children with ADHD (Stevens et al., 2002, Rhodes 
et al., 2005, Rhodes et al., 2012, Martinussen and Tannock, 2006, Klein et al., 2006, 
Rommelse et al., 2008, Rapport et al., 2008, Kofler et al., 2010, Toplak et al., 2009, 
Gibson et al., 2009, Barnett et al., 2009, Gau and Shang, 2010, Alderson et al., 2010, 
Wee et al., 2010, Crocker et al., 2011, Martinussen et al., 2005, Willcutt et al., 2005, 
Kasper et al., 2012) and children with ASD (Bennetto et al., 1996, Minshew and 
Goldstein, 2001, Minshew et al., 1999, Landa and Goldberg, 2005, Williams et al., 
2005, Williams et al., 2006b, Joseph et al., 2005a, Joseph et al., 2005b, Verte et al., 
2005, Nakahachi et al., 2006, Luna et al., 2007, Steele et al., 2007, Loveland et al., 
2008, Cui et al., 2010, Zinke et al., 2010, Yerys et al., 2012) are impaired in all 
components of the Baddley model of WM compared to typically developing controls. 
Although a number of neuropsychological studies have compared visuo-spatial WM 
in ADHD and ASD (Geurts et al., 2004, Goldberg et al., 2005, Happe et al., 2006, 
Corbett et al., 2009, Sinzig et al., 2008), they have produced mixed results and this 
may be due to the small sample sizes and heterogeneity present in the studies. 
Furthermore, none have investigated verbal WM in a homogeneous group of children 
with ADHD and children with ASD to ascertain whether more consistent results are 
obtained using this WM domain. A parametric N-Back task would be an ideal 
paradigm to use in a study comparing these two disorders as it has been shown to tap 
into impairments in both children with ADHD (Klein et al., 2006, Pasini et al., 2007) 
and children with ASD (Cui et al., 2010) and it also enables one to investigate the 




In addition to WM, motor response inhibition and interference inhibition are 
areas of significant cognitive deficit in children with ADHD (Rubia et al., 2001b, 
Rubia et al., 2007a, Martel et al., 2007, de Zeeuw et al., 2008, Lee et al., 2008, Luman 
et al., 2009, Oosterlaan et al., 1998, Willcutt et al., 2005, Lijffijt et al., 2005, Alderson 
et al., 2007, Lipsyzc and Schachar, 2010) and there is research to support the presence 
of poor motor response inhibition in children with ASD compared to controls (Bishop 
and Norbury, 2005, Verte et al., 2005, Christ et al., 2007, Lemon et al., 2011). As 
with studies assessing WM in both ADHD and ASD, small sample sizes and group 
heterogeneity may have led to the mixed results reported in studies which investigate 
motor response inhibition and interference inhibition in these two disorders (Ozonoff 
and Jensen, 1999, Geurts et al., 2004, Geurts et al., 2008, Goldberg et al., 2005, 
Happe et al., 2006, Corbett et al., 2009). When focusing on studies of motor response 
inhibition, as the evidence for deficits in both ADHD and ASD is stronger in this 
domain compared to interference inhibition, those using the Go/No-Go found only 
deficits between ADHD compared to ASD and control children (Happe et al., 2006, 
Sinzig et al., 2008) or in one study no difference at all (Raymaekers et al., 2007). By 
contrast, a study using the Stop Signal task found that both groups were impaired 
compared to controls and that the patient groups did not differ from each other 
(Geurts et al., 2004). This suggests that the more difficult tracking Stop Signal task, 
tapping into withdrawal of an already triggered motor response, is better suited to 
detect deficits in motor response inhibition in children with ADHD and children with 
ASD than the easier Go/No-Go task.  
 
Cognitive flexibility is another important executive function and it has been 
shown that children with ADHD (Kempton et al., 1999, Cepeda et al., 2000, Itami and 
Uno, 2002, Inoue et al., 2008, Oades and Christiansen, 2008, Marzocchi et al., 2008, 
Walshaw et al., 2010, Willcutt et al., 2005, Chamberlain et al., 2011) and children 
with ASD (Ozonoff et al., 1991, Ozonoff and McEvoy, 1994, Ozonoff, 1995, Ozonoff 
et al., 2000, McEvoy et al., 1993, Hughes et al., 1994, Bennetto et al., 1996, Coldren 
and Halloran, 2003, Verte et al., 2005, Yerys et al., 2007, Yerys et al., 2009, Yerys et 
al., 2012, Robinson et al., 2009, Van Eylen et al., 2011), both have difficulties in this 
domain as evidenced by their perservative responses in a variety of tasks assessing 
cognitive flexibility. Research focused on investigating the comparative levels of 
cognitive inflexibility in these disorders has produced conflicting results, with studies 
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using the ID/ED reporting no deficits between either the patient groups or controls 
(Goldberg et al., 2005, Happe et al., 2006, Sinzig et al., 2008, Corbett et al., 2009). 
However, there is evidence for ASD specific deficits compared to typically 
developing and ADHD children in this domain using the WCST (Ozonoff and Jensen, 
1999, Geurts et al., 2004). These findings may be the result of type of task being used 
as both the WCST and ID/ED tap into other cognitive functions. Previous studies of 
both children with ADHD and children with ASD have not yet employed a reward 
reversal learning task and it would be intriguing to see whether reward reversal 
learning is able to uncover the differential deficits in cognitive flexibility in children 
with ADHD and children with ASD. 
 
In conclusion, although there is a wealth of literature supporting the presence of 
executive function deficits in children with ADHD and children with ASD in tasks of 
WM, motor response inhibition and cognitive flexibility, studies directly comparing 
the two disorders produce incongruent results. These conflicting results may be due to 
the small, heterogeneous groups used as well as the different paradigms employed. 
The changes to DSM-IV which will allow co-diagnosis of ASD and ADHD highlight 
the relevance and importance of research which aims to uncover the shared and 
disorder-specific impairments in children with these disorders.  
 
Therefore, it is paramount to compare large, pure groups of children with 
ADHD and children with ASD in tasks of WM, motor response inhibition and reward 
reversal learning, as it has been shown that these cognitive domains are particularly 










Chapter 2 – Brain Structure Abnormalities in ADHD 
and ASD 
 
2.1 – Introduction 
 
In previous studies, it had been observed that individuals suffering from lesions 
of the prefrontal cortex often displayed deficits in executive functions such as WM, 
inhibition and cognitive flexibility (Owen et al., 1990, Aron et al., 2003, Milner, 
1963). This led to the hypothesis that the neural basis of executive functions might lie 
in the prefrontal cortex (Miller and Cohen, 2001, Poldrack et al., 2011). As the 
cognitive impairments observed in these neurological studies mirrored those reported 
in ADHD and ASD, researchers began to postulate that the cognitive deficits in both 
ADHD and ASD might be due to abnormalities in the prefrontal cortex. However, the 
only way in which this hypothesis could be investigated in vivo was by the use of 
neuroimaging techniques. Neuroimaging is the process of imaging and measuring the 
structure, function and biochemistry of the brain. The only way of obtaining in vivo 
structural data about the brain using non ionising radiation is by a technique known as 
structural magnetic resonance imaging (sMRI) it fast became one of the more popular 
methods of neuroimaging (Poldrack et al., 2011). 
 
sMRI often focuses on the two main components of the brain, known as white 
matter and grey matter. White matter refers to the axon extending from a neuron, 
while grey matter refers to the cell body of the neuron (Kandel et al., 2000). Research 
into the developmental trajectory of brain structure using sMRI has found that there is 
a linear increase in white matter during childhood and adolescence up to mid-
adulthood (Paus et al., 2001). This increase is associated with an increase in 
myelination that speeds up information transfer between neurons and improves white 
matter integrity, indicating increased connectivity within the brain which then allows 
for more integrated and co-ordinated responses with increasing age (Giedd and 
Rapoport, 2010, Blakemore, 2011). Conversely, it has been found that grey matter has 
an inverted-U shape trajectory, where it increases with age, peaks in adolescence, and 
declines in adulthood; this has been attributed to the synaptic proliferation that occurs 
in childhood and early adolescence which is then followed by neuronal ‘pruning’ in 
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later adolescence and early adulthood (Giedd and Rapoport, 2010, Blakemore, 2011). 
Therefore, with age we see not only an increase in the ability to transfer information 
within the brain, but a refining of the information itself. It has also been reported that 
subcortical limbic areas reach structural maturity much earlier than the frontal brain 
regions involved in executive function, and it is known that dorsolateral prefrontal 
cortex (DLPFC) is one of the last regions of the brain to reach full maturity (Paus et 
al., 1999, Casey and Jones, 2010). A linear correlation has been observed between 
structural development, particularly of the prefrontal cortex, and executive function 
processes such as inhibition, planning and cognitive flexibility (Casey and Jones, 
2010, Giedd and Rapoport, 2010, Blakemore, 2011). Therefore, abnormalities or 
delays in the development of brain structure and function may play a role in the 
executive dysfunction observed in ADHD and ASD. Consequently, it is important to 
understand the neuroanatomical differences present in ADHD and ASD, as they may 
shed light on the potentially shared or disorder-specific biological bases of the 
cognitive impairments in these disorders and provide potential diagnostic markers.  
 
2.2 – Brain Structure Abnormalities 
 
2.2.1 – Brain Structure Abnormalities in ADHD 
 
It has been consistently observed that both medicated (Mostofsky et al., 2002, 
Hill et al., 2003, Carmona et al., 2005, Wolosin et al., 2009, Batty et al., 2010) and 
medication naïve (Castellanos et al., 2002) ADHD children show significantly 
reduced total cerebral volumes compared to their typically developing peers. 
Decreased total white matter and decreased total grey matter has also been reported in 
children with ADHD compared to controls (Filipek et al., 1997, Overmeyer et al., 
2001, Mostofsky et al., 2002, Sowell et al., 2003b, Carmona et al., 2005, Batty et al., 
2010, Qiu et al., 2011), and there is evidence to suggest that there may be a laterality 
effect of these white and grey matter abnormalities, with white matter deficits being 
more left hemispheric and grey matter deficits being more right hemispheric 
(Overmeyer et al., 2001, Mostofsky et al., 2002). This is suggestive of poor 
interactions between left hemispheric language networks and immature signalling in 
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right hemispheric visuo-spatial attention networks (Hervé et al., 2013), the latter of 
which may play a role in the poor sustained attention observed in ADHD. 
 
When focusing on the frontal lobe, it has been repeatedly reported that children 
with ADHD have decreased total, grey and white matter volumes relative to age 
matched controls (Filipek et al., 1997, Overmeyer et al., 2001, Castellanos et al., 
2002, Sowell et al., 2003b, Hill et al., 2003, Durston et al., 2004, Carmona et al., 
2005, McAlonan et al., 2007, Depue et al., 2010a). One whole brain, cross-sectional 
study reported that the decreased white and grey matter in the frontal lobe accounted 
for 48% of the total decrease in cerebral volume. This highlights the large role that the 
neuroanatomical deficits of the frontal lobe play in the overall structural differences 
observed in the cerebrum of children with ADHD compared to controls (Mostofsky et 
al., 2002). Furthermore, it has been shown in an impressive whole brain longitudinal 
study, which spanned over a decade and consisted of 152 ADHD children, that 
decreased frontal grey matter was linked to worse ADHD symptoms (Castellanos et 
al., 2002). Hence, the structural anatomy of the frontal lobe atypical in children with 
ADHD and this may play a role in the executive dysfunction reported present in this 
population. 
 
This potential link between structural abnormalities in frontal lobe and impaired 
executive function has been supported in a region of interest (ROI) study focusing on 
right inferior frontal cortex (IFC) (Depue et al., 2010a). This study found decreased 
grey matter (Depue et al., 2010a) in 31 medicated, older adolescents with ADHD 
when they were compared to age matched controls. A Digit Span Symbol test, a 
Continuous Performance Task and a Stop Signal task were used in order to assess 
processing speed, inhibition and response variability between groups. It was noted 
that the decrease in right IFC grey matter was positively correlated with processing 
speed and negatively correlated with commission errors on the Continuous 
Performance Task, Stop Signal Reaction Times and response variability. This 
indicated that less grey matter in this area was linked to poorer performance in 
neuropsychological domains that individuals with ADHD are normally impaired in 
(Losier et al., 1996, Willcutt et al., 2005, Lijffijt et al., 2005, Alderson et al., 2007, 
Adams et al., 2008). This finding is highly pertinent, as it is known that right IFC is a 
key area for motor response inhibition (Rubia et al., 2001a, Rubia et al., 2003, Rubia 
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et al., 2006, Rubia et al., 2007c, Aron and Poldrack, 2006, Chevrier et al., 2007, 
Simmonds et al., 2008, Chambers et al., 2009). 
 
Neuroanatomical abnormalities have also been reported in other frontal regions 
that play a role in executive functions. Decreased total and grey matter volume has 
been observed in superior frontal cortex (Filipek et al., 1997, Overmeyer et al., 2001, 
Hill et al., 2003) while decreased local size has been observed in inferior DLPFC 
(Sowell et al., 2003b), and decreased grey matter in the anterior cingulate cortex 
(ACC) (Carmona et al., 2005) of children with ADHD compared to controls. 
 
These findings highlight the significant neuroanatomical differences between 
children and older adolescents with ADHD and their typical developing peers in 
frontal lobe regions that are vital for executive functions, as well as supporting the 
hypothesis that these structural abnormalities are linked to the symptoms of ADHD 
(Filipek et al., 1997, Overmeyer et al., 2001, Castellanos et al., 2002, Sowell et al., 
2003b, Hill et al., 2003, Durston et al., 2004, Carmona et al., 2005, McAlonan et al., 
2007, Garrett et al., 2008, Depue et al., 2010a). This is highly relevant to this thesis 
because these neuroanatomical differences may result in abnormal neurofunctional 
activity in these brain regions. 
 
Although the frontal lobe is intrinsic to executive function, it is not the only 
region involved in these processes. The basal ganglia are highly connected to the 
prefrontal cortex and it is known that they play an integral role in areas of executive 
function that individuals with ADHD are impaired in such as motor response 
inhibition and temporal discounting (Rubia et al., 2007c, McNab and Klingberg, 
2008, Tanaka et al., 2004, Chambers et al., 2009). Consequently, abnormalities in 
these subcortical structures may also be linked to some of the executive dysfunctions 
that are reported in ADHD.  
 
Decreased volume has been observed consistently in both the head, body and 
total caudate, in children with ADHD compared to controls in both cross-sectional 
(Filipek et al., 1997, Tremols et al., 2008, Garrett et al., 2008, Carrey et al., 2012) and 
longitudinal studies (Castellanos et al., 2002). These structural abnormalities in the 
caudate have been linked to more severe forms of ADHD (Castellanos et al., 2002) 
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and better medication response (Filipek et al., 1997). It has also been noted that the 
symmetry of the caudate differs between controls and children with ADHD as there is 
evidence that children with ADHD exhibit more asymmetrical (Tremols et al., 2008), 
and more symmetrical caudate volumes (Filipek et al., 1997). However, some studies 
have shown that these differences are age dependent. 
 
A longitudinal study of 152 children with ADHD showed that differences in 
total caudate volume normalise by adolescence, relative to controls (Castellanos et al., 
2002). A recent cross-sectional ROI study reported that in 26 medication naïve boys 
with combined type ADHD, the younger subgroup of the cohort (aged 5.9-7.3) was 
driving the overall group differences in caudate volume between ADHD and controls 
(Carrey et al., 2012). The medication naivety and homogeneity of the ADHD group in 
Carrey et al’s study make these findings reliable and they have been supported by a 
recent meta-analysis conducted on 378 individuals with ADHD and 344 controls 
which found that caudate and right lentiform nucleus abnormalities in ADHD 
normalised with age and stimulant medication (Nakao et al., 2011, Frodl and 
Skokauskas, 2012). These findings suggest that the structure of the caudate may play 
an integral role in ADHD symptomology, and that the decrease in ADHD symptoms 
with both medication and age may be mediated by normalisation of this subcortical 
brain region. This is of particular pertinence to this thesis as these structural 
abnormalities may result in impaired neurofunctional activity of the caudate.  
 
Structural abnormalities have also been reported in other areas of the basal 
ganglia such as the globus pallidus and ventral striatum. Whole brain studies have 
reported decreased grey matter in the globus pallidus (Overmeyer et al., 2001, 
McAlonan et al., 2007). However, in McAlonan et al’s study, when comorbidity with 
ODD and CD was removed from the ADHD group, the globus pallidus findings were 
no longer significant, highlighting the importance of using non-comorbid groups. 
Decreased grey matter has also been reported in right putamen, as has decreased 
volume in bilateral anterior putamen and increased volume in posterior putamen 
(Overmeyer et al., 2001). 
 
Only one cross-sectional, ROI study using 42 mainly medicated ADHD children 
of mixed sex and subtype, found decreased total ventro-striatal volume relative to 
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control children (Carmona et al., 2009). They also observed that decreased ventro-
striatal volume was correlated with increased hyperactive and inattentive scores. 
Given the role of ventral striatum in reward (Fareri et al., 2008), and the hypothesis 
that hyperactivity and inattention in ADHD are the result of an delay aversion to 
delayed rewards (Sonuga-Barke, 2003), these findings are highly intriguing. 
However, further research is needed to clarify this, particularly with regards to small 
subcortical structures such as the ventral striatum. 
 
Unlike the frontal lobe and basal ganglia, the cerebellum was initially thought to 
be involved in motor skills only, and was therefore relatively under researched in 
ADHD. However, it has now been established that it plays a role in executive 
functions that are impaired in ADHD such as attention and timing (Riva and Giorgi, 
2000, Schmahmann and Caplan, 2006, Bellebaum and Daum, 2007, Timmann and 
Daum, 2007). This therefore makes the consistent findings of structural abnormalities 
in this region in children with ADHD particularly pertinent. Decreased cerebellar 
volumes have been reported in total cerebellum, (Castellanos et al., 2002, Durston et 
al., 2004) superior vermis of the cerebellum (Mackie et al., 2007), the inferior 
posterior vermis of the cerebellum (Berquin et al., 1998, Bledsoe et al., 2009) and 
cerebellar lobes I-V and VIII-X (Hill et al., 2003, Seidman et al., 2005), in children 
with ADHD compared to controls. It has also been observed in two longitudinal 
studies that decreased total volume of the cerebellum in children with ADHD is 
correlated with increased ADHD symptoms (Castellanos et al., 2002) and that a 
developmental trajectory that leads to a progressive total decrease in cerebellar 
volume is correlated with worse clinical outcomes (Mackie et al., 2007). This 
suggests that a continuation of total cerebellar volume decrease throughout 
development maybe be key in identifying the ADHD children whose ADHD persists 
into adulthood.   
 
Neuroanatomical differences have also been observed in other regions of the 
brain. The majority of studies that observe structural abnormalities of the temporal 
lobe in children with ADHD report decreased grey matter (Castellanos et al., 2002, 
Sowell et al., 2003b, Carmona et al., 2005, Sasayama et al., 2010) and white matter 
volume (McAlonan et al., 2007) compared to controls. However, there is evidence for 
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increased grey matter in posterior temporal lobe in ADHD children relative to typical 
developing children (Sowell et al., 2003b).  
 
There is also evidence for both increased (Sowell et al., 2003b) and decreased 
(McAlonan et al., 2007) grey matter volume in inferior parietal lobe. The fact that 
Sowell et al included 11 girls in their ADHD group, which had a total of 27, while 
McAlonan et al used an all boy sample of 28, may account for the incongruity of 
these findings. Decreased grey matter has also been reported in right superior parietal 
lobe in young adults with ADHD compared to age matched controls, and this 
abnormality has been shown to correlate with increased response variability (Depue et 
al., 2010a). This suggests that there may be a link between the structure of superior 
parietal lobe, a key area for attentional orientation (Bisley and Goldberg, 2010) and 
lapses in attention in ADHD. 
 
Abnormalities in the neuroanatomy of the occipital lobe have also been 
observed in children with ADHD compared to controls, particularly decreased grey 
matter volume in left occipital lobe (Sowell et al., 2003b, McAlonan et al., 2007, 
Sasayama et al., 2010), with some evidence for white matter volume reduction also 
(Durston et al., 2004). One study noted that this decrease in grey matter volume was 
correlated with inattention scores (Sowell et al., 2003b). However more research is 
needed to corroborate these findings. 
 
Areas of the limbic system have also been reported to be structurally abnormal 
in older adolescents and children with ADHD compared to aged matched controls, as 
decreased grey matter volume has been observed in anterior insula and amygdala. 
(Lopez-Larson et al., 2009, Depue et al., 2010a, Lopez-Larson et al., 2012). 
Furthermore, decreased grey matter volume in the anterior insula has been shown to 
correlate with poorer processing speed (Depue et al., 2010a).  
 
Understanding the interhemispheric connection between these structurally 
abnormal brain regions is of great importance because aberrant connectivity leads to 
mal co-ordinated brain responses. The corpus callosum has the vital role of 
connecting both hemispheres and is one of the largest white matter tracts in the brain 
(Bloom and Hynd, 2005). There is a large body of evidence to show that there are 
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abnormalities in the corpus callosum of children with ADHD compared to controls, as 
reduced volume, surface area, thickness and fibre organisation of this white matter 
tract have been reported (McAlonan et al., 2007, Hill et al., 2003, Luders et al., 2009, 
Cao et al., 2010). A meta-analysis of 13 studies focusing on the corpus callosum in 
ADHD found that children and adolescents have a smaller splenium; this result is 
largely attributable to the females with ADHD as boys with ADHD were found to 
have smaller rostral bodies (Hutchinson et al., 2008). In addition to these cross-
sectional structural differences, abnormalities in the development of the corpus 
callosum have been reported. It has been observed in a longitudinal study of 236 
children with ADHD, predominantly right handed, that there is an increased growth 
rate in anterior corpus callosum compared to controls, and the authors propose that 
this may be linked to some of the differences in cortical asymmetry reported in 
children with ADHD (Gilliam et al., 2011, Shaw et al., 2009a). However, more 
longitudinal studies are needed to understand how this increase in corpus callosal 
growth ties in with the consistent reports of reduced volume, thickness and area 
(McAlonan et al., 2007, Hill et al., 2003, Luders et al., 2009, Cao et al., 2010, 
Schnoebelen et al., 2010, Hutchinson et al., 2008).   
 
Thickness of the cortex itself has also been investigated in children with ADHD 
and has yielded intriguing results. The cortex is described as the neuronal layer of 
cells present on the surface of the brain and the developmental trajectory of the 
thickness of this layer has been shown to correlate with IQ (Kandel et al., 2000, Shaw 
et al., 2006a). 
 
One of the first studies to assess this neuroanatomical construct in children with 
ADHD was a longitudinal study by Shaw et al 2006. They observed that in 163 
children with mainly combined type ADHD there was significant cortical thinning 
across the whole brain compared to typically developing children, particularly in 
bilateral medial prefrontal cortex (mPFC), bilateral superior frontal cortex, left 
precentral and right mesial temporal. When these structural differences were 
investigated with regards to clinical outcome it was noted that thinner mPFC, 
cingulate and superior frontal cortices were correlated with worse clinical outcome as 
defined by DSM-IV and Childrens Global Assessment Scale and that normalisation of 
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cortical thickness in right parietal lobe at age 17 was associated with better outcome 
and remission and ADHD symptoms.  
 
This finding was supported by another longitudinal study by Shaw et al 2007 
(Shaw et al., 2007). This found that, although the pattern of development was similar 
between children with ADHD and healthy controls, children with ADHD reached 
peak cortical thickness in 50% of the cortical points significantly later than controls, 
particularly in middle/superior frontal cortices, mPFC and middle/superior temporal 
lobe. Earlier peak thicknesses in primary motor cortices were also reported in children 
with ADHD. Cross-sectional studies have supported these longitudinal findings of 
decreased frontal and increased motor cortex thickness and have found these 
structural abnormalities to be linked to an increased number of DSM-IV ADHD 
criteria (Narr et al., 2009, Almeida et al., 2010, Almeida Montes et al., 2012, Duerden 
et al., 2012). This has led to the hypothesis that children with ADHD have delayed 
cortical maturation and that this may play a role in their age inappropriate behaviour. 
 
In order to gain a holistic look at the neuroanatomical abnormalities reported in 
ADHD a number of meta-analyses have been conducted (Valera et al., 2007, Ellison-
Wright and Ellison-Wright, 2008, Frodl and Skokauskas, 2012, Nakao et al., 2011). 
Earlier meta-analyses using ROIs found decreased total cerebellar, cerebral, right 
caudate and splenium of the corpus callosum volume in children and adults with 
ADHD (Valera et al., 2007). However, more recent whole brain meta-analyses have 
found grey matter reduction in bilateral putamen/globus pallidus and decreased grey 
matter and total volume of the caudate in children and adults with ADHD (Ellison-
Wright and Ellison-Wright, 2008, Frodl and Skokauskas, 2012, Nakao et al., 2011). 
Nakao et al conducted meta-regressions on age and medication and found that 
increasing age and stimulant medication use was associated with grey matter in right 
lentiform nucleus and caudate (Nakao et al., 2011). This mirrors the findings of 
reduced structural abnormalities in the caudate with increasing age that were reported 
by Castellanos et al (2002) and Carrey et al (2012). One of the meta-analyses also 
observed increased grey matter in left posterior cingulate cortex (PCC) in ADHD 




The findings of these individual studies and meta-analyses provide consistent 
evidence for a reduction in total cerebral, cerebellar and basal ganglia volumes, as 
well as reduced cortical thickness in several regions, in particular frontal lobe, parietal 
lobe and temporal lobe in children with ADHD compared to controls (Filipek et al., 
1997, Castellanos et al., 2002, Mostofsky et al., 2002, Hill et al., 2003, Durston et al., 
2004, Carmona et al., 2005, Shaw et al., 2006b, Shaw et al., 2007, Tremols et al., 
2008, Garrett et al., 2008, Wolosin et al., 2009, Qiu et al., 2009, Narr et al., 2009, 
Batty et al., 2010, Almeida et al., 2010, Nakao et al., 2011, Carrey et al., 2012, 
Almeida Montes et al., 2012, Frodl and Skokauskas, 2012). There is also interesting 
evidence to support the link between neuroanatomical abnormalities in children with 
ADHD and ADHD symptom severity (Castellanos et al., 2002, Sowell et al., 2003b, 
Mackie et al., 2007, Carmona et al., 2009, Depue et al., 2010a, Almeida et al., 2010, 
Almeida Montes et al., 2012) as well as the role of the normalisation of these 
structural differences in the remission and persistence of these symptoms (Castellanos 
et al., 2002, Mackie et al., 2007). Consistent evidence for smaller volume and area of 
the corpus callosum in children with ADHD compared to typically developing 
children has also been reported (Hill et al., 2003, McAlonan et al., 2007, Luders et al., 
2009, Cao et al., 2010, Roessner et al., 2004, Schnoebelen et al., 2010, Hutchinson et 
al., 2008). However, the key findings that are of particular relevance to ADHD are the 
structural abnormalities in prefrontal cortex, caudate and cerebellum, as these 
structures play an integral role in the executive functions that are impaired in ADHD 
and there is evidence that these abnormalities are linked to ADHD behaviour and 
persistence (Castellanos et al., 2002, Mackie et al., 2007, Depue et al., 2010a). 
However, there are many caveats of the studies reviewed above; namely, the use of 
small, previously medicated, comorbid, mixed sex patient groups, as all of these 
factors have been shown to have an effect on brain structure (Shaw et al., 2009b, 
McAlonan et al., 2007, Luders et al., 2003, Cosgrove et al., 2007, Kanner, 1943). This 
highlights the need for more studies in this field that use homogeneous, one-sex, non-
comorbid and medication-naïve groups, as important but subtle structural differences 





2.2.2 – Brain Structure Abnormalities in ASD 
 
Leo Kanner described the presence of abnormally “large heads” in 5 of the 11 
case studies he reported in his seminal paper of 1943 (Kanner, 1943). This was the 
first, albeit qualitative, evidence that abnormal brain structure may be present in 
Autism. Further research into this area found that approximately 20-40% of young 
children with ASD can be classified as having macrocephaly, which is defined as a 
head circumference above the 97
th
 percentile (Acosta and Pearl, 2004, Mosconi et al., 
2006, Verhoeven et al., 2009, Stigler et al., 2011). However, it was not until the 
advent of sMRI that the biological basis of these findings could be investigated. 
 
A landmark paper by Courchesne et al showed that at birth 30 boys with Autism 
had a normal head circumference, but by age 2-4, 90% of the sample had a larger than 
normal brain volume with 34% being classified as macrocephelic (Courchesne et al., 
2001). Further research indicated that in boys aged 2-3 years old there was an increase 
in cerebral grey matter volume and white matter volume, 12% and 18% respectively, 
in addition to a 39% increase in cerebellar white matter. However, none of these 
abnormalities were present in the 30 older autistic boys, aged 12-16, who were also 
scanned. From these findings the authors proposed that Autism is characterised by a 
post-natal increase in brain growth which then slows down through development, 
leading to normalisation by adolescence. A number of studies have provided evidence 
for increased total brain volume (Sparks et al., 2002, Nordahl et al., 2012), and total 
grey matter volume (Calderoni et al., 2012), in children aged 2-7 with ASD which 
supports this hypothesis and is of particular interest as this overgrowth occurs at the 
same point in development that Autistic traits become apparent (American et al., 
1994). However, there is also evidence of increased brain volume, grey matter volume 
and white matter volume in some, but not all, adolescents and adults with ASD (Piven 
et al., 1992, Palmen et al., 2005, Hazlett et al., 2006, Brun et al., 2009, Freitag et al., 
2009) which questions the progressive normalisation that is proposed to occur with 
increasing age. This inconsistency draws to light the fact that more longitudinal 
studies are needed to clarify the developmental trajectory of the neuroanatomy of the 




Structural abnormalities have also been observed in children and adolescents 
with ASD. Increased total volume has been observed in the frontal lobe, particularly 
in the DLPFC (Waiter et al., 2004, Carper and Courchesne, 2005, Hazlett et al., 2006, 
Brun et al., 2009, Mitchell et al., 2009b, Stigler et al., 2011) as well as increased grey 
matter volume in mPFC, ACC, DLPFC and left superior frontal cortex (Waiter et al., 
2004, Bonilha et al., 2008, Calderoni et al., 2012) in both children and adolescents 
with ASD compared to controls. Furthermore, it has been observed in a cross-
sectional ROI study that this increased DLPFC volume was associated with increased 
Autism severity as assessed by the Autism Diagnostic Observation Schedule (ADOS) 
in both young children and adolescents with ASD (Mitchell et al., 2009b). However, 
decreases in grey matter volume in adolescents with ASD have also been reported in 
right orbitofrontal cortex (OFC), IFC and middle frontal cortex and the body of the 
cingulate cortex relative to controls (Kwon et al., 2004, McAlonan et al., 2005). This 
suggests that late developing areas such as DLPFC may be particularly abnormal in 
ASD and that this may be related to ASD symptoms. This is of particular relevance to 
this thesis because it is known that DLPFC is involved in WM (Wager and Smith, 
2003). 
 
It has also been shown that the cerebellum has a role in WM (Timmann and 
Daum, 2007) and the neuroanatomy of this area in ASD has long been a point of 
interest. An early sMRI paper reported decreased volume in cerebellar vermis lobules 
VI-VII in 18 children and adults with Autism, and although a few studies have been 
able to replicate this finding (Courchesne et al., 1988, Courchesne et al., 1994, 
Courchesne et al., 2001), several were unable to do so (Piven et al., 1992, Hashimoto 
et al., 1992, Holttum et al., 1992). This inconsistency may be due to the large age 
ranges that were used in some of the studies, and there may be subgroups within ASD 
that are characterised by either significantly larger (hyperplasia), or significantly 
smaller (hypoplasia), cerebellar vermi as evidenced in Courchesne et al (1994). 
Studies focusing solely on children and adolescents have found both increased 
(Sparks et al., 2002, Palmen et al., 2005, Bonilha et al., 2008) and decreased  total 
cerebellar volumes, grey matter volumes and white matter volumes compared to 
controls, as well as decreased total cerebellar vermis volume (Courchesne et al., 2001, 
Brun et al., 2009, Webb et al., 2009). These differing findings highlight the need for 
more research to be conducted separately in child, adolescent and adult populations of 
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ASD focusing on the cerebellum as a whole, as well as the vermis, in order to help 
advance our knowledge of this brain region and its role in ASD.  
 
The basal ganglia and thalamus are areas of the brain that are not often focused 
upon in ASD, despite evidence for their roles in restrictive and repetitive behaviours 
(Langen et al., 2011). However, an ROI study found increased total volume of the 
caudate in 38 children and adolescents with ASD compared to controls and this 
increased volume was correlated with poorer performance on the WCST, increased 
impulsivity and increased omission errors on the Continuous Performance Task 
(Voelbel et al., 2006). Decreased grey matter volume has also been observed in 
children and adolescents with ASD, relative to controls, in the caudate (McAlonan et 
al., 2005). With regards to thalamus structure, it has been found that total thalamus 
volume and grey matter volume in the right thalamus are significantly smaller in 
children and adolescents with ASD than in their typically developing peers (Tamura 
et al., 2010). It was also noted that this reduction in total volume was correlated with 
decreased ability to relate to people as assessed by the Childhood Autistic Rating 
Scale. These findings tentatively suggest that the structural differences present in the 
caudate and thalamus may play a part in the symptoms observed in ASD; however, 
many more studies are needed to support or refute this hypothesis.     
 
The structure of the parietal lobe, an area involved in sensory integration 
(Blakemore and Sirigu, 2003), has also been investigated in ASD. A whole brain 
study of 12 Autistic male adolescents observed increased grey matter volume and 
decreased white matter volume in the parietal lobe of adolescents with ASD compared 
to typically developing controls (Bonilha et al., 2008). However, a study of 17 
medication naïve, Autistic adolescents with no comorbidities found decreased grey 
matter in parietal lobe (McAlonan et al., 2005). 
 
Mixed findings have also been reported for the structure of the temporal lobe in 
children with ASD. Increased total volume (Waiter et al., 2004, Jou et al., 2010, Brun 
et al., 2009), in addition to increased (Bonilha et al., 2008, Waiter et al., 2004) and 
decreased (Kwon et al 2004) grey matter volume, and decreased white matter volume 
(Bonilha et al., 2008, Waiter et al., 2005) have all been observed in the temporal lobe 
of children and adolescents with ASD compared to controls. Whole brain sMRI of 
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children and adolescents with ASD have also found an increase in total volume of the 
fusiform gyrus (Waiter et al., 2004), as well as evidence for both increased (Waiter et 
al., 2004) and reduced (Kwon et al., 2004) grey matter volume in this area.  
 
Structures of the limbic system, which are found in the medial temporal lobe, 
have long been a point of interest with regards to ASD research due to their role in 
emotion processing (LeDoux, 2000) and the results from sMRI studies in children 
with ASD have shown relatively consistent results in these brain regions. Increased 
total volume of the amygdala, and faster growth, have been reported in young 
children with ASD compared to healthy controls (Sparks et al., 2002, Schumann et al., 
2004, Schumann et al., 2009, Nordahl et al., 2012). Furthermore, this amygdala 
overgrowth has been shown to be associated with greater social and communication 
difficulties (Munson et al., 2006, Schumann et al., 2009, Mitchell et al., 2009b), but 
better joint attention (Mosconi et al., 2009). Increased total volume of the 
hippocampus and decreased grey matter volume in entorhinal cortex have also been 
reported in children and adolescents with ASD relative to typically developing 
children. The increased volume of these structures may lead to increased anxiety and 
fear during social interactions in individuals with ASD. 
 
In addition to impaired limbic structure, abnormalities of the corpus callosum 
have also been observed in children with ASD, as reduced volume, thickness and 
surface area have been reported relative to controls (Waiter et al., 2005, Freitag et al., 
2009, Hong et al., 2011). Furthermore, there are consistent findings of decreased 
fractional anisotropy, which is a measure of how organised and directional the fibres 
in a tract are, in the corpus callosum of children with ASD compared to controls 
(Barnea-Goraly et al., 2001, Freitag et al., 2009, Noriuchi et al., 2010, Shukla et al., 
2011, Cheon et al., 2011, Wolff et al., 2012, Poustka et al., 2012). There is one study 
which showed increased fractional anisotropy in young children with ASD (Weinstein 
et al., 2011). However, this finding may be explained by the low mean age of 
Weinstein et al’s group, which was 3.2 years old, as it has been shown in other 
neurodevelopmental disorders that increased fractional anisotropy can be indicative of 
decreased branching (Silk et al., 2009b). Given this, it is likely that increased 
fractional anisotropy in young children with ASD is due to the decreased branching of 
the corpus callosal fibres in their immature brain rather than greater fibre organisation 
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and directionality. A meta-analysis of the abnormalities of the corpus callosum in 
ASD using 10 studies and a total of 253 children and adults with ASD and 250 
controls found decreased total area of the corpus callosum, with the rostral body 
showing the largest decrease (Frazier and Hardan, 2009). The studies above provide 
strong evidence for a decrease in the area and fibre organisation in the corpus 
callosum in children with ASD and suggest that aberrant inter-hemispheric 
connectivity may play a role in this disorder. 
 
Cortical thickness, on the other hand, produces relatively conflicting findings. In 
children and adolescents with ASD there is evidence for both increased (Hardan et al., 
2006, Hardan et al., 2009, Hyde et al., 2010, Jiao et al., 2010, Mak-Fan et al., 2012) 
and decreased (Wallace et al., 2010, Hyde et al., 2010, Misaki et al., 2012, Jiao et al., 
2010) cortical thickness in frontal, temporal and parietal lobes. These discrepancies 
may be due to the relatively small sample sizes, heterogeneity of the groups and large 
age ranges used. This highlights the need for more studies to be conducted in this area 
in order to elucidate whether there is an increase or decrease in cortical thickness in 
children and adolescents with ASD compared to controls. 
 
Although there are many caveats of the studies reviewed above, such as small 
sample size, mixed sex groups, medication use and large age ranges, they provide an 
intriguing insight into the structural abnormalities observed in children and 
adolescents with ASD. Findings of increased total cerebral, DLPFC and amygdala 
volumes have been reliably replicated in children and adolescents with ASD 
compared to their age matched peers (Sparks et al., 2002, Waiter et al., 2004, 
Schumann et al., 2004, Schumann et al., 2009, Hazlett et al., 2006, Munson et al., 
2006, Brun et al., 2009, Carper and Courchesne, 2005, Mitchell et al., 2009b, Stigler 
et al., 2011, Nordahl et al., 2012). Furthermore, these abnormalities have been linked 
to increased Autistic behaviours and are often found in younger children (Munson et 
al., 2006, Schumann et al., 2009, Mitchell et al., 2009b), suggesting that there is an 
important link between brain and behaviour that is established during the time when 
Autistic traits first become prominent (American et al., 1994).  There is also evidence 
to support the presence of a smaller total area of the corpus callosum and decreased 
fibre organisation, suggesting that connections between the left and right hemisphere 
are impaired in the brains of Autistic children (Barnea-Goraly et al., 2001, Waiter et 
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al., 2005, Freitag et al., 2009, Noriuchi et al., 2010, Hong et al., 2011, Shukla et al., 
2011, Cheon et al., 2011, Wolff et al., 2012, Poustka et al., 2012). A meta-analysis of 
the structural abnormalities present in ASD supports these findings as they also found 
increased volumes in total brain, but they failed to find increased total volumes of 
DLPFC and amygdala (Stanfield et al., 2008). However, this may be because this 
meta-analysis included both child and adult studies; it has been shown that the 
neuroanatomy of the Autistic brain can be very different in childhood, adolescence 
and adulthood (Courchesne et al., 2001). There is also evidence for decreased 
cerebellar vermis volumes in children and adolescents with ASD (Courchesne et al., 
2001, Brun et al., 2009, Webb et al., 2009), although the findings for total cerebellar 
volume and parietal and temporal lobe structural abnormalities are quite incongruent 
and require further investigation in order to disentangle where increased or decreased 
total, grey and white matter volumes are present. 
 
2.2.3 – Shared and Disorder-Specific Brain Structure Abnormalities 
in ADHD and ASD 
 
Only two studies have directly compared the neuroanatomy of children with 
ADHD, children with ASD and typically developing controls. One study found that 
both patient groups showed a reduction of grey matter volume in left hippocampus-
amygdala complex and an increase in grey matter volume in left inferior parietal 
cortex. They also observed that children with ASD showed a specific increase in right 
supramarginal gyrus grey matter volume relative to both controls and ADHD, but 
these findings did not survive correction for multiple testing (Brieber et al., 2007). 
This may be due to the fact that two of the children in the ASD group were on 
Risperidone and 10 of the ADHD children were taking methylphenidate (MPH). 
Furthermore, there was no difference between parent rated ADHD symptoms between 
the two patient groups which may account for Breiber et al’s findings not surviving 
multiple corrections. The only other to compare boys with ADHD and boys with ASD 
using sMRI found that with stringent multiple correction testing, ADHD boys showed 
disorder-specific decreased grey matter of the right posterior cerebellum compared to 
controls and ASD (Lim et al., 2013), and this is line with the consistent evidence for 
smaller cerebellar volumes in children with ADHD (Castellanos et al., 2002, Durston 
et al., 2004, Mackie et al., 2007). 
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2.3 – White Matter Integrity 
 
2.3.1 – White Matter Integrity in ADHD 
 
The structure and integrity of the tracts between each brain region is as 
important as the structure of the brain regions themselves as the brain is based on a 
series of neural networks which work collaboratively to provide information and 
guide behaviour (Kandel et al., 2000). 
 
A recent neuroimaging technique called diffusion tensor imaging (DTI) 
investigates the structure of the white matter tracts in the brain by analysing the 
diffusion of the water molecules in the axons (Basser et al., 1994). 
 
DTI research in children with ADHD has consistently reported decreased 
fractional anisotropy, indicating impaired white matter integrity, in fronto-striato-
cerebellar, fronto-parietal and fronto-limbic areas compared to controls, which is 
suggestive of delayed white matter maturation (Ashtari et al., 2005, Bechtel et al., 
2009, Hamilton et al., 2008, Nagel et al., 2011, Pavuluri et al., 2009, Konrad and 
Eickhoff, 2010, Liston et al., 2011). A small number of studies have found increased 
fractional anisotropy in fronto-striatal and parieto-occipital areas in children with 
ADHD relative to typically developing children (Silk et al., 2009a, Silk et al., 2009b, 
Davenport et al., 2010, Li et al., 2010, Tamm et al., 2012); this may be indicative of 
impaired branching of fibres, and therefore evidence of delayed white matter 
development, in children with ADHD.   
 
Furthermore, a recent meta-analysis supports the findings of decreased white 
matter integrity in children with ADHD compared to their typically developing peers 
in right anterior corona radiata, right forceps minor, bilateral internal capsule and left 
cerebellar white matter (van Ewijk et al., 2012).  This suggests that children with 
ADHD may have intact branching but poor integrity of important fronto-striato-
cerebellar tracts, leading to poor connectivity. This is of particular importance when 




2.3.2 – White Matter Integrity in ASD 
 
The theory of long range under-connectivity and short range over-connectivity 
in ASD was first brought to light in a Positron-Emission Tomography (PET) study by 
Horwitz et al in 1988 where it was observed that there were different metabolic levels 
between frontal and posterior regions (Horwitz et al., 1988). It was then formally 
postulated by Just et al (2004) and Courchesne et al (2005) who, by use of functional 
connectivity, observed decreased fronto-posterior connectivity in individuals with 
ASD compared to controls (Just et al., 2005, Courchesne et al., 2005). 
 
As DTI became more popular, studies were conducted in children and 
adolescents with ASD in order to elucidate whether there were connectivity 
abnormalities present at a structural level. As was theorised, poor white matter 
integrity was consistently reported in children with ASD. Decreased fractional 
anisotropy has been observed in a large number of brain regions and tracts in children 
and adolescents with ASD compared to controls, namely, frontal lobe, internal and 
external capsule, superior longitudinal fasciculus and uncinate fasciculus (Barnea-
Goraly et al., 2001, Sundaram et al., 2008, Noriuchi et al., 2010, Cheng et al., 2010, 
Shukla et al., 2011, Cheon et al., 2011, Wolff et al., 2012, Poustka et al., 2012). As 
the superior longitudinal fasciculus connects the posterior and anterior regions of the 
brain, consistent findings of its impaired integrity (Barnea-Goraly et al., 2001, 
Sundaram et al., 2008, Shukla et al., 2011, Poustka et al., 2012) provide compelling 
structural evidence  for this abnormality and complements the metabolic and 
functional connectivity abnormalities previously reported.  
 
2.4 – Overall Summary of Brain Structure Abnormalities in 
ADHD and ASD 
 
There are intriguing similarities and differences between the neuroanatomy and 
developmental trajectory of children with ADHD and children with ASD compared to 




One of the most striking potential differences between the two disorders is the 
way in which their neuroanatomy changes with increasing age. One of the key 
findings regarding the structural development of children with ADHD is that they 
have the same trajectory of cortical thickness development as their typically 
developing peers, but this development appears to be delayed by 2-5 years, in 
particular in frontal and temporal regions (Shaw et al., 2007). In contrast, one of the 
key findings regarding the structural development of ASD is that they have an 
aberrant developmental trajectory that involves a rapid period of brain overgrowth in 
young childhood followed by a period of decreased growth (Courchesne et al., 2001). 
However, no study has directly compared the developmental trajectories of these two 
disorders so at present no conclusions can be drawn about whether they differ in this 
area. 
 
Furthermore, there appears to be a decrease in total cerebral, frontal and caudate 
volumes in youths with ADHD compared to controls (Filipek et al., 1997, Overmeyer 
et al., 2001, Castellanos et al., 2002, Hill et al., 2003, Mostofsky et al., 2002, Sowell 
et al., 2003a, Durston et al., 2004, Carmona et al., 2005, McAlonan et al., 2007, 
Wolosin et al., 2009, Batty et al., 2010, Depue et al., 2010a, Nakao et al., 2011, Frodl 
and Skokauskas, 2012). Conversely, studies in children with ASD have shown an 
increase in the volume of these areas compared to controls (Sparks et al., 2002, 
Waiter et al., 2004, Hazlett et al., 2006, Voelbel et al., 2006, Brun et al., 2009, Carper 
and Courchesne, 2005, Mitchell et al., 2009b, Stigler et al., 2011). However, the only 
two studies to directly compare between ADHD and ASD found no significant 
differences in these regions (Brieber et al., 2007, Lim et al., 2013), but disorder-
specific decreased right posterior cerebellar grey matter has been reported in children 
with ADHD compared to both controls and ASD. 
 
There is also some evidence for potential similarities, as  both disorders have 
repeatedly shown that the corpus callosum is reduced in size, area, thickness and fibre 
organisation in children with ADHD relative to controls (Hill et al., 2003, McAlonan 
et al., 2007, Luders et al., 2009, Cao et al., 2010, Schnoebelen et al., 2010, 
Hutchinson et al., 2008), and children with ASD relative to controls (Barnea-Goraly 
et al., 2001, Waiter et al., 2005, Freitag et al., 2009, Noriuchi et al., 2010, Shukla et 
al., 2011, Hong et al., 2011, Cheon et al., 2011, Wolff et al., 2012, Poustka et al., 
56 
 
2012). DTI studies have also found that both disorders show poor white matter 
integrity in fronto-striatal tracts (Barnea-Goraly et al., 2001, Pavuluri et al., 2009, 
Cheng et al., 2010, Shukla et al., 2011, Nagel et al., 2011, van Ewijk et al., 2012). 
This highlights the potentially important role that impaired connectivity plays in both 
of these disorders, particularly in areas involved in motor response inhibition.  
 
Cortical thickness is an important structure in the brain and although there is 
evidence to support the presence of thinner frontal cortices and thicker motor and 
somatosensory cortices in children with ADHD compared to controls (Shaw et al., 
2007, Shaw et al., 2006b, Narr et al., 2009, Almeida et al., 2010, Almeida Montes et 
al., 2012, Duerden et al., 2012), it is extremely difficult to come to a conclusion on 
whether one would predict similar or different abnormalities in this construct if the 
two disorders were to be directly compared, due to the inconsistent findings of 
cortical thickness in children with ASD compared to controls (Hardan et al., 2006, 
Hardan et al., 2009, Wallace et al., 2010, Hyde et al., 2010, Jiao et al., 2010, Misaki et 
al., 2012, Mak-Fan et al., 2012)   
 
In conclusion, children with ADHD appear to be characterised by decreased 
volume in fronto-striatal-cerebellar areas, as well as temporal and parietal lobe, 
compared to controls (Filipek et al., 1997, Overmeyer et al., 2001, Mostofsky et al., 
2002, Castellanos et al., 2002, Hill et al., 2003, Sowell et al., 2003b, Durston et al., 
2004, Carmona et al., 2005, McAlonan et al., 2007, Wolosin et al., 2009, Batty et al., 
2010, Depue et al., 2010b, Nakao et al., 2011, Frodl and Skokauskas, 2012). Delayed 
developmental trajectory and reduced levels of cortical thickness in frontal, temporal 
and parietal lobe have also been reported (Shaw et al., 2006b, Shaw et al., 2007, Narr 
et al., 2009, Almeida Montes et al., 2012, Almeida et al., 2010, Duerden et al., 2012). 
In contrast, children with ASD appear to be characterised by a rapid overgrowth of 
the brain which leads to increased volume in fronto-limbic regions (Sparks et al., 
2002, Waiter et al., 2004, Schumann et al., 2004, Schumann et al., 2009, Carper and 
Courchesne, 2005, Hazlett et al., 2006, Munson et al., 2006, Brun et al., 2009, 
Mitchell et al., 2009b, Stigler et al., 2011, Nordahl et al., 2012). These potentially 
differing structural abnormalities are of relevance to this thesis as they may lead to 
differing functional abnormalities in each disorder. 
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3.1 – Introduction 
 
Functional magnetic resonance imaging (fMRI) is an aspect of neuroimaging 
which enables researchers to observe the activation of the brain either while the 
participant is at rest or while he or she performs a particular task in a magnetic 
resonance imaging scanner (Poldrack et al., 2011). 
 
This method of fMRI neuroimaging first became popular during the 1990’s and 
is based on the fact that when a part of the brain is activated, it needs more oxygen 
and glucose. The brain seems to overcompensate and send more blood to that area 
than is necessary for the increased glucose and oxygen extraction of the activated 
neurons.  The net effect of this mechanism is that areas that are activated have more 
oxygenated blood than areas that are not. This compensatory increase in blood, and its 
effect on the surrounding tissue, is known as the Blood Oxygenation Level Dependent 
(BOLD) effect, and this effect is integral for BOLD fMRI (Ogawa et al., 1990, Kim 
and Ugurbil, 1997). The BOLD effect is based on the magnetic properties of 
oxyhaemoglobin and deoxyhaemoglobin, as they are isomagnetic and paramagnetic, 
respectively. Therefore, deoxyhaemoglobin causes a perturbation in the magnetic 
field induced by the MRI scanner. This perturbation of the magnetic field affects the 
magnetic resonance of the protons in the water molecules surrounding the 
deoxyhaemoglobin and this change is detected by the MRI scanner (Turner et al., 
1998).  
 
The excellent spatial resolution of both sMRI and fMRI made them popular 
research tools for psychiatry. This is particularly the case for young, vulnerable 
patient groups who had been unable to take part in neuroimaging studies that required 
the injection of radioactive isotopes, such as PET or Single-Photon Emission 
Computed Tomography (SPECT) studies (Poldrack et al., 2011). These strengths of 
sMRI and fMRI led to a large increase in their use in children with ADHD and 
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children with ASD. Given that this PhD focuses on functions of WM, motor response 
inhibition, and cognitive flexibility, the literature regarding the use of fMRI in 
children and adolescents in these patient groups in these tasks will be reviewed in 
detail. Adult studies will only be reported when there is little research in children and 
adolescents in this field, which applies to fMRI studies of executive functions in 
ASD. The fMRI literature on other cognitive functions and functional connectivity 
will also be briefly reviewed.  
 
3.2 – Working Memory 
 
3.2.1 – fMRI of Working Memory in ADHD 
 
As mentioned in Chapter 1 there is strong neuropsychological evidence for a 
WM deficit in ADHD (Willcutt et al., 2005, Martinussen et al., 2005, Rapport et al., 
2008, Kasper et al., 2012) and it has been suggested that this deficit may be the key 
cognitive impairment in ADHD (Alderson et al., 2010). However, there have been 
surprisingly few fMRI studies focused on uncovering the neural correlates of this WM 
impairment in children and adolescents with ADHD.  
 
In healthy children and adolescents fronto-parietal networks are activated during 
tasks of WM and it has been reported that activation in these areas increases with high 
WM loads (Casey et al., 1995, Klingberg et al., 2002, Luna et al., 2010).  
 
Two whole brain fMRI studies focusing on spatial WM during a task of mental 
rotation found decreased activation in a group of seven, and a group of 12, medication 
naïve children with ADHD in areas such as bilateral IFC, left superior frontal cortex, 
caudate, right superior/inferior parietal lobe, right superior temporal lobe and right 
occipital lobe compared to controls. (Silk et al., 2005, Vance et al., 2007). Increased 
activation was also observed in default mode network (DMN) areas such as PCC and 
mPFC, as well as middle and superior temporal gyri (Silk et al., 2005). Silk et al also 





The DMN consists of a number of functionally connected, medially located 
brain regions, including mPFC, PCC, precuneus, inferior temporal lobe and inferior 
parietal lobe (Raichle et al., 2001, Sonuga-Barke and Castellanos, 2007, Northoff et 
al., 2010). These brain regions show spontaneous, low frequency (<0.1Hz) activation 
during rest (Greicius et al., 2003, Fox et al., 2005, Sonuga-Barke and Castellanos, 
2007, Northoff et al., 2010) and this DMN activation has been associated with 
stimulus independent, self-referential thought (Mason et al., 2007, Sonuga-Barke and 
Castellanos, 2007). It has been consistently reported that activation of this DMN is 
anti-correlated with brain regions involved in the performance of the task, indicating 
that when task positive networks are active, the task-negative DMN is deactivated 
(Greicius et al., 2003, Fox et al., 2005, Northoff et al., 2010). This occurs to enable 
effective completion of the task at hand and if there is poor deactivation of the DMN, 
a competition occurs between goal-directed behaviour and stimulus independent 
thoughts, leading to poor performance and attention lapses, presumably due to “mind 
wandering” (Sonuga-Barke and Castellanos, 2007, Northoff et al., 2010). 
Furthermore, it has been observed that the functional connectivity of the DMN 
increases with age, as does the ability to deactivate it during goal-directed 
performance (Power et al., 2010). Therefore, findings of poor deactivation in DMN 
areas in children with ADHD during a WM task is likely to reflect abnormalities with 
switching off task-irrelevant thinking (Silk et al., 2005).    
 
Two whole-brain fMRI studies using a delayed match to sample task reported 
decreased activation in right IFC, ACC and bilateral caudate during encoding and 
retrieval of information in a group of 10 girls, and a group of 12 boys, with ADHD 
compared to their typically developing peers (Sheridan et al., 2007, Prehn-Kristensen 
et al., 2011). Sheridan et al then investigated the correlation between reaction time 
and three ROIs in left ventrolateral prefrontal cortex (VLPFC), left DLPFC and 
primary motor cortex. It was observed that there was a significant correlation between 
faster information retrieval and increased VLPFC activation in the ADHD group and 
this correlation pattern was also evident in, but not significant for, DLPFC. 
Nonetheless, ADHD group RT-ROI correlations in VLPFC and DLPFC were 
significantly different from that of the control group where faster retrieval was 
correlated with decreased activation in these areas (Sheridan et al., 2007). Both 
studies used participants with a history of stimulant medication and Prehn-Kristensen 
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et al observed that after a 48hr washout period the ADHD group were significantly 
less accurate in their responses compared to controls. 
 
A visual serial addition task which tapped into WM processes found increased 
activation compared to controls in a group of 12 medicated adolescent ADHD 
participants after a 48 hour washout period in mPFC when using mPFC, PCC, 
precuneus and ACC as ROIs. No behavioural differences were reported between the 
two groups, however, it was observed that reaction time variability was positively 
correlated with ventromedial prefrontal cortex (vmPFC) activation and negatively 
correlated with superior mPFC activation in the ADHD group alone (Fassbender et 
al., 2009). Another study by the same group using the same paradigm and mainly the 
same participants showed increased activation in right IFC, insula and right putamen 
in 13 children with ADHD compared to controls in a whole brain analysis. However, 
an ROI analysis using inferior and middle frontal cortices showed decreased 
activation in ADHD subjects in left middle frontal cortex compared to controls. The 
only significant behavioural difference observed was that the ADHD group made 
more omission errors on the visual serial addition task than controls (Fassbender et 
al., 2011). Only one study in 14 children with ADHD used the classic verbal N-Back 
task and they observed that after a 24hr medication washout the ADHD children 
showed decreased activation in left precentral cortex, bilateral parietal lobe and right 
cerebellum compared to controls (Kobel et al., 2009). It was also noted that the 
ADHD group performed significantly worse on the 2-Back and 3-Back conditions 
compared to typically developing children (Kobel et al., 2009). 
 
There are large differences in the tasks and subject groups in each of these 
studies. Many used different WM paradigms which elicit activation in different brain 
regions; as it is known, for example, that spatial WM involves more right hemispheric 
brain regions and verbal WM more left hemispheric brain regions (D'Esposito et al., 
1998). In addition, the inclusion of mixed gender groups, co-morbidities and small 
sample sizes are all caveats when investigating neurofunctional abnormalities in 
ADHD during tasks of WM. The problems of including mixed gender groups in 
ADHD during a task of WM has been highlighted in an fMRI study on WM in a 
group of 44 adults with ADHD, of which 21 were female.  It was noted that the 
inclusion of females with ADHD, who showed no deficits relative to female controls, 
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overshadowed the differences observed in males alone in fronto-striato-cerebellar 
regions, which are key regions of dysfunction in ADHD. This highlights how crucial 
it is that single sex groups are tested in fMRI studies in order to increase homogeneity 
and understand brain differences according to gender (Valera et al., 2010). 
Nonetheless, taking these caveats into account, it can be concluded that during tasks 
of WM, children and adolescents with ADHD have decreased activation in vital areas 
for WM such as right IFC, bilateral caudate and bilateral parietal lobe as well as 
decreased deactivation in the DMN, in particular mPFC, both of which may play a 
role in the poor task performance observed in some of the studies (Vance et al., 2007, 
Silk et al., 2005, Sheridan et al., 2007, Prehn-Kristensen et al., 2011, Kobel et al., 
2009, Fassbender et al., 2009, Fassbender et al., 2011).  
 
3.2.2 – fMRI of Working Memory in ASD 
 
Although the evidence for WM deficits in ASD is not as robust as those for 
ADHD, it has been reported that individuals with ASD have impaired WM (Williams 
et al., 2005, Steele et al., 2007, Geurts and Vissers, 2012). Despite these 
neuropsychological findings only one study has investigated the neural correlates of 
WM in children with ASD using fMRI (Silk et al., 2006). This whole brain fMRI 
study used the same mental rotation task that was used in children with ADHD to 
assess spatial WM (Silk et al., 2005, Vance et al., 2007). In  seven children who met 
the DSM-IV criteria for Autistic Disorder or Asperger’s a significant decrease in 
activation was reported in right IFC, right mPFC, ACC and  right caudate, while 
decreased activation in left DLPFC was just below significance, compared to controls. 
 
However, a small number of ROI fMRI studies in adults have attempted to 
uncover the neurofunctional underpinnings of the WM deficit in ASD (Luna et al., 
2002, Koshino et al., 2005, Koshino et al., 2008). Studies using a variation of the N-
Back task found decreased activation in a group of 14 High Functioning Autistics 
(HFA), and a group of 11 Autistic subjects, compared to controls in left DLPFC, left 
inferior/middle frontal cortex, left inferior parietal lobe and right superior/middle 
temporal lobe. It was also observed that individuals with ASD had increased 
activation in right superior/inferior frontal cortex, right superior/inferior parietal lobe, 
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left inferior temporal and left occipital lobe (Koshino et al., 2005, Koshino et al., 
2008).  
 
An ROI study using a delayed match to sample task, where subjects had to 
remember the location of a brief stimulus to the left or right of the centre of the screen 
(at 9, 18 or 27 degrees) and shift their gaze to the remembered location after a delay 
period of 1, 2, 4 or 8 seconds, observed decreased activation in right DLPFC and PCC 
in 11 Autistic adults compared to healthy adults (Luna et al., 2002). Autistic 
individuals were significantly less accurate in their eye movements compared to 
controls outside of the scanner. However, there was no scanner performance data, as 
eye tracking could not be performed in the scanner, and this is a large caveat of this 
study (Luna et al., 2002, Rajah and D'Esposito, 2005). 
 
As the majority of these studies used adults, only tentative hypotheses can be 
drawn about how many of these deficits would be present in the child and adolescent 
ASD population, as it has been previously shown that brain activation in children and 
adults differ in tasks of WM (Rajah and D'Esposito, 2005, Luna et al., 2010). 
Furthermore, the small number of studies in this field, the heterogeneity of the 
participants and the fact that most of the adult studies used ROI analyses (Luna et al., 
2002, Koshino et al., 2005) may lead to unclear and slightly biased results.   
 
However, after acknowledging these limitations it can be concluded that 
children with ASD have been shown to have decreased activation in right fronto-
striatal regions during tasks of spatial WM (Silk et al., 2006). Adults with ASD show 
decreased activation during verbal WM tasks in mainly left hemispheric areas such as 
left inferior/middle frontal cortex and inferior parietal lobe, as well as bilateral 
DLPFC, but exhibit increased activation in mainly right hemispheric areas such as 
right superior/inferior frontal cortex and right superior/inferior parietal lobe (Luna et 







3.2.3 – Summary of fMRI of Working Memory in ADHD and ASD  
 
Although there is limited fMRI knowledge of WM in both ADHD and ASD the 
studies reviewed above are still able to shed light on the potential neurofunctional 
abnormalities underlying the cognitive deficit in this domain in these disorders  
 
Both children with ADHD (Silk et al., 2005, Vance et al., 2007, Kobel et al., 
2009, Fassbender et al., 2011, Prehn-Kristensen et al., 2011), and children with ASD 
(Silk et al., 2006), have shown abnormal activation compared to controls in IFC, ACC 
and caudate during WM tasks.  
 
Abnormalities have also been reported in mPFC, with children with ADHD  
showing increased activation (Silk et al., 2005, Fassbender et al., 2009), and children 
with ASD showing decreased activation (Silk et al., 2006), during tasks of WM 
compared to controls.  
 
Decreased activation in parietal lobes and increased activation in PCC while 
performing tasks of WM has been reported in children with ADHD compared to 
typically developing youths (Silk et al., 2005, Vance et al., 2007, Kobel et al., 2009). 
However, there are too few studies in WM in children with ASD to discern whether 
this deficit is present in this patient group.   
 
Adults with ASD show a slightly different pattern of abnormalities during verbal 
WM tasks, with decreased left fronto-parietal activation, and increased right fronto-
parietal activation, being reported (Koshino et al., 2005, Koshino et al., 2008). It has 
been hypothesised that this increase in right hemispheric activation may be due to the 
adult ASD group viewing the verbal and facial N-Back stimuli as an object and 
therefore using less phonetic strategies, which would require less left brain activation, 
to view and encode the information (Koshino et al., 2005, Koshino et al., 2008). This 
has been supported by the differences in the laterality of the WM deficits during tasks 
of verbal WM in adults with ASD and spatial WM in children with ASD (Silk et al., 
2006). However, this needs to be corroborated by studies including verbal and spatial 




In summary, during WM there is evidence that children with ADHD (Vance et 
al., 2007, Silk et al., 2005, Sheridan et al., 2007, Prehn-Kristensen et al., 2011, Kobel 
et al., 2009, Fassbender et al., 2009, Fassbender et al., 2011) and children ASD (Silk 
et al., 2006) both have abnormal activation in a right hemispheric network involving 
important areas for WM such as IFC, mPFC, ACC and caudate. However it is not 
known whether these deficits are shared between the disorders. 
 
Adults with ASD have increased right hemispheric activation and it has been 
speculated that this increased activation may be compensation for the more left 
hemispheric deficits in inferior frontal cortices and parietal lobe during tasks of verbal 
WM (Koshino et al., 2005, Koshino et al., 2008). 
 
It is not possible to compare childhood and adult fMRI data due to the large 
differences in brain activation between children and adults during WM tasks (Rajah 
and D'Esposito, 2005, Luna et al., 2010). Therefore little can be said about potential 
differences and similarities in brain activation during WM given that there is only one 
fMRI study in children with ASD that assesses WM. 
 
3.3 – Motor and Interference Inhibition 
 
3.3.1 – fMRI of Motor Response Inhibition in ADHD 
 
Given the consistent evidence for deficits in motor response inhibition in ADHD 
(Oosterlaan et al., 1998, Rubia et al., 2001b, Rubia et al., 2007a, Nigg and Casey, 
2005, Willcutt et al., 2005, Lijffijt et al., 2005, Alderson et al., 2007, Adams et al., 
2008), a large amount of fMRI research has been conducted in order to discern 
whether there are neurofunctional abnormalities in the inhibitory network in the 
brains of children with ADHD. 
 
In healthy adolescents and adults performing tasks of motor response inhibition 
activation has most consistently been observed in IFC, supplementary motor area 
(SMA), ACC, subthalamic nucleus and caudate (Rubia et al., 2001a, Rubia et al., 
2003, Rubia et al., 2006, Rubia et al., 2007c, Aron and Poldrack, 2006, Chevrier et al., 
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2007, Simmonds et al., 2008, Chambers et al., 2009). Furthermore, linear, 
developmentally induced changes in neurofunctional activity during motor response 
inhibition have been reported. Increased activity in right IFC, ACC, OFC and caudate 
were observed in a linear pattern in healthy adults compared to healthy adolescents 
during successful motor response inhibition and this increased activity was related to 
better task performance. These findings suggest that there is a ‘frontalisation’ of 
neurofunctional activity during typical development which leads to better motor 
response inhibition with increasing age (Rubia et al., 2007c, Rubia et al., 2006, Bunge 
et al., 2002, Bunge and Wright, 2007). 
 
Both whole brain and ROI studies focusing on the Go/No-Go task in children 
and adolescents with ADHD found relatively consistent results (Durston et al., 2003, 
Durston et al., 2006, Schulz et al., 2004, Booth et al., 2005, Smith et al., 2006, Epstein 
et al., 2007, Suskauer et al., 2008, Mulder et al., 2008). Most studies found that 
children with ADHD exhibited decreased activation in task relevant frontal regions, 
such as ACC, SMA and inferior/middle/superior frontal cortex and key subcortical 
and posterior areas such as the caudate, putamen, thalamus and cerebellum, when 
compared to their typically developing peers (Schulz et al., 2004, Tamm et al., 2004, 
Booth et al., 2005, Durston et al., 2006, Smith et al., 2006, Epstein et al., 2007, 
Suskauer et al., 2008, Mulder et al., 2008). However, a minority of studies, using 
mainly ROI analyses, also provided evidence for increased activation in 
middle/superior frontal cortex and ACC during successful inhibition in children and 
adolescents with ADHD when compared to healthy controls (Durston et al., 2003, 
Schulz et al., 2004). However, the ADHD group in Schulz et al’s study had an upper 
age limit of 20 years old and a mean group age of 18, so their patterns of brain 
activation may be more akin to that of adults with ADHD. Furthermore, Durston et al 
used a small sample size of seven medicated ADHD children of mixed sex and 
subtype. Thus, the age of the participants in Schulz et al, and the heterogeneity of the 
participants in Durston et al, may account for their findings of increased activation in 
middle/superior frontal cortex and ACC which are contrary to the findings of 
decreased activation in these areas in the majority of studies (Tamm et al., 2004, 




There is also evidence for abnormal functioning of the temporal and parietal 
lobe in children and adolescents with ADHD during successful motor response 
inhibition in a Go/No-Go task (Durston et al., 2003, Durston et al., 2006, Tamm et al., 
2004, Schulz et al., 2004, Epstein et al., 2007, Suskauer et al., 2008). Studies have 
found increased activation in children with ADHD compared to controls in left 
inferior/middle temporal lobe and bilateral superior temporal lobe (Durston et al., 
2003, Tamm et al., 2004). However, other studies have found decreased activation in 
right inferior temporal lobe and the right temporo-parietal junction (Schulz et al., 
2004, Suskauer et al., 2008). Both increased (Schulz et al., 2004, Durston et al., 
2003), and decreased activation (Durston et al., 2006, Epstein et al., 2007) have been 
reported in bilateral inferior parietal lobe in children with ADHD compared to healthy 
children during a Go/No-Go task, making it difficult to hypothesise the direction of 
the brain dysfunction in these areas during this task. However, as temporal and 
parietal lobes are involved in visual-spatial attention (Colby and Goldberg, 1999, 
Rubia et al., 2007b, Zhang et al., 2009, Bisley and Goldberg, 2010) one can speculate 
that the abnormalities observed in these regions are due to the attentional demands of 
the task. 
 
Other areas that have shown altered neurofunctional ability during successful 
inhibition in a Go/No-Go task performed by children with ADHD compared to 
controls are rostral mPFC, precentral gyrus and occipital lobe (Durston et al., 2003, 
Tamm et al., 2004, Schulz et al., 2004, Booth et al., 2005, Smith et al., 2006, Suskauer 
et al., 2008, Mulder et al., 2008). 
 
As mentioned in Chapter 1, another classic paradigm for testing motor response 
inhibition is the Stop Signal task. Whereas the aforementioned Go/No-Go task 
requires the participant to either make or inhibit a response, the Stop Signal task 
requires the participant to inhibit a response that has already been triggered and is in 
the process of being made. Consequently, the inhibitory load present in the Stop 
Signal task is much higher than that of the Go/No-Go task, making the Stop Signal 
task a more focused paradigm for investigating motor response inhibition. For this 
reason, this task has been used in numerous fMRI studies to elucidate the 
neurofunctional underpinnings of the inhibitory impairment in ADHD (Rubia et al., 
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1999, Rubia et al., 2005b, Rubia et al., 2008, Rubia et al., 2010b, Rubia et al., 2011c, 
Pliszka et al., 2006).  
 
The majority of fMRI studies that have used the Stop Signal task have used 
children who are medication naïve, all diagnosed with the combined subtype of 
ADHD, all male, all right handed and who had no comorbidities apart from 
oppositional defiance disorder/conduct disorder (Rubia et al., 1999, Rubia et al., 
2005b, Rubia et al., 2008, Rubia et al., 2010b, Rubia et al., 2011c). These studies also 
used whole brain fMRI analyses. Consequently, it is not surprising that the use of 
these homogeneous groups in a challenging task of motor response inhibition has 
produced more consistent results than those using the Go/No-Go task (Schulz et al., 
2004, Booth et al., 2005, Durston et al., 2006, Epstein et al., 2007). 
      
During successful inhibition decreased activation has consistently been observed 
in children with ADHD compared to their typically developing peers in frontal-striatal 
brain regions, most prominently in the right IFC, right OFC, right mPFC, left DLPFC, 
bilateral caudate, thalamus and putamen (Rubia et al., 1999, Rubia et al., 2005b, 
Rubia et al., 2008, Rubia et al., 2010b, Rubia et al., 2011c). In some of these studies 
children with ADHD also showed increased activation, alongside reduced activation, 
during successful inhibition in a small cluster in SMA (Rubia et al., 1999) ACC and 
right DLPFC, when compared to controls (Pliszka et al., 2006). 
 
When combining the fMRI findings from the Go/No-Go task and the Stop 
Signal task in children with ADHD there is consistent evidence for reduced activation 
in right inferior/middle/superior frontal cortices, right OFC, mPFC, bilateral striatum 
and bilateral thalamus during successful inhibition compared to controls (Rubia et al., 
1999, Rubia et al., 2005b, Rubia et al., 2010b, Rubia et al., 2011c, Tamm et al., 2004, 
Booth et al., 2005, Durston et al., 2006, Smith et al., 2006, Epstein et al., 2007). These 
findings have been corroborated by two meta-analyses (Dickstein et al., 2006, Hart et 
al., 2013). Dickstein et al used 16 studies in their meta-analysis and when focusing on 
response inhibition decreased activation was observed in IFC, left parietal lobe, right 
caudate and bilateral ACC of individuals with ADHD compared to controls. Increased 
activation in ADHD patients was observed in medial frontal gyrus and left paracentral 
gyrus relative to controls. Hart et al’s is the most recent meta-analysis of fMRI 
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inhibition studies in ADHD, including 15 studies and a total of 187 individuals with 
ADHD and 206 controls, when focusing on motor response inhibition. The results 
were very similar to those reported by Dickstein et al, as consistently decreased 
activation across studies was observed in individuals with ADHD in right IFC, 
SMA/ACC, right thalamus and left caudate compared to controls. This suggests that 
there is consistent evidence for inferior and medial fronto-striato-thalamic deficits in 
children with ADHD during successful inhibition (Dickstein et al., 2006, Cortese, 
2012, Hart et al., 2013).  
 
Failed inhibition is when a subject makes an incorrect go response at any point 
during the stop trial. The subsequent stop signal then acts as feedback, informing the 
participant of their error. The brain activation observed during failed inhibition can 
enhance our knowledge of the neurofunctional underpinnings of error detection and 
performance monitoring. Activation in IFC, ACC, PCC and temporo-parietal regions 
have been consistently reported in healthy children and adults during motor inhibition 
failures and are considered part of an error detection and performance monitoring 
network (Rubia et al., 2003, Rubia et al., 2007c, Rubia, 2012, Li et al., 2006, Chevrier 
et al., 2007). Furthermore, frontal parts of this network such as IFC and ACC have 
been shown to increase in activation in a linear manner with increasing age (Rubia et 
al., 2007c, Velanova et al., 2008).  
 
Some studies have measured error detection in the Go/No-Go task. However, in 
ADHD our knowledge of the neurofunctional abnormalities in failed inhibition are 
based mainly on findings from the tracking Stop Signal task. This is because the 
tracking algorithm of the stop signal task ensures that participants fail to inhibit their 
response 50% of the time. Therefore there are a high number of failed inhibition trials 
to analyse, as well as an equal number of successful and unsuccessful trials to 
compare and contrast against each other (Logan et al., 1997).   
 
These studies show that deficits in inferior and medial fronto-striatal, but also 
thalamic, regions such as right middle/inferior frontal cortex, ACC, striatum and 
bilateral subthalamic nuclei are also present during failed inhibition (Rubia et al., 
2010a, Rubia et al., 2011c, Pliszka et al., 2006). However, as opposed to the evidence 
for deficits during successful trials, there is additional evidence for more posterior 
69 
 
deficits in right PCC, precuneus, and cerebellum, presumably mediating visual-spatial 
attention to saliency, given that errors are highly salient stimuli (Rubia et al., 2005b, 
Rubia et al., 2008, Rubia et al., 2011c). Thus, in addition to exhibiting decreased 
activation in key areas of inhibition, children with ADHD also exhibit decreased 
activation in performance monitoring networks when they fail to inhibit. 
 
In addition to these neurofunctional abnormalities, and despite the relatively 
small numbers of fMRI studies and hence reduced power for neuropsychological data 
analyses, several fMRI studies have shown that individuals with ADHD perform 
worse on these tasks as they make more commission and omission errors, have larger 
reaction time variability and longer SSRTs (Durston et al., 2003, Rubia et al., 2005b, 
Rubia et al., 1999, Rubia et al., 2008, Rubia et al., 2011c, Durston et al., 2006, Tamm 
et al., 2004, Schulz et al., 2004, Booth et al., 2005, Pliszka et al., 2006, Smith et al., 
2006, Epstein et al., 2007, Suskauer et al., 2008, Mulder et al., 2008). However, most 
fMRI studies report no differences in performance between groups due to the 
relatively small sample size of groups in fMRI studies. A sample size with 
approximately 20 in each group has been shown to provide adequate power in fMRI 
studies (Thirion et al., 2007) compared to neuropsychological studies which typically 
require larger sample sizes for adequate power.  
 
In order to gain further knowledge on the link between brain dysfunction and 
performance, many studies correlated brain activation with performance measures. 
From these investigations it was noted that in ADHD children increased activation in 
right IFC and right parietal lobe during successful motor response inhibition was 
linked to better accuracy and ability to distinguish targets from non-targets, 
respectively (Durston et al., 2006, Epstein et al., 2007).  It was also observed that in 
the ADHD group increased post-error slowing in the Stop Signal task was correlated 
with increased PCC activation during successful inhibition and activation in a 
performance monitoring network of left IFC and dorsomedial prefrontal cortex 
(dmPFC) during failed inhibition (Rubia et al., 2011c). Furthermore, correlations of 
brain activation and ADHD symptoms have shown that higher scores on the 
hyperactive/inattention subscale of the Strengths and Difficulties Questionnaire 
(SDQ) were correlated with lower activation in right IFC and PCC during successful 




As previously mentioned the use of small sample sizes, subjects with psychiatric 
comorbidities, large age ranges, mixed sex groups, history of previous medication and 
mixed subtypes are all caveats of the studies above, particularly those who used the 
Go/No-Go task (Durston et al., 2003, Schulz et al., 2004, Pliszka et al., 2006, 
Suskauer et al., 2008, Mulder et al., 2008).  
 
Despite these limitations some consistent brain abnormalities have been found 
when combining all studies that have investigated motor inhibition in children in 
ADHD. In conclusion, children with ADHD have deficits in a right lateralised fronto-
striatal-thalamic inhibition network during both successful and unsuccessful 
inhibition. However, these deficits extend into more posterior regions such as right 
PCC and right precuneus during unsuccessful inhibition (Rubia et al., 1999, Rubia et 
al., 2005b, Rubia et al., 2008, Rubia et al., 2010a, Rubia et al., 2011c, Tamm et al., 
2004, Booth et al., 2005, Durston et al., 2006, Smith et al., 2006, Epstein et al., 2007, 
Hart et al., 2013). 
 
3.3.2 – fMRI of Interference Inhibition in ADHD 
 
Another form of inhibition is interference inhibition, which requires the 
suppression of a predominant response in order for the subject to respond to a 
conflicting, non-dominant response. It can be assessed using a number of tasks, the 
most popular of which are the Stroop, the Simon and the Flanker task (Golden, 1978, 
Simon, 1990, Eriksen and Schultz, 1979). 
 
Studies in healthy adults and children have found that the inhibition of a 
prepotent dominant response, and the execution of a less dominant conflicting 
response, activates DLPFC, IFC, ACC posterior parietal lobe and anterior insula 
(Rubia et al., 2006, Christakou et al., 2009b, Derrfuss et al., 2005, Chevrier et al., 
2007, Nee et al., 2007). However, the pattern of brain activation elicited during 
interference inhibition differs with age as a linear increase in activation is observed in 
inferior frontal and temporo-parietal brain regions in healthy adults when compared to 
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typically developing children and adolescents (Adleman et al., 2002, Rubia et al., 
2006, Marsh et al., 2006, Wood et al., 2009, Christakou et al., 2009b). 
    
Findings of interference inhibition deficits have not always been consistent in 
ADHD (Homack and Riccio, 2004, Van Mourik et al., 2005, Lansbergen et al., 2007, 
Schwartz and Verhaeghen, 2008, Mullane et al., 2009). A number of studies, many of 
which have used medication naïve patient groups and whole brain fMRI analysis 
(Konrad et al., 2006, Smith et al., 2006, Rubia et al., 2009c, Rubia et al., 2011b, Rubia 
et al., 2011a), have researched the neural correlates of interference inhibition in 
children with ADHD using fMRI (Schulz et al., 2005, Vaidya et al., 2005, Konrad et 
al., 2006, Rubia et al., 2009c, Rubia et al., 2011b, Rubia et al., 2011a, Vloet et al., 
2010). 
 
 Focusing on brain activation during conflict trials in a Simon task, a spatial 
stimulus response task and a modified Flanker task, it has been observed that ADHD 
children show decreased activation in right SMA and ACC, left mPFC, left precentral 
gyrus, bilateral putamen, right inferior/superior parietal lobe and bilateral 
middle/superior temporal lobe, relative to typically developing children (Konrad et 
al., 2006, Rubia et al., 2009c, Rubia et al., 2011b, Rubia et al., 2011a, Vloet et al., 
2010). However, there have also been findings of no deficits (Smith et al., 2006). 
Both decreased (Vaidya et al., 2005, Rubia et al., 2011b) and increased (Schulz et al., 
2005) activation have been observed in bilateral IFC in children with ADHD during 
conflict trials compared to controls; however, the study reporting increased activation 
in this area has more limitations than those reporting decreased activation. The patient 
group in Schulz et al’s study consisted of only eight ADHD patients of mixed 
handedness, four of which are described as being in remission. Thus, the larger patient 
numbers and superior diagnostic criteria in Vaidya et al and Rubia et al’s studies 
make the relatively reproducible finding of decreased IFC activation in children with 
ADHD during interference inhibition more reliable than that of decreased activation 
(Vaidya et al., 2005, Rubia et al., 2011b). 
 
When focusing on six studies of interference inhibition, a recent meta-analysis 
including 100 ADHD patients and 114 controls found consistently decreased 
activation in ADHD individuals in left ACC, insula and parietal lobe and right 
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IFC/insula and caudate compared to controls (Hart et al., 2013). Compared to the 
motor inhibition findings from this meta-analysis, the neurofunctional abnormalities 
during interference inhibition in ADHD were more left hemispheric and did not 
involve the key areas for motor response inhibition, such as the SMA and thalamus. 
 
The performance data from these studies suggest that children with ADHD are 
impaired in behavioural measures of interference inhibition as it has been shown that 
they make significantly more errors and are less accurate in their responses than 
typically developing children (Konrad et al., 2006, Vaidya et al., 2005, Vloet et al., 
2010). 
 
 Correlating behaviour and brain activation during interference inhibition has 
shown that, in children with ADHD, an increased number of symptoms correlates 
with decreased activation in the basal ganglia and increased activation in left IFC 
(Schulz et al., 2005, Konrad et al., 2006, Rubia et al., 2011b), whereas better 
interference suppression is correlated with increased activation in left IFC, thalamus 
and middle temporal lobe (Vaidya et al., 2005).  
 
To conclude; during tasks of interference inhibition, children with ADHD show 
activation deficits in IFC, right SMA/ACC, bilateral putamen and temporo-parietal 
regions compared to healthy controls (Schulz et al., 2005, Vaidya et al., 2005, Konrad 
et al., 2006, Rubia et al., 2009c, Rubia et al., 2011a, Rubia et al., 2011b, Vloet et al., 
2010), with the left IFC, ACC and striatum being the most consistent areas of deficit 
across studies (Hart et al., 2013). 
 
3.3.3 – fMRI of Motor Response and Interference Inhibition in ASD 
 
While there is evidence for motor response inhibition deficits in individuals with 
ASD (Christ et al., 2007, Hill, 2004, Sanders et al., 2008, O'Hearn et al., 2008, 
Rommelse et al., 2011), and slightly more mixed evidence for interference inhibition 
deficits (Hill, 2004, Christ et al., 2007, Christ et al., 2011, Solomon et al., 2008, 
Adams and Jarrold, 2009, Robinson et al., 2009), only three studies have used fMRI 
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to uncover the neurofunctional basis of this executive dysfunction in individuals with 
ASD.  
 
Thus far, no study has tested the neurofunctional deficits of motor response 
inhibition in ASD children. However, one ROI study has tested interference inhibition 
in 22 children with HFA/Asperger’s using a Preparing to Overcome Prepotency task, 
which is similar to a Simon task.  While children with ASD performed this task, 
decreased activation was observed in bilateral middle/superior frontal cortex, bilateral 
superior parietal lobe, bilateral precuneus, left inferior parietal lobe and left premotor 
cortex, compared to controls. It was also observed that the patient group made 
significantly more errors than the control group on the incongruent trials. (Solomon et 
al., 2009). 
 
In adults with ASD, two whole brain fMRI studies have investigated motor 
response inhibition (Kana et al., 2007, Schmitz et al., 2006). During successful 
inhibition in a Go/No-Go task, 12 adults with HFA showed decreased activation in 
right insula, right IFC, right ACC and right premotor cortex compared to healthy 
controls (Kana et al., 2007). However, another study found that 10 adults with 
Asperger’s syndrome showed increased activation during optimal task performance in 
left IFC and OFC compared to their typically developing peers (Schmitz et al., 2006).  
 
The strengths of the studies mentioned above are that they were conducted on 
ASD individuals who were diagnosed using gold standard diagnostic tools, such as 
the ADI and the ADOS and that the participants had no comorbidities (Kana et al., 
2007, Schmitz et al., 2006, Solomon et al., 2009). However, most studies involved 
small patient groups with mixed sex and handedness and a number of the participants 
were on medication (Schmitz et al., 2006, Kana et al., 2007, Solomon et al., 2009). 
These limitations may explain the different results obtained by Kana et al compared to 
Schmitz et al (Kana et al., 2007, Schmitz et al., 2006). However, results from the child 
study of interference inhibition support the findings of decreased activation during 
inhibitory processes in individuals with ASD, particularly in frontal areas (Solomon et 




These caveats limit the reliability of the results obtained from these studies, but 
it has been observed that during successful motor response and interference inhibition 
children and adults with ASD show decreased activation in ACC, right IFC, bilateral 
superior/middle cortex and bilateral premotor cortex (Solomon et al., 2009, Kana et 
al., 2007). Increased activation in left IFC and left OFC has also been observed in 
adults with Asperger’s (Schmitz et al., 2006). However, the inconsistency of these 
findings in the adult literature highlights the need for further studies in this field.  
 
 3.3.4 – Summary of fMRI of Inhibition in ADHD and ASD 
 
One of the most consistent deficits in ADHD is that of motor response inhibition 
(Oosterlaan et al., 1998, Nigg and Casey, 2005, Willcutt et al., 2005, Lijffijt et al., 
2005, Alderson et al., 2007, Adams et al., 2008); consequently, a large proportion of 
ADHD fMRI research has focused on uncovering the neural correlates of this deficit. 
There is a large body of fMRI research investigating the brain dysfunction of children 
with ADHD during tasks of inhibitory control  (Durston et al., 2003, Durston et al., 
2006, Tamm et al., 2004, Booth et al., 2005, Schulz et al., 2005, Vaidya et al., 2005, 
Konrad et al., 2006, Smith et al., 2006, Epstein et al., 2007, Suskauer et al., 2008, 
Mulder et al., 2008, Rubia et al., 1999, Rubia et al., 2005b, Rubia et al., 2008, Rubia 
et al., 2009c, Rubia et al., 2010a, Rubia et al., 2011c, Rubia et al., 2011b, Rubia et al., 
2011a, Vloet et al., 2010). Despite the evidence for motor response and interference 
inhibition deficits in ASD (Hill, 2004, Christ et al., 2007, Christ et al., 2011, Solomon 
et al., 2008, Sanders et al., 2008, Robinson et al., 2009, Rommelse et al., 2011), 
surprisingly few studies have researched the underlying neurofunctional abnormalities 
of these impairments (Schmitz et al., 2006, Kana et al., 2007, Solomon et al., 2009). 
The studies that have investigated inhibition in ASD have used adults, apart from one 
study researching interference inhibition in children. (Solomon et al., 2009). It is 
therefore difficult to hypothesise potential differences or similarities in brain 
activation deficits between the two disorders. 
 
     Nonetheless, it has been observed that there is a right lateralised fronto-
striatal and temporo-parietal deficit in children with ADHD during successful motor 
response inhibition compared to controls (Rubia et al., 1999, Rubia et al., 2008, Rubia 
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et al., 2011c, Tamm et al., 2004, Booth et al., 2005, Vaidya et al., 2005). This has 
been confirmed in two meta-analyses which found predominately right hemispheric 
deficits in IFC, ACC/SMA and caudate/thalamus (Dickstein et al., 2006, Hart et al., 
2013). Children with ASD have also been shown to exhibit middle/superior fronto-
parietal deficits (Solomon et al., 2009). However, as these deficits are observed in 
only one study focusing on interference inhibition it is difficult to compare these 
findings to the wealth of fMRI literature on inhibition in children with ADHD.  
 
Adults with ASD appear to exhibit a similar pattern of dysfunction as children 
with ADHD when compared to their typically developing peers, as they too have 
decreased right frontal activation during motor response inhibition(Kana et al., 2007). 
This decreased activation is observed particularly in right ACC and right 
inferior/middle frontal cortex (Kana et al., 2007, Solomon et al., 2009), which has 
also been observed in children with ADHD (Rubia et al., 1999, Booth et al., 2005, 
Epstein et al., 2007, Hart et al., 2013). 
 
  However, ASD individuals have been shown to have left lateralised frontal 
abnormalities during successful inhibition, as an increase in activation in left IFC and 
left OFC has been reported in adults with ASD, and a decrease in activation in left 
premotor cortex and left parietal lobe in children with ASD compared to age matched 
controls during Go/No-Go and Preparing to Overcome Prepotency tasks, respectively. 
(Schmitz et al., 2006, Solomon et al., 2009).  
 
Adolescents with ADHD have also been shown to have consistent deficits in 
striatal activation during successful inhibition (Rubia et al., 1999, Rubia et al., 2005b, 
Durston et al., 2003, Booth et al., 2005, Epstein et al., 2007), which has so far not 
been reported to be abnormal in adults with ASD during successful inhibition in 
Go/No-Go tasks (Kana et al., 2007, Schmitz et al., 2006). However, there is only one 
study in children with ASD and so few studies in adults with ASD that hypothesising 
potential differences or similarities in brain abnormalities is not possible. 
 
As previously mentioned, the heterogeneity of the individual studies 
investigating the neural correlates of inhibition in ADHD and ASD, the wealth of 
research in this field in children with ADHD compared to individuals with ASD and 
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the difficulties in comparing adult and child studies mean that one cannot 
convincingly postulate about potential similarities and differences. While there is 
consistent evidence for ADHD children to have reduced frontal and striato-thalamic 
deficits during motor and interference inhibition, there is some preliminary evidence 
that children with ASD and adults with ASD also have abnormalities in frontal areas, 
but more in the left hemisphere (Schmitz et al., 2006, Solomon et al., 2009), while 
striato-thalamic deficits have not been observed. 
 
3.4 – Cognitive Flexibility 
 
3.4.1 – fMRI of Cognitive Flexibility in ADHD 
 
As mentioned in Chapter 1, cognitive flexibility is the ability of a person to 
make stimulus-response associations and adapt them based on feedback (Milner, 
1963) and this executive function can be assessed using tasks such as the WCST, 
Meiran Switch task and reversal learning tasks such as the ID/ED task of the 
CANTAB (Milner, 1963, Meiran, 1996, Robbins et al., 1994).  
 
During switching tasks, healthy children and adults activate IFC, DLPFC, ACC 
and parietal lobe (Derrfuss et al., 2005, Rubia et al., 2006, Loose et al., 2006, Ravizza 
and Carter, 2008, Christakou et al., 2009b). Developmental differences have also been 
observed during switching tasks, as it has been reported that healthy adults activate 
IFC, ACC, DLPFC, parietal lobe and basal ganglia more than typically developing 
children, and there is evidence for linear activation increase between childhood and 
adulthood (Casey et al., 2004, Rubia et al., 2006, Christakou et al., 2009b).  
 
However, in healthy adults, reward reversal learning recruits a slightly different, 
more medial network of brain regions, including mPFC, medial OFC and ACC, as 
well as VLPFC, and the striatum (O'Doherty et al., 2001, O'Doherty et al., 2003, 
Cools et al., 2002, Remijnse et al., 2005, Cohen et al., 2008, Kehagia et al., 2010). 
Only one ROI study has investigated the developmental trajectory of reversal learning 
and found that children and adolescents recruited VLPFC more during switching 
whereas adults recruited it more for rule representation (Crone et al., 2006). No 
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studies have used reward reversal learning paradigms in individuals with ASD, which 
is surprising given the vast amount of evidence for cognitive inflexibility in this 
patient group (Ozonoff et al., 1991, Ozonoff and McEvoy, 1994, Ozonoff, 1995, 
Ozonoff et al., 2000, McEvoy et al., 1993, Hughes et al., 1994, Bennetto et al., 1996, 
Coldren and Halloran, 2003, Verte et al., 2005, Yerys et al., 2007, Yerys et al., 2009, 
Yerys et al., 2012, Robinson et al., 2009, Van Eylen et al., 2011).  
 
Although both switching and reward reversal learning tasks tap into cognitive 
flexibility, the reward aspect of reward reversal learning elicits activation in areas of 
reward processing such as OFC and vmPFC (Rolls, 2000, O'Doherty, 2004). 
 
Despite the fact that cognitive flexibility is consistently impaired in ADHD 
(Kempton et al., 1999, Cepeda et al., 2000, Itami and Uno, 2002, Inoue et al., 2008, 
Oades and Christiansen, 2008, Marzocchi et al., 2008, Walshaw et al., 2010, Willcutt 
et al., 2005, Chamberlain et al., 2011), only a small number of studies have 
investigated the underlying neural substrates of cognitive flexibility in children with 
ADHD (Smith et al., 2006, Finger et al., 2008, Rubia et al., 2010b, Rubia et al., 
2010a).  Several whole brain fMRI studies used an fMRI adapted version of the 
Meiran Switch Task, which measures relatively simple visual spatial switching 
between horizontal and vertical spatial dimensions with only small loads on WM. 
These studies reported decreased activation in medication naïve ADHD children and 
adolescents in bilateral IFC, insula, superior temporal lobe, inferior parietal lobe and 
striatum compared to healthy control children (Smith et al., 2006, Rubia et al., 2010b, 
Rubia et al., 2010a). One study that used a reward reversal learning task in 14 children 
with ADHD after a 48 hour medication washout showed increased activation in the 
ADHD group in precuneus, right superior frontal and superior temporal cortices 
relative to healthy controls (Finger et al., 2008).  
 
These conflicting results may be due to the fact that reward reversal learning 
tasks activate areas of reward processing such as OFC and vmPFC which are not 
typically activated during switching tasks. Furthermore, the ADHD group in Finger et 
al’s study (2008) was previously medicated, of mixed sex and had a significantly 
higher IQ than the control group. The other fMRI studies of cognitive flexibility in 
children with ADHD used medication naïve, male only, IQ matched samples; these 
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strengths increase the reliability of their findings (Smith et al., 2006, Rubia et al., 
2010b, Rubia et al., 2010a), especially as it has been shown that there are 
neurofunctional differences between males and females with ADHD (Valera et al., 
2010). 
 
In summary, children with ADHD show consistent underactivation in fronto-
striatal and temporo-parietal brain regions during tasks of cognitive switching (Smith 
et al., 2006, Rubia et al., 2010b, Rubia et al., 2010a). However, more research is 
needed using reward reversal learning tasks to test whether the deficits during 
cognitive switching are also observed during reward reversal learning. 
 
 3.4.2 – fMRI of Cognitive Flexibility in ASD 
 
Despite the restrictive and repetitive behaviours observed in ASD, and the 
evidence for impaired switching and reversal learning (Geurts et al., 2004, Ozonoff et 
al., 2004, Verte et al., 2005, Sanders et al., 2008), only two whole brain studies have 
researched the neural substrates of cognitive flexibility in adults with ASD and they 
produced conflicting results (Schmitz et al., 2006, Shafritz et al., 2008). The switch 
task used by Shafritz et al involved shapes being shown one by one on the screen. The 
participants had to press one button every time they saw a target shape, and another 
button every time they saw a non-target shape. The target shape would switch 
between a triangle and a circle every after two runs and these switch trials were used 
to analyse brain activation during switching. Using this task, they found decreased 
activation in DLPFC, ACC, intraparietal sulcus, basal ganglia and insula in the left 
hemisphere when comparing 18 adults with HFA to typically developing adults. 
However, Schmitz et al (2006) found increased activation in right IFC and left mesial 
parietal cortex when comparing adults with HFA to controls during a visuo-spatial 
switch task. Only Shafritz et al (2008) observed a performance difference, finding that 
the HFA group were significantly less accurate in target-shift trials compared to their 
typically developing peers.    
 
Both studies have their strengths and weaknesses as Shafritz et al’s study had an 
ASD sample size of 18 with no comorbidities who had all been diagnosed using the 
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ADI and ADOS. However, the study was conducted on a mixed sex patient sample 
and one participant was taking psychotropic medication. Schmitz et al used a HFA, all 
male sample who were, right handed, medication naïve and had no co-morbidities. 
However, the patient sample consisted of only 10 HFA adults, only seven of which 
had been diagnosed using the ADI.  
 
Thus, one can tentatively conclude that during tasks of cognitive flexibility 
adults with ASD exhibit decreased activation in left fronto-striatal regions (Shafritz et 
al., 2008) with some evidence for increased activation in right IFC (Schmitz et al., 
2006). Surprisingly, no studies have used fMRI to investigate switching in children 
with ASD and no previous study has used a reward reversal learning paradigm in 
fMRI to elucidate the neural correlates of cognitive inflexibility in adults and children 
with ASD. This exposes a gap in the ASD fMRI literature and highlights the need for 
research to be conducted in this area.  
 
3.4.3 – Summary of fMRI of Cognitive Flexibility in ADHD and ASD 
 
Due to the small number of studies that have been conducted in order to 
elucidate the brain abnormalities present in ADHD and ASD during tasks of cognitive 
flexibility and reversal learning, and the incongruity of the results obtained, it is 
difficult to create a robust hypothesis.  
 
Nonetheless, children with ADHD exhibited bilateral fronto-striatal and 
temporo-parietal deficits compared to controls during tasks of cognitive flexibility 
(Smith et al., 2006, Rubia et al., 2010b, Rubia et al., 2010a), and while there is also 
evidence of a fronto-striatal deficit in adults with ASD, the decreased activation in 
these areas is more left lateralised (Shafritz et al., 2008). Another study found 
increased activation in right IFC in adults with HFA (Schmitz et al., 2006), which was 
not observed in youths with ADHD (Smith et al., 2006, Finger et al., 2008, Rubia et 
al., 2010b, Rubia et al., 2010a). Parietal dysfunction has been reported in both adults 
with ASD and children with ADHD; however, while it has been consistently shown 
that this dysfunction is a decrease in activation for children with ADHD (Smith et al., 
2006, Rubia et al., 2010b, Rubia et al., 2010a), there is evidence for both increased 
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and decreased activation in this area in adults with ASD (Schmitz et al., 2006, 
Shafritz et al., 2008). Children with ADHD also show deficits in temporal lobe 
activation during tasks of cognitive flexibility compared to their typically developing 
peers (Smith et al., 2006, Finger et al., 2008, Rubia et al., 2010b, Rubia et al., 2010a) 
and this deficit has not yet been reported in adult ASD studies.  
 
3.5 – Other Cognitive Domains 
 
3.5.1 – ADHD 
  
In addition to deficits in WM, inhibition and cognitive flexibility, individuals 
with ADHD have also shown to be consistently impaired in timing processes, 
including motor timing, time estimation, time discrimination and temporal 
discounting (Rubia et al., 2009a, Noreika et al., 2013). Deficits in attention functions, 
most prominently in selective and sustained attention, have also been observed 
(Losier et al., 1996, Willcutt et al., 2005, Pasini et al., 2007, Rubia et al., 2007a, 
Sonuga-Barke, 2003, Sonuga-Barke and Halperin, 2010) as have impairments in 
reward processing and sensitivity (Sagvolden et al., 2005, Luman et al., 2010). 
  
A small number of whole brain (Smith et al., 2008, Rubia et al., 2009a) and ROI 
(Vloet et al., 2010) fMRI studies have focused on the neural correlates of timing 
deficits in children with ADHD. Those that focused on time discrimination have 
reported decreased activation in ADHD children relative to controls in typical timing 
regions of right DLPFC, IFC, ACC, caudate and cerebellum (Smith et al., 2008, 
Rubia et al., 2009a, Vloet et al., 2010). Only one study has investigated the 
neurofunctional abnormalities present in ADHD children during temporal discounting 
and they observed reduced activation in vmPFC, striato-thalamic, parietal and 
cerebellar regions (Rubia et al., 2009a). A recent meta-analysis of timing processes in 
ADHD including 11 studies in 150 ADHD patients relative to 145 controls showed 
that individuals with ADHD exhibit consistently decreased activation in a 
predominantly left hemispheric timing network of left VLPFC, left parietal lobe and 




fMRI research has also been conducted in children with ADHD during tasks of 
sustained attention in order to elucidate the neurofunctional underpinnings of their 
impairment in this domain (Willcutt et al., 2005). These whole brain studies reported 
decreased activation in ventrolateral, ventromedial and dorsolateral prefrontal 
cortices, as well as in parietal lobe, striatum and thalamus, which are all involved in 
attention (Rubia et al., 2009b, Rubia et al., 2009d, Christakou et al., 2013). These 
results were corroborated by a recent meta-analysis which included 13 studies that 
investigated attention functions in individuals with ADHD and found consistently 
reduced activation in 171 patients with ADHD compared to 178 controls in right 
DLPFC, basal ganglia, thalamus and right inferior and superior parietal lobes (Hart et 
al., 2013).  
 
With regards to reward, surprisingly little fMRI research has been conducted in 
children with ADHD. Whole brain studies that have investigated rewarded sustained 
attention have reported reduced activation in PCC, precuneus and cerebellum, as well 
as increased OFC and temporal lobe activation in children with ADHD compared to 
controls (Rubia et al., 2009b, Rubia et al., 2009a). Decreased activation has also been 
observed in the ventral striatum of children with ADHD compared to controls during 
reward anticipation, and this neurofunctional abnormality was correlated with higher 
symptom scores as assessed by parents (Scheres et al., 2007). An ROI study also 
reported that during successful reward outcome, children with ADHD showed 
increased striatal activation compared to controls (Paloyelis et al., 2010).  
 
3.5.2 – ASD 
 
As stated in Chapter 1, children with ASD have difficulties in ToM. fMRI 
research focusing on the neurofunctional abnormalities present in children with ASD 
during tasks involving irony comprehension through vocal tone and facial expression, 
found decreased activation in typical areas of ToM such as mPFC (Gallagher and 
Frith, 2003, Gallagher et al., 2000, Vollm et al., 2006b), and increased activation in 
right inferior frontal lobe and bilateral temporal lobe compared to healthy controls 
when using whole brain and ROI analyses (Wang et al., 2006, Wang et al., 2007). 
Whole brain studies investigating ToM in adult ASD have reported decreased mPFC, 
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ACC, inferior OFC and amygdala activation in adults with ASD compared to age 
matched controls, as well as increased activation in superior temporal lobe (Baron-
Cohen et al., 1999, Mason et al., 2008, Kana et al., 2009, Schroeder et al., 2010). 
These studies provide evidence for the presence of abnormal activation in the neural 
ToM network (Gallagher and Frith, 2003, Gallagher et al., 2000, Vollm et al., 2006b) 
in both children and adults with ASD compared to controls.  
 
Whole brain (Manjaly et al., 2007) and ROI (Lee et al., 2007) studies 
investigating the neural correlates of ‘weak’ central coherence in adolescents with 
ASD during an embedded figures task found decreased activation in areas which have 
been shown to be involved in central coherence (Ferstl and Von Cramon, 2001, Ferstl 
and von Cramon, 2002), such as dorsal premotor regions, right superior parietal lobe, 
and left occipital lobe. A whole brain fMRI study of the embedded figures task in 
adults with ASD found decreased activation in bilateral parietal lobe and right DLPFC 
in addition to increased activation in right occipital lobe and inferior temporal lobe 
(Ring et al., 1999).  
 
Due to the impairments in social interaction in ASD, many studies have used 
passive face observation, face detection and face recognition tasks to elucidate the 
basis of this impairment. The fMRI studies that have investigated face observation, 
detection and recognition have consistently found individuals with ASD to have 
decreased activation in lateral fusiform gyrus, a key area of face processing 
(Kanwisher et al., 1997, Kanwisher and Yovel, 2006, Gauthier et al., 2000, Grill-
Spector et al., 2004), when compared to typically developing controls (DiCicco-
Bloom et al., 2006, Schroeder et al., 2010, Minshew and Keller, 2010). These 
intriguing results of decreased activation in the ‘fusiform face area’ are in line with 
the poor facial and emotion recognition abilities in individuals with ASD (Harms et 
al., 2010). However, it has been suggested that this decreased activation may be due 
to the fact that ASD individuals are less likely to look at the eyes of the face (Harms 
et al., 2010), as it has been shown that activation in the lateral fusiform gyrus 
increases with the amount of time spent looking at the eyes (Dalton et al., 2005, 




Recently, the fMRI literature in ASD has focused quite intently on the mirror 
neuron system (MNS). The MNS is a selection of neurons that fire both when you 
perform a goal directed action and when you observe a goal directed action being 
performed by someone else (Williams et al., 2006d, Williams et al., 2001, Perkins et 
al., 2010, Kana et al., 2010). It was first described in non-human primates (Gallese et 
al., 1996, Rizzolatti et al., 1996) and has been linked to empathy (Rizzolatti and 
Craighero, 2004, Kaplan and Iacoboni, 2006, Gazzola et al., 2006). The mediating 
regions in humans are premotor regions, IFC, superior temporal sulcus and inferior 
parietal lobe (Rizzolatti and Craighero, 2004, Iacoboni et al., 2005, Chong et al., 
2008, Kilner et al., 2009).  Due to the role of imitation in social development and 
interaction, in addition to the imitation difficulties observed in those with ASD, 
research has been conducted in order to test whether individuals with ASD exhibit 
abnormal activity in the MNS. These studies provide some evidence for decreased 
activation of the MNS, particularly IFC (pars opercularis), in children and adults with 
ASD compared to healthy controls during tasks of imitation and imitation observation 
(Williams et al., 2001, Williams et al., 2006a, Dapretto et al., 2006, Perkins et al., 
2010, Kana et al., 2010). However, further studies are needed to support these 
findings. 
 
3.5.3 – ADHD and ASD 
 
Despite the genetic, behavioural and cognitive overlap between ADHD and 
ASD (Rommelse et al., 2011) only one study has directly compared brain activation 
between children with ADHD, children with ASD and healthy control children 
(Christakou et al., 2013). During increasing loads of sustained attention, controls 
increased activation in DLPFC, while progressively decreasing activation in 
precuneus, the latter of which was thought to be representative of deactivation of the 
DMN. However, both patient groups exhibited decreased activation compared to 
controls in striato-thalamic regions, left DLPFC, pre and postcentral gyri and superior 
parietal lobe, as well as increased activation in the precuneus, which was thought to 
be indicative of impaired deactivation of the DMN. The decreased DLPFC activation 
was significantly greater in the ADHD group compared to the ASD group. 
Furthermore, the ASD group exhibited increased activation in the cerebellum 
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compared to both ADHD and controls boys, which was anti-correlated with DLPFC 
and presumably compensating for frontal deficits (Christakou et al., 2013). This 
seminal study has shed light on the shared and disorder-specific neurofunctional 
abnormalities in ADHD and ASD and highlights the need for more studies that 
compare these two overlapping disorders.  
 
3.6 – Functional Connectivity 
 
3.6.1 – Functional Connectivity in ADHD 
 
Functional connectivity is described as the temporal correlation of the time 
course of brain activation in physically remote areas of the brain (Poldrack et al., 
2011) and there has been increasing interest in this area in children and adolescents 
with ADHD.  
 
Studies that have investigated the functional connectivity of the brain in children 
with ADHD during rest have observed abnormal connectivity of the DMN compared 
to controls (Cao et al., 2009, Castellanos et al., 2009, Fair et al., 2010, Konrad and 
Eickhoff, 2010, Liston et al., 2011, Tomasi and Volkow, 2011, Sun et al., 2012). 
 
 It was therefore hypothesised that in children with ADHD, decreased 
attenuation of this network during task performance may account for some of the 
neurofunctional abnormalities that are observed in task-positive regions (Konrad and 
Eickhoff, 2010, Castellanos et al., 2009).  This hypothesis was investigated and it has 
in fact been shown that ineffective deactivation of the DMN is associated with more 
attentional lapses and worse performance in attention tasks in ADHD (Sonuga-Barke 
and Castellanos, 2007, Broyd et al., 2009, Konrad and Eickhoff, 2010, Christakou et 
al., 2013). 
 
Only a few studies have investigated functional connectivity in children with 
ADHD during task performance and they have reported decreased connectivity in 
fronto-striato-parieto-cerebellar networks during tasks of rewarded sustained 
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attention, interference inhibition and timing, and motor response inhibition, relative to 
controls (Rubia et al., 2009b, Vloet et al., 2010, Mulder et al., 2011). 
 
In conclusion, abnormal functional connectivity in the DMN has been observed 
in children with ADHD during rest, and increased activation of this network during 
task performance has been linked to abnormalities in task positive brain activation 
(Cao et al., 2009, Fair et al., 2010, Liston et al., 2011, Tomasi and Volkow, 2011, Sun 
et al., 2012, Konrad and Eickhoff, 2010, Castellanos et al., 2009). During tasks of 
timing and attention, decreased functional connectivity has been observed in fronto-
striato-parieto-cerebellar networks (Rubia et al., 2009b, Vloet et al., 2010, Mulder et 
al., 2011). This suggests that not only are children with ADHD impaired in particular 
brain regions but also in the functional inter-regional interconnectivity of these 
regions. 
 
3.6.2 – Functional Connectivity in ASD 
 
There have been many studies focusing on functional connectivity in ASD in 
order to provide further evidence for the theory of long range under-connectivity and 
short range over-connectivity in ASD. As mentioned in the previous chapter, there has 
been a lot of interest in connectivity in ASD, particularly because it has been observed 
that long range connectivity increases with age while short range connectivity 
decreases, suggesting that individuals with ASD show an immature pattern of 
functional connectivity (Fair et al., 2009). 
 
Due to the wealth of knowledge available on this topic various reviews have 
been published in order to clarify whether current research is consistent with the 
hypothesis of decreased long range connectivity and increased local connectivity in 
ASD (Minshew and Keller, 2010, Vissers et al., 2011, Kana et al., 2011, Philip et al., 
2012, Just et al., 2012). These reviews have found a general consensus in the literature 
confirming the presence of decreased long range functional connectivity between 
fronto-cortical regions, particularly fronto-parietal connectivity, in individuals with 
ASD, relative to controls, during tasks of planning, cognitive flexibility, social 
cognition and emotion processing. However, there was less evidence for the presence 
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of increased short range connectivity within neighbouring areas in the frontal lobe, in 
this patient group (Minshew and Keller, 2010, Vissers et al., 2011, Kana et al., 2011, 
Philip et al., 2012, Just et al., 2012).  
 
Furthermore, poor functional connectivity between frontal and parietal lobes has 
been linked to social impairment as measured by the ADI, while increased 
connectivity between the frontal eye field and dorsal ACC has been linked to higher 
levels of restrictive and repetitive behaviours (Vissers et al., 2011).  
 
When focusing on the literature regarding resting state functional connectivity in 
children and adults with ASD, decreased connectivity of the DMN has been reported 
compared to typically developing controls (Broyd et al., 2009, Minshew and Keller, 
2010, Vissers et al., 2011, Philip et al., 2011). Furthermore, the importance of this 
decreased resting state connectivity has been highlighted by a recent study in which 
abnormal resting state connectivity was used to correctly classify 89% of ASD 
adolescents in their sample when using machine learning (Anderson et al., 2011). It 
was noted that the most important connectivity areas for classification were the DMN, 
superior parietal lobe, anterior insula and fusiform gyrus (Anderson et al., 2011). 
 
Although there is a general consensus on decreased fronto-posterior connectivity 
during tasks of planning, cognitive flexibility, social cognition and emotion 
processing and decreased DMN connectivity during rest in individuals with ASD 
compared to controls, there are also studies that have found increased connectivity in 
the DMN during these same tasks (Turner et al., 2006).  
 
In summary, the current literature supports the hypothesis of decreased fronto-
posterior connectivity in ASD, relative to controls, during tasks of planning, cognitive 
flexibility, social cognition and emotion processing. However, there is limited 
evidence for the presence of increased frontal to frontal connectivity (Minshew and 
Keller, 2010, Vissers et al., 2011, Kana et al., 2011, Philip et al., 2012, Just et al., 
2012). The presence of under connectivity in the DMN during the resting state 
analysis has also been reported and the abnormalities in both functional and resting 
state connectivity have been linked to clinical symptoms of ASD (Minshew and 
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Keller, 2010, Vissers et al., 2011, Philip et al., 2012, Kana et al., 2011, Anderson et 
al., 2011). 
 
3.6.3 – Summary of Functional Connectivity in ADHD and ASD 
 
There is a large body of functional connectivity research in both ADHD and 
ASD and this has led to quite consistent results being obtained for each patient group 
(Castellanos et al., 2009, Cao et al., 2009, Rubia et al., 2009b, Fair et al., 2010, 
Minshew and Keller, 2010, Vloet et al., 2010, Konrad and Eickhoff, 2010, Liston et 
al., 2011, Anderson et al., 2011, Kana et al., 2011, Tomasi and Volkow, 2011, Vissers 
et al., 2011, Philip et al., 2012, Wong and Stevens, 2012). 
 
During tasks of executive functions children with ADHD show under 
connectivity in fronto-striato-parieto-cereballar networks compared to controls (Rubia 
et al., 2009b, Vloet et al., 2010) and children and adults with ASD show decreased 
connectivity in fronto-parietal regions during cognitive and social tasks (Minshew and 
Keller, 2010, Vissers et al., 2011, Kana et al., 2011, Philip et al., 2012, Just et al., 
2012). Thus, both children with ADHD and children and adults with ASD appear to 
exhibit decreased functional connectivity in fronto-parietal networks compared to 
controls. However, there is some evidence that children with ADHD have under-
connectivity in fronto-striatal and fronto-cerebellar networks. (Minshew and Keller, 
2010, Vissers et al., 2011, Kana et al., 2011, Philip et., al 2012, Just et al., 2012, 
Rubia et al., 2009b, Vloet et al., 2010). 
 
During the resting state, functional connectivity both in children with ADHD 
(Cao et al., 2009, Fair et al., 2010, Liston et al., 2011, Tomasi and Volkow, 2011, Sun 
et al., 2012, Konrad and Eickhoff, 2010, Castellanos et al., 2009) and children and 
adults with ASD (Minshew and Keller, 2010, Vissers et al., 2011, Philip et al., 2012, 
Kana et al., 2011, Anderson et al., 2011) have shown decreased connectivity of the 
DMN compared to controls. 
 
In summary, it appears as if children with ADHD and children with ASD both 
have deficits of under-connectivity in fronto-parietal regions during tasks with a high 
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cognitive demand and under-connectivity in the DMN during the resting state. 
However, children with ADHD have also shown decreased connectivity in fronto-
striatal and fronto-cerebellar networks, a deficit which has not been observed in ASD 
thus far (Cao et al., 2009, Fair et al., 2010, Liston et al., 2011, Tomasi and Volkow, 
2011, Sun et al., 2012, Konrad and Eickhoff, 2010, Castellanos et al., 2009, Rubia et 
al., 2009b, Vloet et al., 2010, Wong and Stevens, 2012, Minshew and Keller, 2010, 
Vissers et al., 2011, Philip et al., 2011, Kana et al., 2011, Anderson et al., 2011, Just 
et al., 2012). 
 
3.7 – Overall Conclusions 
 
This chapter has reviewed the abnormalities present in children with ADHD and 
children and adults with ASD during tasks of WM, inhibition, cognitive flexibility 
and in inter-regional functional connectivity. Due to study limitations (discussed in 
each section), as well as the lack of research in specific areas, particularly with 
regards to childhood fMRI studies in ASD, it is difficult to produce a hypothesis on 
the potential similarities and differences of brain dysfunction present in ADHD and 
ASD.  
 
However, taking these confounds into account, it has been reported that during 
tasks of WM, both children with ADHD and children and adults with ASD show 
decreased activation in IFC and parietal lobe relative to controls, although the 
laterality of this deficit differs between the two patient groups, with evidence 
suggesting that ASD individuals have more left lateralised brain dysfunctions. This 
evidence for decreased activation in key areas of WM in both disorders suggests that 
there may be similar neurofunctional deficits in ADHD and ASD underlying their 
cognitive impairments in this domain. However, a direct comparison between the two 
disorders is needed in order to ascertain whether there is a shared fronto-parietal 
dysfunction. It would also be of particular interest to see whether any laterality effects 
are observed in a direct comparison of a classic verbal WM task such as the N-Back, 
as previous research would suggest that children with ASD may show more left 
lateralised deficits (Koshino et al., 2005, Koshino et al., 2008). The N-Back has only 
been utilised once in an fMRI study of children with ADHD (Kobel et al., 2009) and 
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never in children with ASD. Therefore, the role of increasing WM load has rarely 
been investigated in these patient groups, and has never been directly compared. 
Consequently, it would be highly pertinent to assess whether deficits in DLPFC, a key 
area for the manipulation and storage information during WM, were present in 
children with ADHD and children with ASD with increasing WM load. Howover, it 
has previously been reported that increased sustained attention load did not lead to 
progressively increased activation in DLPFC in children with ADHD and children 
with ASD, relative to controls. Therefore, in this PhD an N-Back WM task was 
employed in the MRI scanner to investigate the potential shared and disorder-specific 
neurofunctional effects of increasing WM load in children with ADHD and children 
with ASD.   
 
During successful inhibition of a prepotent motor response decreased activation 
was observed in children with ADHD compared to controls in right lateralised 
inhibition networks of IFC, SMA/ACC, caudate and thalamus (Tamm et al., 2004, 
Booth et al., 2005, Durston et al., 2006, Epstein et al.,  2007, Smith et al., 2006, Rubia 
et al., 1999, Rubia et al., 2005, Rubia et al., 2010, Rubia et al., 2011), which are also 
the key areas of dysfunction found in a meta-analysis of 15 studies of motor inhibition 
(Hart et al., 2013). As there are no studies that have used fMRI to investigate motor 
response inhibition in children with ASD, only adult studies can be commented upon. 
Adults with ASD also exhibited decreased right frontal activation compared to 
controls in ACC and inferior/middle frontal cortices during motor response inhibition 
(Kana et al., 2007). However, it has also been shown that adults with ASD have 
increased activation in left IFC and left OFC during successful inhibition of a 
prepotent motor response (Schmitz et al., 2006). Due to the deficits in inhibition 
networks in children with ADHD (Hart et al., 2013), and the role of these inhibition 
networks in repetitive behaviours (Langen et al., 2011), it would be highly appropriate 
to use fMRI to directly compare the neurofunctional abnormalities present in motor 
response inhibition in children with ADHD and children with ASD. For this reason, in 
this PhD a tracking Stop Signal task was used in the MRI scanner to elucidate the 
potential shared and disorder-specific neural abnormalities of motor response in 




During tasks of interference inhibition, children with ADHD have shown 
decreased activation in inferior, and medial frontal,-striatal and temporo-parietal 
regions compared to healthy controls (Konrad et al., 2006, Schulz et al., 2005, Vaidya 
et al., 2005, Vloet et al., 2010, Rubia et al., 2009, Rubia et al., 2011a, Rubia et al., 
2011b), confirmed to be consistent across studies in a meta-analysis of 6 studies of 
interference inhibition (Hart et al., 2013). Children with ASD have also shown 
decreased activation in frontal and parietal regions compared to age matched controls 
during interference inhibition, but this deficit appears to be more left lateralised 
(Solomon et al., 2009).  
 
Relatively few studies have tested for cognitive flexibility. Compared to 
controls, children with ADHD and adults with ASD both exhibit IFC, DLPFC, striatal 
and parietal deficits; however, these deficits have been shown to be more left 
lateralised in adults with ASD (Shafritz et al., 2008) and more right hemispheric in 
ADHD (Smith et al., 2006, Rubia et al., 2009, Rubia et al., 2010). Children with 
ADHD have been shown to have decreased activation in temporal lobe, which has not 
been observed in ASD thus far (Smith et al., 2006, Rubia et al., 2010). The lack of 
fMRI research in children with ASD in this field is surprising, given consistent 
evidence for cognitive flexibility problems at the behavioural and cognitive level 
(McEvoy et al., 1993, Hughes et al., 1994, Ozonoff et al., 1991, Ozonoff and 
McEvoy, 1994, Ozonoff et al., 1995, Ozonoff et al., 2000, Bennetto et al., 1996, 
Coldren et al., 2003, Verte et al., 2005, Yerys et al., 2007, Yerys et al., 2009, Yerys et 
al., 2012, Robinson et al., 2009, Velazquez et al., 2009, van Eylen et al., 2011). The 
interesting similarities and differences between the neurofunctional abnormalities 
present in children with ADHD and adults with ASD suggest that a direct comparison 
is warranted between the two disorders in groups of similar age. In this PhD, a reward 
reversal learning task was used in fMRI to uncover the potential shared and disorder-
specific neural dysfunction of reward-associated cognitive flexibility in children with 
ADHD and children with ASD. 
 
When assessing functional connectivity it was observed that both children with 
ADHD and children and adolescents with ASD have under-connectivity in fronto-
parietal regions with ADHD children exhibiting this dysfunction during tasks of 
rewarded sustained attention and motor response inhibition (Rubia et al., 2009, Vloet 
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et al., 2010) and ASD individuals exhibiting this dysfunction during tasks of cognitive 
flexibility, planning, social cognition and emotion processing (Minshew and Keller, 
2010, Vissers et al., 2011, Kana et al., 2011, Philip et al., 2011, Just et al., 2012). In 
addition, both disorders show under-connectivity in the DMN during the resting state 
(Cao et al., 2009, Fair et al., 2010, Liston et al., 2011, Tomasi and Volkow, 2011, Sun 
et al., 2012, Konrad and Eickhoff, 2010, Castellanos et al., 2009, Rubia et al., 2009, 
Vloet et al., 2010, Wong and Stevens, 2012, Minshew and Keller, 2010, Vissers et al., 
2011, Philip et al., 2011, Kana et al., 2011, Anderson et al., 2011, Just et al., 2012). 
However, children with ADHD also exhibit decreased connectivity in fronto-striatal 
and fronto-cerebellar regions which has not been observed in ASD thus far. 
 
Although poor fronto-parietal connectivity has been observed in both disorders 
it is elicited more by tasks of attention and inhibition in ADHD and tasks of social and 
emotional understanding in ASD. However, this may be due to the research bias 
present in both conditions, which has focused more on executive functions in ADHD 
and on socio-emotional functions in ASD. It would be interesting to directly compare 
the two disorders to investigate whether fronto-parietal connectivity deficits were 
present in both patient groups in tasks that are relevant both to ADHD and ASD. 
Direct comparison of children with ADHD and children with ASD would also clarify 
whether both groups show poor connectivity of the DMN during rest. This is of 
particular interest because DMN connectivity increases with age, so poor connectivity 
is suggestive of an immature DMN (Fair et al., 2008, Power et al., 2010). In this PhD 
I will therefore also focus on testing for task-related DMN abnormalities in both 
disorders. 
 
In conclusion, during tasks of executive functions such as WM, cognitive 
flexibility and inhibitory functions, children with ADHD (Rubia et al., 1999, Rubia et 
al., 2008, Rubia et al., 2009, Rubia et al., 2010, Rubia et al., 2011, Tamm et al., 2004, 
Booth et al., 2005, Vaidya et al., 2005, Smith et al., 2006, Vance et al., 2007, Kobel et 
al., 2009) and children and adults with ASD seem to both have decreased activation in 
IFC and parietal lobes, but these deficits appear to be located more predominantly in 
the right hemisphere for children with ADHD (Rubia et al., 1999, Rubia et al., 2005, 
Rubia et al., 2011a, Rubia et al., 2011b, Silk et al., 2005, Booth et al., 2005, Vance et 
al., 2007)  and more predominantly in the left hemisphere for children and adults with 
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ASD (Silk et al., 2005, Koshino et al., 2005, Koshino et al., 2008, Kana et al., 2007, 
Shafritz et al., 2008). However, children with ADHD also exhibit decreased activation 
in the striatum and temporal lobe during tasks of motor response inhibition and WM, 
which has not been observed thus far in ASD (Rubia et al., 1999, Rubia et al., 2005, 
Rubia et al., 2010, Durston et al., 2003, Silk et al., 2005, Booth et al., 2005, Smith et 
al., 2006, Epstein et al., 2007, Fassbender et al., 2009).  
 
The only study to compare brain activation in these two disorders directly using 
fMRI was from our group. We showed that during a parametric task of sustained 
attention, the two patient groups shared deficits compared to controls in left DLPFC, 
striato-thalamic, superior and parietal brain regions. Also, both groups showed less 
deactivation of the DMN with increased sustained attention load relative to controls. 
However, ADHD boys were more impaired in left DLPFC activation relative to ASD 
boys while ASD boys appeared to activate more cerebellum compared to ADHD and 
control boys, which was anticorrelated with the frontal deficits, presumably to 
compensate for the deficits in DLPFC (Christakou et al., 2013). In conclusion we 
found relatively similar fronto-striato-thalamic and DMN deficits in both disorders, 
with more severe DLPFC deficits in ADHD and a disorder-specific fronto-cerebellar 
dysregulation in ASD. 
 
There are remarkably few fMRI studies which focus on executive functions in 
ASD (Luna et al., 2002, Koshino et al., 2005, Koshino et al., 2008, Schmitz et al., 
2006, Kana et al., 2007, Shafritz et al., 2008) and there are hardly any fMRI studies in 
children and adolescents (Silk et al., 2006, Solomon et al., 2009). The few existing 
studies have a number of limitations, including small sample sizes, inclusion of 
psychiatric co-morbidities, psychotropic medication and mixed sex groups, which are 
caveats also observed in many of the fMRI studies of executive function in children 
with ADHD. Small sample sizes reduce the power of the study to find subtle 
neurofunctional differences (Thirion et al., 2007), while psychiatric co-morbidities 
such as conduct disorder in ADHD (Rubia et al., 2010) and anxiety in ASD (White et 
al., 2009, Juranek et al., 2006) reduce the disorder-specificity of the findings of the 
study. It is known that psychotropic medication such as stimulants (Konrad et al., 
2007, Rubia et al., 2009b, Rubia et al., 2011b, Rubia et al., 2011c) and Selective 
Serotonin Reuptake Inhibitors (SSRIs) (Del-Ben et al., 2005, Murphy et al., 2009, 
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Murphy S.E, 2010) have both short and long acting neurofunctional effects which 
may affect fMRI results. It is also known that there is substantial sexual dimorphism 
in the brain (Cosgrove et al., 2007, Sacher et al., 2012), particularly during 
development (Giedd and Rapoport, 2010, Sowell et al., 1999), so single sex or 
matched groups should be used in order to reduce the effect of sex on the results. 
However, the use of single sex groups is particularly relevant in ADHD and ASD, as 
in addition to typical sexual dimorphism, there is evidence to suggest that the clinical 
manifestation, cognition and neural correlates of these disorders differ between males 
and females (Lord et al., 1982, Arnold, 1996, Gaub and Carlson, 1997, Baron-Cohen, 
2002, Valera et al., 2010, Rivet and Matson, 2011). 
 
As mentioned in Chapter 1, there is a high level of co-morbidity between 
ADHD and ASD (Goldstein et al., 2004, Gadow et al., 2006, Simonoff et al., 2008, 
Rommelse et al., 2012), and neuropsychological studies investigating WM, inhibition 
and cognitive flexibility in these patient groups have found cognitive deficits in these 
domains in both children with ADHD (Cepeda et al., 2000, Inoue et al., 2008, 
Willcutt et al., 2005) and ASD compared to controls (Williams et al., 2005, Williams 
et al., 2006, Steele et al., 2007, Christ et al., 2007, Christ et al., 2011, Yerys et al., 
2009, Van Eylen et al., 2011).  
 
However, despite the surprisingly small number of fMRI studies on executive 
function in children with ASD, the caveats that are present in fMRI studies of 
executive function in children with ASD and children with ADHD, and the deficits in 
WM, inhibition and cognitive flexibility that are present in both disorders, there is 
only one study from our group which addressed these issues. Christakou et al (2012) 
used fMRI to directly compare a group of majority medication naïve, non-comorbid, 
age and IQ matched children with ADHD to children with ASD during a task of 
parametrically modulated sustained attention, finding both disorder-specific and 
shared brain dysfunctions. 
 
This highlights the need for more studies that use fMRI to directly compare the 
neurofunctional differences and similarities in tasks in which both disorders are 
impaired, such as WM, inhibition, attention and cognitive flexibility, in large single 
sex groups of children with ADHD and children with ASD who are free of psychiatric 
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comorbidities and psychotropic medication. Furthermore, the modifications to the up-
coming DSM-V, which allows co-diagnosis of these two overlapping disorders 
(http://www.dsm5.org), underline the importance of studies directly comparing 
homogenous groups of children with ADHD and children with ASD in tasks which 
are relevant to both disorders. Therefore, it is important for future studies to uncover 
the common and disorder-specific neurofunctional underpinnings of executive 
functions that are impaired in both disorders, as a better understanding of the 
differential neural correlates of these two complex and overlapping 
neurodevelopmental disorders may have the potential to improve both differential 
diagnosis and disorder-specific treatment. 
 
In this PhD, fMRI is used to scan 22 non-comorbid children with combined type 
ADHD and 22 non-comorbid children with ASD (either HFA or Asperger’s 
syndrome) while they performed a cognitive test battery involving an N-Back task, a 
Stop Signal task and a reward reversal learning task to investigate the neurofunctional 
differences and similarities in these two disorders that often exhibit overlapping 




















Chapter 4 – Serotonin and its role in ADHD and ASD 
 
4.1 – Introduction 
 
Serotonin, often known as 5-hydroxytryptamine (5-HT), was first discovered in 
the late 1930s by an Italian scientist who came across a molecule that was produced 
by enterochromaffin cells in the gut of the rabbit and caused smooth muscle and blood 
vessels to contract. He named the substance enteramine and began investigating the 
origins and function of this newly discovered molecule (Feldman et al., 1997, Sibley 
et al., 2007). In the 1940s, a group of American scientists were analysing the serum of 
clotted blood and were able to isolate a molecule that induced contractions in smooth 
muscle. They named this molecule “sero-”, due to the fact it was found in serum, “-
tonin”, due to the tonic effect it had on smooth muscle (Feldman et al., 1997, Sibley et 
al., 2007). After the molecular structure of 5-HT and enteramine were elucidated in 
1952, it was discovered that 5-HT and enteramine were in fact the same molecule, and 
in the present day, this molecule is normally referred to as 5-HT.  
 
The research amassed on 5-HT  indicated that 90% of the 5-HT in the body was 
present in the enterochromaffin cells of the gastric mucosa, 8-10% in platelets, and 
the rest was thought to be present in small amounts in blood vessels and smooth 
muscles (Feldman et al., 1997, Sibley et al., 2007, Rang et al., 2012). It took a number 
of years before the work from the Page laboratory was able to convince the scientific 
community that 5-HT was present in the brain as a neurotransmitter and it is known 
that only 1-2% of the 5-HT in our body is found in the brain (Feldman et al., 1997). 
Nonetheless, 5-HT plays a pivotal role in a large number of functions mediated by the 
brain, such as mood regulation, aggression, sleep, arousal, impulsivity, cognitive 
flexibility, memory and learning (Lucki, 1998). This chapter will cover the 
neurobiology of the serotonergic system and the pharmacokinetics of the SSRI 
Fluoxetine. The way in which Fluoxetine and other methods of 5-HT manipulation 
have been used to shed light on the role of 5-HT in WM, inhibition and cognitive 
flexibility in healthy individuals will be discussed, as will the evidence for 




4.2 – The Serotonergic System 
 
5-HT is an indolamine and its production is dependent on its amino acid 
precursor, tryptophan. As tryptophan is an essential amino acid, the body cannot 
create it and depends on our dietary intake of this molecule to create 5-HT (Feldman 
et al., 1997, Sibley et al., 2007, Rang et al., 2012). The biosynthetic pathway which 
leads to the production of 5-HT involves two important enzymes known as tryptophan 
hydroxylase and L-aromatic amino acid decarboxylase (Feldman et al., 1997, Sibley 
et al., 2007, Rang et al., 2012). Tryptophan hydroxylase is the rate-limiting step of the 
pathway and the amount of 5-HT produced is highly dependent on the rate at which 
this enzyme catalyses the reaction of tryptophan to 5-hydroxy-tryptophan. The 
catabolism of 5-HT is catalysed mainly by the A isomer of the mitochondrial bound 
monoamine oxidase (MAO) enzyme, which is also involved in the catabolism of other 
key monoamines such as dopamine and noradrenaline. The products of the reaction 
between MAO and 5-HT are further broken down by aldehyde dehydrogenase to give 
the final waste product of 5-HT, 5-hydroxyindole acetic acid (5-HIAA), which is 
excreted into the cerebral spinal fluid (Feldman et al., 1997, Sibley et al., 2007, Rang 
et al., 2012) (Figure 1). 
 
5-HT is the most widely dispersed neurotransmitter in the brain and its extensive 
neural projections are found in almost all regions (Sibley et al., 2007, Lesch and 
Waider, 2012). 5-HT production in the brain occurs mainly in the medulla oblongata 
and midbrain in nine clusters of 5-HT producing cells called nuclei. These nuclei are 
often referred to as B1-B9 and are split into the caudal and rostral system, with B1 
being the most caudal nuclei. The caudal system consists of B1-B4 and projects 
mainly to the spinal cord and medulla. The rostral system consists of B5-B9 and 
projects mainly to the brain. The cerebellum is innervated by a mixture of caudal and 
rostral projections as it receives neurons from B2, B3 and B5 (Tork, 1990, Feldman et 
al., 1997, Sibley et al., 2007). Due to the scope of this PhD the remainder of this 












The rostral system can be further divided into the dorsal raphe nucleus (DRN), 
which consists of B6 and B7, and the median raphe nucleus (MRN), which consists of 
B5, B8 and B9. The DRN contains approximately 165, 000 5-HT neurons, making it 
the largest collection of serotonergic neurons in the brain (Tork et al., 1990, Feldman 
et al., 1997). Neurons from the DRN project to the cerebral cortex, thalamus, caudate, 
putamen and nucleus accumbens. They also project to the substantia nigra and ventral 
tegmental area, highlighting the neuromodulatory role that 5-HT plays in dopamine 
release (Tork et al., 1990, Feldman et al., 1997, Sibley et al., 2007, Di Matteo et al., 
2008). The MRN also innervates the cerebral cortex, basal ganglia and thalamus, and 
it sends particularly large projections to the limbic system (Feldman et al., 1997, 
Sibley et al., 2007). There has been evidence to show that the OFC in particular is 
densely innervated by the serotonergic system and that 5-HT plays an important role 
in its function (Roberts et al., 2011). 
 
In addition to their slightly differing projections in the brain, the structure of the 
neurons emanating from the DRN and MRN also differ somewhat. Due to the large 
number of cells in the DRN, neurons from this area are the most common in the brain. 
These neurons have long, thin fibres which branch often and contain small 
varicosities along its length. Neurons from the MRN have much thicker fibres which 
branch less and have large, round varicosities (Figure 2). 
 
 
Figure 2 – Neurons of the dorsal raphe nucleus (small, thin arrows) and neurons of 




The varicosities on 5-HT neurons rarely make conventional synaptic 
connections and 60-80% of 5-HT undergoes non-synaptic release in what is known as 
volume transmission (Feldman et al., 1997, Sibley et al., 2007). Once 5-HT is 
released from serotonergic neurons, it can interact with a number of 5-HT receptors. 
There are currently 7 different classes and 14 different subtypes of receptor in the 5-
HT system, all of which are part of the G-protein coupled receptor family, apart from 
the 5-HT3 receptor, which is a ligand gated ion channel. As most of our knowledge 
regarding the receptors of the serotonergic system is founded on research into the 5-
HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptors, this section will review the role and 
function of these receptors only (Sibley et al., 2007, Rang et al., 2012). 
 
The 5-HT1 class of receptors is the largest and consists of 5-HT1A, 5-HT1B, 5-
HT1D, 5-HT1E and 5-HT1F. The 5-HT1A receptors act as negative feedback autoreceptors 
on the somatodendrites of the DRN and MRN and regulate chronic 5-HT release by 
hyperpolarising the neuron to reduce neuronal firing (Sibley et al., 2007, Di Matteo et 
al., 2008). They are present postsynaptically in the limbic system, particularly in the 
hippocampus, to further attenuate 5-HT release. Postsynaptic 5-HT1A receptors are 
also present on dopaminergic neurons in the ventral tegmental area and selective 5-
HT1A agonists lead to an increase in dopamine in the hippocampus and prefrontal 
cortex (Di Matteo et al., 2008). 
 
5-HT1B receptors, much like 5-HT1A receptors, are located both presynaptically 
and postsynaptically and can act as autoreceptors on 5-HT neurons and 
heteroreceptors on non-serotonergic neurons, respectively. There are a high number of 
5-HT1B receptors in the basal ganglia and ventral tegmental area and specific 5-HT1B 
activation decreases 5-HT in the hippocampus and frontal cortex, but increases 
dopamine in the striatum (Sibley et al., 2007, Di Matteo et al., 2008). 
 
The 5-HT2 class of receptors consist of 5-HT2A, 5-HT2B and 5-HT2C. 5-HT2A and 
5-HT2C receptors are mainly postsynaptic excitatory receptors and have quite an 
extensive distribution as they are found in most cortical regions in addition to the 
ventral tegmental area and choroid plexus. 5-HT2B has a slightly more restricted 
expression in the central nervous system and is found in high concentration in the 
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cerebellum (Sibley et al., 2007, Di Matteo et al., 2008). It has been shown that 
activation of 5-HT2A receptors can increase dopamine release in the mPFC. However, 
it is well known that 5-HT2C is the 5-HT receptor which plays the largest 
neuromodulatory role in dopamine-serotonin interactions in the brain, as activation of 
this receptor reduces both tonic and phasic dopamine release in the mesocorticolimbic 
system (Sibley et al., 2007, Di Matteo et al., 2008). 
 
It is evident that the 5-HT system extends into almost all regions of the brain, 
distributes 5-HT via the wide reaching method of volume transmission, and that its 
receptors play a large role not only in the regulation of 5-HT but of dopamine also 
(Tork et al., 1990, Feldman et al., 1997, Sibley et al., 2007). Therefore, it is not 
surprising that recent research has produced compelling evidence for the essential role 
of 5-HT in neurodevelopment (Daubert and Condron, 2010, Lesch and Waider, 2012). 
Cell culture research and animal studies have shown that 5-HT is required for the 
migration and transcription of important cell adhesion molecules, as well as the 
insertion of AMPA receptors, all of which are key for synaptic plasticity (Daubert and 
Condron, 2010, Lesch and Waider, 2012). Due to the dense serotonergic innervation 
of the limbic system it has been observed that this brain region and its involvement in 
emotional intelligence are particularly sensitive to changes in prenatal 5-HT levels 
(Daubert and Condron, 2010, Bonnin and Levitt, 2011, Lesch and Waider, 2012). 
This leads one to question the role of 5-HT in neurodevelopmental disorders such as 
ASD and ADHD, where there is a wealth of evidence for structural and functional 
brain abnormalities, as reviewed previously.  
 
4.3 – Selective Serotonin Reuptake Inhibitors 
 
Due to the role of the serotonergic system in mood regulation, the receptors and 
enzymes involved in this neurochemical pathway have long been a target of 
pharmaceutical manipulation in the quest for an effective medication for major 
depressive disorder (Wong et al., 1995). After the relative success of tricyclic 
antidepressants, which non-selectively increase 5-HT in the brain, pharmaceutical 
companies focused on designing a medication which specifically and selectively 
increased the amount of 5-HT present in the synaptic cleft of serotonergic neurons in 
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the brain (Wong et al., 1995, Goodnick and Goldstein, 1998). In 1972, using the 
structure of tricyclic antidepressants as their foundation, a lab at Lilly pharmaceuticals 
created a drug that was able to selectively inhibit the 5-HT reuptake transporter, 
leading to an increase in 5-HT in the brain. This drug was named Fluoxetine and was 
the first SSRI to be created (Wong et al., 1995) (Figure 3).  
 
Figure 3 - Chemical structure of Fluoxetine (Wong et al., 1995) 
 
The serotonin reuptake transporter (SERT) is a 12 transmembrane protein which 
is present in the presynaptic membrane of serotonergic neurons. Its role is to transport 
5-HT back into the neuron from the synaptic cleft so that it can either be broken down 
by MAO or repackaged into a vesicle for future release (Feldman et al., 1997, Murphy 
et al., 2004). The SERT relies on the binding of a sodium ion and a chloride ion in 
addition to the binding of protonated 5-HT in order to undergo the correct 
conformational change to transport these molecules back into the neuron. Once 5-HT 
has been effectively transported, a potassium ion binds to the SERT and is transported 
across the membrane into the synaptic cleft. This is essential, as it causes the SERT to 
express its binding site on its extracellular surface once more so it is able to bind with 
another 5-HT molecule, or an inhibitor such as Fluoxetine (Sghendo and Mifsud, 
2012). 
 
Following the creation of Fluoxetine, five other SSRIs were designed and these 
were named Paroxetine, Fluvoxamine, Sertraline, Citalopram and Escitalopram 
(Hiemke and Härtter, 2000). Although the main method in which these drugs exert 
their mood regulating effect is via inhibition of the SERT, they all have very different 




Fluoxetine is an equal mixture of two chemical stereoisomers named S-
Fluoxetine and R-Fluoxetine. Both S and R Fluoxetine molecules contain the exact 
same chemical composition observed in Figure 3, but the way in which their chemical 
groups are arranged in 3D space differ. Stereoisomers often differ in their 
pharmacological potency and selectivity, and it is known that S-Fluoxetine is slightly 
more potent and selective for the SERT than R-Fluoxetine (Wong et al., 1995, 
Goodnick et al., 1998, Hiemke and Harrter, 2000). Although Fluoxetine is easily 
absorbed, it takes between 5-8 hours for it to reach its peak in plasma and it has a 
half-life of between 1-3 days (Wong et al., 1995, DeVane, 1994, Catterson and 
Preskorn, 1996). This relatively long half-life has been attributed to the high level of 
tissue accumulation and plasma protein binding that Fluoxetine undergoes, as well as 
the fact that it inhibits the 2D6 isomer of the cytochrome p450 liver enzyme system 
responsible for its metabolism (Catterson and Preskorn, 1996, Sánchez and Hyttel, 
1999). 
 
N-demethylation, the removal of a CH3  methyl group from nitrogen, is part of 
the metabolism that Fluoxetine undergoes and this leads to the production of a 
metabolite called Norfluoxetine. Surprisingly, Norfluoxetine is a more potent and 
selective blocker of the 5-HT reuptake transporter than Fluoxetine, and S-
Norfluoxetine is significantly more efficacious than R-Norfluoxetine (Wong et al., 
1995, Sanchez et al., 1999, Hiemke and Harrter, 2000). Norfluoxetine also has a 
longer half-life than Fluoxetine, as it takes between 5-16 days for this metabolite to 
reach half its peak levels (Wong et al., 1995, Sanchez et al., 1999, Hiemke and 
Harrter, 2000). 
 
Fluoxetine is specific for the SERT and although it has some affinity for the 
noradrenaline reuptake transporter, the amount of Fluoxetine needed to inhibit the 
noradrenaline reuptake transporters by 50%, known as the inhibition constant or Ki, is 
significantly higher than the Ki for the 5-HT reuptake transporter. This means that the 
amount of Fluoxetine needed to significantly inhibit the SERT is too small to have a 
significant effect on the noradrenaline reuptake transporters both in in vitro and in 




It has been reported that Fluoxetine has an affinity for, and is an antagonist of, 
the 5-HT2C and 5-HT2A receptor (Stahl, 2009). The role that this antagonism plays in 
the clinical action of Fluoxetine has yet to be elucidated, but it has been postulated 
that it could have a role in the increase in noradrenaline and dopamine that has been 
observed in some animal studies despite no significant binding of Fluoxetine to the 
reuptake transporters of these monoamines (Stahl, 2009). 
 
This mechanism of Fluoxetine action has been quite popular as it provides a 
potential explanation for the 4-6 week delay in symptom improvement that is reported 
in individuals with depression who are on Fluoxetine (Wong et al., 1995, Stahl, 2009). 
However, recent reviews and meta-analyses have shown that symptom improvement 
can be observed after two weeks of SSRI treatment (Taylor et al., 2006, Papakostas et 
al., 2006). Furthermore, changes in response to emotional faces in healthy adolescents 
and young adult volunteers have been observed six hours after one acute dose of 
Fluoxetine (Capitao et al., 2012). This rapid effect after an acute dose of an SSRI can 
be linked to changes in brain activation. Decreased activation in the amygdala has 
been observed in fMRI studies focusing on the effect of an acute clinical dose of 
Citalopram on emotion processing after three hours in healthy individuals (Murphy et 
al., 2009). This provides further evidence for the swift action of SSRIs such as 
Fluoxetine, on both behaviour and brain function. 
 
Although Fluoxetine was initially created as an antidepressant, it has also been 
used to treat Obsessive Compulsive Disorder, anxiety disorders and eating disorders 
(Masand and Gupta, 1999). This has led researchers to question the role of 5-HT in 
cognitive processes such as inhibition, cognitive flexibility and WM. Furthermore, the 
relative safety and selectively of SSRIs compared to their predecessors, in addition to 
the fact that Fluoxetine is the only SSRI approved for use in children and adolescents, 











4.4 – Serotonergic Manipulation in Healthy Humans 
 
4.4.1 – Working Memory 
 
WM requires the temporary storage and manipulation of information and it has 
been observed that tasks of WM typically recruit the DLPFC and parietal lobe 
(Baddeley et al., 1997, D’Esposito et al., 1998, 2000). Studies that have focused on 
the effect that an increase in 5-HT has on WM have produced mixed findings. 
Neuropsychological studies using Escitalopram in healthy adults have found no effect 
on spatial WM (Wingen et al., 2007), while studies using tryptophan loading and 
fenfluramine challenge have found that it leads to poorer WM ability (Luciana et al., 
2001, Luciana et al., 1998). Acute tryptophan loading (ATL) and depletion (ATD) are 
popular methods of increasing and decreasing 5-HT respectively. They involve 
priming the body with a ratio of amino acids that will lead to an increase or decrease 
in tryptophan and therefore an increase or decrease in 5-HT, as dietary tryptophan is 
precursor of 5-HT synthesis (Mendelsohn et al., 2009, Silber and Schmitt, 2009). 
Fenfluramine is a molecule which increases 5-HT release by disrupting 5-HT 
containing vesicles in the neuron and reversing the effect of SERT. As 5-HT produces 
an increase in prolactin release from the pituitary gland, prolactin measurements are 
taken as a reflection of serotonergic function (Feldman et al., 1997). 
 
An fMRI study using Escitalopram to increase 5-HT in a group of 10 healthy 
adults while they performed an N-Back task found no differences in behaviour or 
whole brain activation. However, ROI analysis showed that Escitalopram led to a 
WM load dependent increase in activation in left IFC (Rose et al., 2006). 
 
Studies focused on elucidating the effect that a decrease in 5-HT has on WM 
have used ATD and they have found no effect of a decrease in 5-HT in WM ability in 
healthy adults (Mendelsohn et al., 2009, Harrison et al., 2004)(Harrison et al 2004, 
Mendelsohn et al 2009). However, an fMRI study using ATD has found that 
decreased 5-HT leads to decreased activation in right superior frontal cortex, and 
attenuation of PCC deactivation, during the 2-Back condition of the N-Back task. No 
behavioural differences were reported and this highlights the increased sensitivity of 
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fMRI to detect subtle changes between groups or conditions (Allen et al., 2006). A 
PET study investigating the binding potential of a 5-HT2A receptor antagonist in 
healthy males performing a WM task found increased binding potential in OFC which 
the authors suggest is indicative of the increased 5-HT uptake in this area during WM 
(Hautzel et al., 2011).  
 
A small number of genetic imaging studies have been conducted to assess the 
effect of serotonergic gene polymorphisms on WM, and the serotonergic genes that 
have received the most focus are the SCL6A4 gene, which codes for SERT; the 5-
HT1B gene, the TPH1 and TPH2 genes, which code for the two isomers of tryptophan 
hydroxylase; and the MAO genes (Murphy et al., 2004, Hahn and Blakely, 2007).  
 
There are a number of polymorphisms in the SCL6A4 gene, but the most 
intensely researched of these are the long (l) and short (s) alleles of the long 
polymorphic repeat (5-HTTLPR) region in this gene. The l allele leads to increased 
production of SERT and it is has been proposed that this leads to lower levels of 
synaptic 5-HT, whereas the s allele leads to decreased SERT production and therefore 
increased 5-HT levels (Murphy et al., 2004, Hahn and Blakely, 2007). There is also a 
variable number tandem repeat polymorphism in the SCL6A4 gene known as STin2 
and it has been reported that the 12 allele polymorphism of STin2 leads to increased 
transcription of SERT, which is proposed to lead to decreased levels of 5-HT 
(Murphy et al., 2004, Hahn and Blakely, 2007). 
 
In healthy women performing an N-Back task, increased activation in left and 
right IFC was observed, with increasing WM load, in women with the s/s genotype of 
5-HTTLPR compared to women with the l/l repeat. Women with the s/s alleles also 
performed poorer than women with the l/l alleles during the highest WM load 
(Jonassen et al., 2012). Genetic imaging studies have also investigated the effect of 
polymorphisms of the THP2 gene in a group of healthy adults while performing an N-
Back task and have found that individuals with the T/T polymorphism have increased 
activation in left DLPFC and parietal cortex with increasing WM load compared to 




These studies suggest that although an increase or decrease in 5-HT may not 
produce a behavioural effect that is observed in a laboratory setting, it may play a role 
in the activity of OFC, IFC and parietal lobe, all of which are involved in WM 
(D'Esposito et al., 1998, D'Esposito et al., 2000, Honey et al., 2000).   
 
4.4.2 – Inhibition and Impulsivity 
 
It is well known that 5-HT plays a role in impulsivity (Robbins et al., 2010).  
For this reason, a large proportion of research into 5-HT has focused on the effect that 
changes in 5-HT levels play in inhibition and impulsivity. It has been observed 
repeatedly that SSRIs lead to decreased impulsive aggression in children and adults 
with impulsive aggression, and that better response to SSRI treatment is associated 
with the l/l genotype of 5-HTTLPR (Coccaro and Kavoussi, 1997, Armenteros and 
Lewis, 2002, Silva et al., 2007, Butler et al., 2010). 
 
Studies focusing on an increase in 5-HT and its effect on motor response 
inhibition have found that Citalopram produces no behavioural differences in healthy 
adults during a Stop Signal task (Chamberlain et al., 2006). However, as with studies 
investigating 5-HT and WM, fMRI studies appear to produce quite different findings 
from neuropsychological studies; this may be due to the ability of fMRI to capture the 
subtle differences that are sometimes missed in neuropsychological studies.  
 
In a group of healthy adults it has been reported that administration of 
Citalopram increases activation in DLPFC and right lateral OFC during successful 
inhibition in a Go/No-Go task (Del-Ben et al., 2005). Increased activation of right 
lateral OFC has also been observed in healthy males during successful inhibition in 
the Go/No-Go task after administration of the 5-HT2C agonist mCPP, along with 
increased activation in caudate, superior and inferior temporal lobe and inferior 
parietal lobe (Anderson et al., 2002). Mirtazapine, an antidepressant which leads to 
increased noradrenaline and 5-HT, has also been shown to increase activation in right 
lateral OFC in healthy males during the successful inhibition in Go/No-Go task 
(Vollm et al., 2006a). Furthermore, it has been reported that daily Fluoxetine 
treatment for 12 weeks in adults with impulsive aggression leads to increased 
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metabolism in OFC and decreased aggression (New et al., 2004). This shows that 
there is consistent evidence that an increase in 5-HT leads to increased brain 
activation in key inhibition areas during successful inhibition.  
 
A study focusing on the effects of Citalopram while healthy adults lay in the 
scanner found increased activation in key areas of response inhibition such as the 
caudate, striatum and thalamus (McKie et al., 2005). This provides evidence for the 
modulating effect of SSRIs in areas of motor response inhibition in the absence of a 
task and it has previously been reported that SSRIs sequester in the thalamus (Smith, 
1999). 
 
 Neuropsychological studies investigating the effect of a decrease in 5-HT in 
inhibition have frequently used the Continuous Performance Identical Pairs task, 
where participants have to make a motor response if the number or shape shown on 
the screen is the same as the one before it. Studies employing this task have found that 
ATD leads to increased impulsivity, as evidenced by an increase in commission 
errors, and that this effect is increased if the participant has an s allele for 5-HTTLPR 
(Walderhaug et al., 2002, Walderhaug et al., 2010, Walderhaug et al., 2008). 
However, there is evidence that ATD does not affect motor response inhibition in 
healthy adults or aggressive adolescents and that it may even improve motor response 
inhibition (LeMarquand et al., 1998, Clark et al., 2005, Cools et al., 2005, Crean et al., 
2002).  
 
An fMRI study has shown that in a group of healthy adults performing a Go/No-
Go task ATD leads to decreased activation in right IFC, a key area of inhibition, and 
right OFC in addition to increasing activation in left superior and right middle 
temporal lobe during successful no-go trials (Rubia et al., 2005a). However, there 
have been findings of no changes in brain activation during successful inhibition in a 
Go/No-Go task after ATD (Evers et al., 2006); this may be due to the fact that Evers 
et al used only men, since it is known that women are more sensitive to the effect of 
ATD (Nathan et al., 2007). 
 
Lamar et al used fMRI to investigate the effect of ATD in a group of elderly 
women on a task of visuo-spatial interference inhibition. They found decreased 
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activation in left IFC, ACC and basal ganglia, as well as increased activation in 
parietal lobe and cerebellum (Lamar et al., 2009). Another study using the Stroop task 
to investigate the effect of ATD on interference inhibition in healthy adults found 
increased activation in mPFC, OFC and DLPFC (Horacek et al., 2005). These 
differing results may be due to the different tasks, age ranges and sexes used in the 
two studies and suggest that further research is needed to elucidate the effect of ATD 
on both motor response and interference inhibition. 
 
Genetic imaging studies have shown that healthy adults with the l/l allele for 5-
HTTLPR and MAO-A gene have decreased activation in ACC compared to carriers 
of the s allele and it was previously seen that this group of adults activated ACC 
during successful inhibition in a Go/No-Go task (Passamonti et al., 2008).  
 
There is considerable evidence to suggest an increase in 5-HT leads to increased 
brain activation in key inhibition areas during successful inhibition, and this is of 
particular interest with regards to ADHD where fronto-striatal deficits are consistently 
observed during tasks of motor response inhibition (Anderson et al., 2002, Del-Ben et 
al., 2005, Vollm et al., 2006a, Hart et al., 2013).  
 
4.4.3 – Cognitive Flexibility 
 
Animal studies have consistently shown that a decrease in 5-HT impairs 
cognitive flexibility, particularly during tasks of reversal learning, and this has led 
people to investigate the effect of 5-HT manipulation on cognitive flexibility in 
humans (Clarke et al., 2004, Clarke et al., 2008, Clarke et al., 2005, Clarke et al., 
2007, Masaki et al., 2006, Robbins, 2007). 
 
Relatively few studies have assessed the effect that an increase in 5-HT has on 
cognitive flexibility. However, one study of tryptophan loading found that an increase 
in 5-HT had no effect in healthy volunteers with low impulsivity, but impaired 
switching in individuals with high impulsivity during an attentional switch task 
(Markus and Jonkman, 2007). A study using Escitalopram in healthy individuals also 
found it had no effect on reversal learning (Wingen et al., 2007). However, the task 
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used by Markus et al involved other processes of executive function such as selective 
attention, which, together with the small sample used by Wingen et al, may account 
for these findings.   
 
Research into the association between cognitive flexibility and a decrease in 5-
HT has shown that during a task of reversal learning, ATD in healthy volunteers 
reduces their ability to learn new stimulus reward contingencies and slows responding 
(Rogers et al., 1999, Murphy et al., 2002). However, it has also been observed that 
ATD produces no effect or can improve performance in healthy volunteers 
performing a reversal learning task (Talbot et al., 2006, Evers et al., 2005, Cools et 
al., 2008). 
 
An fMRI study of ATD in healthy individuals performing a reversal learning 
task found that a decrease in 5-HT led to an increase in activation in dmPFC (Evers et 
al., 2005). The mixed findings in this field suggest that further research is needed in 
order to clarify the behavioural and neurofunctional effect that 5-HT manipulation has 
on cognitive flexibility. 
 
4.5 – Serotonergic Abnormalities in ADHD 
 
4.5.1 – The Dopamine Hypothesis of ADHD 
 
Due to the rapid ameliorative affect that MPH, a form of stimulant medication 
which exerts its effects by blocking the dopamine reuptake transporter (Volkow et al., 
1998), has in children and adults with ADHD, it has long been hypothesised that 
abnormalities of the dopaminergic system underlie the symptoms observed in this 
disorder (del Campo et al., 2011). Neuroimaging studies showing reduced dopamine 
binding in the striatum of medication naïve individuals with ADHD, as well as 
decreased activation in dopamine rich fronto-striatal areas during tasks of motor 





However, there is evidence that MPH is not effective in all cases and that it’s 
clinical efficacy wanes after 2-3 years (Jensen et al., 1997, Abikoff et al., 2004, 
Gualtieri and Johnson, 2008), suggesting that dopamine may not be the only 
neurotransmitter involved in the aetiology of ADHD. The first indication that 5-HT 
could be involved in the pathophysiology of ADHD came from the landmark paper by 
Gainetdinov et al (1999) in which dopamine knockout was used to induce a 
hyperdopaminergic state in mice, leading to hyperactivity. This hyperactivity was 
reduced by stimulants only when 5-HT was augmented, suggesting that the effect of 
stimulants in ADHD is mediated by 5-HT (Gainetdinov et al., 1999). As previously 
mentioned, dopamine and 5-HT are highly linked in the brain (Di Matteo et al., 2008) 
and there is consistent evidence to support the role of 5-HT in inhibition and 
impulsivity, both of which are diagnostic symptoms of ADHD (Coccaro and 
Kavoussi, 1997, Anderson et al., 2002, Armenteros and Lewis, 2002, Del-Ben et al., 
2005, Vollm et al., 2006a, Silva et al., 2007, Butler et al., 2010, Robbins et al., 2010). 
In spite of this, there is still a dopamine bias in the ADHD literature and there has 
been a call for a more holistic approach with regards to research into to the 
biochemical basis of this disorder (Oades, 2006, Oades, 2007, Oades, 2008, Oades, 
2010, Rastmanesh, 2010). Research that has investigated the role of the serotonergic 
system in ADHD has produced intriguing results and these shall be reviewed below.  
 
4.5.2 – Genetic 
 
ADHD is a highly heritable disorder and this has led to a large number of 
genetic studies being conducted in order to try and elucidate the susceptibility genes 
associated with ADHD and ADHD traits (Faraone and Biederman, 2005, Gizer et al., 
2009).  
 
A recent meta-analysis has reported an association between the l allele of 5-
HTTLPR and ADHD, suggesting that lower levels of 5-HT may play a role in ADHD 
(Gizer et al., 2009). This same meta-analysis also found an association between the 5-
HT1B gene and ADHD and this is of particular interest because the receptor that this 
gene codes for is involved in inhibition of 5-HT release and increase of dopamine 




A number of recent studies have provided further support for the hypothesis that 
there is a genetic link between serotonergic dysfunction and ADHD. Research into the 
role of 5-HTTLPR in delay aversion in children with ADHD found that ADHD 
children with the s/l genotype were the more delay averse (Sonuga-Barke et al., 
2011). Furthermore, it has been observed that children with ADHD who are 
homozygote for the l allele are the best responders to MPH treatment, and this 
highlights the importance of dopamine-serotonin interactions in ADHD (Thakur et al., 
2010).  
 
An association between the 5-HT1B gene, the 12 allele of the STin2 
transcriptional regulator of SERT and risk of ADHD has been observed. It has also 
been reported that this 12 allele of STin2 leads to poorer response to MPH medication 
in children with ADHD (McGough et al., 2009, Banerjee et al., 2012).  
 
An interest study focusing on genetic polymorphisms in the serotonergic system 
of mothers found that the children of women with TPH1 mutations were more likely 
to have ADHD symptoms, and this is in line with current research which highlights 
the importance of prenatal 5-HT in neural developmental (Halmoy et al., 2010, Lesch 
and Waider, 2012). 
 
4.5.3 – Biochemistry 
 
Due to the role of 5-HT in impulsivity and aggression, a number of studies have 
focused on the functioning of the serotonergic system in individuals with ADHD 
(Robbins et al., 2010).  
 
Fenfluramine challenge has been used by a small number of studies to 
investigate the activity of the serotonergic system in boys with ADHD. Increased 
prolactin levels, and therefore increased serotonergic responsivity, was observed in 
aggressive ADHD boys compared to ADHD boys without aggression (Halperin et al., 
1997). Another study found that serotonergic responsivity decreased over a period of 
2.5 years in a group of ADHD boys (Pick et al., 1999). However, one of the main 
112 
 
caveats of these studies is the lack of a control group as it makes it difficult to assess 
the relative importance of these findings. 
 
Research has also been conducted into 5-HIAA, which is the excretory product 
of 5-HT metabolism, in ADHD. Increased 5-HT metabolism (Oades et al., 1998, 
Oades and Müller, 1997) and a decreased dopamine:serotonin ratio (Oades and 
Müller, 1997), as evidenced by excretory metabolites in urine, have been reported in 
children with ADHD. Studies investigating cerebrospinal fluid and urinary levels of 
dopamine and 5-HT metabolites have also found correlations between these two 
neurotransmitters (Castellanos et al., 1994). This highlights the presence of 
serotonergic abnormalities in ADHD and its potential relationship to dopamine. 
 
Studies using ATD in male children with ADHD after a 24 hour medication 
washout period have found increased laboratory provoked aggression, as well as 
decreased heart rate, which was used as an indicator of increased aggression, in 
children with ADHD after ATD (Stadler et al., 2007, Zepf et al., 2009, Zepf et al., 
2008b). It has also been observed that ATD leads to an increased number of errors on 
the Go/No-Go task in ADHD children with high levels of aggression (Zepf et al., 
2008a). A recent study has reported a decrease in lapses of attention in children with 
ADHD, relative to controls, two hours after receiving ATD. However, these 
differences were no longer observed at approximately four and five hours after ATD, 
which suggests that 5-HT may modulate attention functions in a different way to 
impulsivity (Zepf et al., 2010).  
 
Measurements of platelet/whole blood 5-HT levels and MAO activity have been 
used in children with ADHD to assess the function of the 5-HT system. It has been 
shown that non-comorbid children with ADHD have significantly lower whole blood 
5-HT levels than ADHD children who are co-morbid with CD/ODD, and that there is 
a trend between lower levels of whole blood 5-HT and increased ADHD severity 
(Cook et al., 1995, Spivak et al., 1999). When non-comorbid, medication naïve 
children with ADHD are compared to healthy controls, there appears to be no 
difference in platelet 5-HT concentrations. However, a positive correlation was 




Research using Paroxetine binding to elucidate SERT binding on the platelets of 
children with ADHD found that decreased affinity was associated with poor inhibition 
on a Stop Signal task, suggesting that higher levels of 5-HT are associated with worse 
inhibition in ADHD (Oades et al., 2002). 
 
A study has shown that medication naïve, non-comorbid children with ADHD 
have significantly lower MAO-B activity than their typically developing peers (Nedic 
et al., 2009). However as MAO-B is involved in the catabolism of 5-HT, dopamine 
and noradrenaline it is best to view these findings as evidence of monoamine 
dysfunction in ADHD as opposed to solely serotonergic dysfunction. 
 
4.5.4 – Neuroimaging 
 
To my knowledge, only one SPECT study has assessed SERT binding in adults 
with ADHD using a dopamine transporter radioligand with moderate affinity for 
SERT. The thalamus and midbrain were used as 5-HT specific ROIs, and although no 
significant differences in binding were found in the ADHD group in these regions 
relative to controls, the authors acknowledge that the small sample size and poor 
specificity of the radioligand may account for their lack of findings (Hesse et al., 
2009). A SPECT study in children with foetal alcohol syndrome and ADHD found 
decreased 5-HT transporter binding in mPFC (Riikonen et al., 2005). However, as the 
main diagnosis of these children was foetal alcohol syndrome, the applicability of 
these findings to ADHD is limited. No fMRI study has ever investigated the role of 5-
HT in children or adults with ADHD and this highlights a large gap in the ADHD 
literature which future research should seek to fill. 
 
4.5.5 – Clinical Trials 
 
There has been little research focusing on the use of SSRIs or similar medication 
in children and adults with ADHD. However, promising results have been produced 




A study of 19 children and adolescents with ADHD who took a daily dose of 
20mg of Fluoxetine for six weeks after a two week stimulant medication washout 
found a significant improvement in Clinical Global Impression score as well as Parent 
and Teacher Conners’ scores. Furthermore, 68% of parents wanted to continue with 
Fluoxetine treatment (Barrickman et al., 1991). Similar findings have been reported in 
a study of Fluoxetine monotherapy in 30 children and adolescents with ADHD and a 
comorbid mood disorder. Subjects had a 1-2 week washout of their stimulant 
medication and children who weighed less than 40kg were given 10mg of Fluoxetine, 
and children over 40kg were given 20mg daily for 6-12weeks. It was reported that 
47% of participants showed a decrease in inattentive and hyperactive symptoms as 
well as decreased aggression. This was reflected by a significant reduction in the 
Conners’ Parent Rating Scale (CPRS), and 83% of the children chose to continue 
Fluoxetine monotherapy after the trial had finished (Quintana et al., 2007). 
 
Two studies have researched combined Fluoxetine and MPH medication in 
individuals with ADHD and co-morbid mood disorders. Gammon et al found that 
adding Fluoxetine to the normal MPH medication of 32 children for a period of 12 
weeks led to a 94% improvement in ADHD symptoms (Gammon and Brown, 1993). 
Findling et al also found that Fluoxetine and MPH improved ADHD symptoms. 
However, as they observed no change in ADHD symptoms under Fluoxetine alone, 
they attribute the reduction in ADHD traits observed during combined therapy to 
MPH (Findling, 1996). This lack of improvement during Fluoxetine monotherapy 
may be due to the small sample size and large age range of the group, as there were 
only eight people in the Fluoxetine-MPH arm of this study and the study included 
individuals from 10-44 years old (Findling, 1996). A study investigating the effect of 
combined Atomoxetine and Fluoxetine medication in children with ADHD and co-
morbid mood disorders observed that there was a significant improvement in both 
depressive and ADHD symptoms after five weeks of either Atomoxetine and placebo 
or Atomoxetine and Fluoxetine medication (Kratochvil et al., 2005). During the first 
three weeks of the study the participants were on either Fluoxetine or placebo only, 
but as the authors did not assess ADHD or depressive symptoms during this period of 
monotherapy, the effect of Fluoxetine alone cannot be compared to baseline or 




A small number of studies have been conducted to investigate the effect that 5-
HT and noradrenaline reuptake transporter blockers (SNRIs) have on individuals with 
ADHD. A study focusing on the effects of the antidepressant Duloxetine in 17 
children and adolescents with ADHD observed a significant improvement in scores 
on the CPRS (Mahmoudi-Gharaei et al., 2011). A case study on Duloxetine treatment 
in a 16 year old female with ADHD inattentive subtype (Niederhofer, 2010) and a 53 
year old male with ADHD (Tourjman and Bilodeau, 2009) yielded similar positive 
results, as did a case study of milnacipran treatment in an 24 year old woman with 
ADHD (Kako et al., 2007). Furthermore, a recent study in which the amino acid 
precursors of 5-HT and dopamine were given to children and adolescents with ADHD 
over a 8-10 week period reported that 67% of participants had a significant 
improvement in ADHD symptoms (Hinz et al., 2011). 
 
These studies highlight the ability of SSRIs and SNRIs to reduce ADHD 
symptoms to a clinically significant standard and it would be of great interest and 
relevance if future research focused on elucidating the neurofunctional underpinnings 
of this ameliorative effect produced by an increase in 5-HT.   
 
4.6 – Serotonergic Abnormalities in ASD 
 
4.6.1 – Genetic 
 
Although a recent meta-analysis focusing on the SCL6A4 gene in ASD found 
no association between polymorphisms in this gene and ASD, there are a number of 
other genetic studies which have found associations between ASD other serotonergic 
genes (Huang and Santangelo, 2008). 
 
It has been reported that polymorphisms of the 5-HT1B, 5-HT2A and 5-HT3A 
gene are associated with an increased risk for autism (Orabona et al., 2009, Hranilovic 
et al., 2010, Anderson et al., 2009), and single nucleotide polymorphisms in the TPH2 
gene have been associated with higher scores on the repetitive and stereotyped 
behaviours subscale of the ADI (Coon et al., 2005). Polymorphisms of the promoter 
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for the MAO-A gene, which leads to low activity, have been associated with 
increased total cortical volume in 2-3 year old boys with ASD (Davis et al., 2008).  
 
 Other genetic imaging studies focusing on the 5-HTTLPR have found that the s 
allele is associated with increased grey matter in the cerebral cortex of children with 
ASD, as well as poorer response to a 10 week course of Escitalopram and a 12 week 
course of fluvoxamine (Sugie et al., 2005, Wassink et al., 2007, Owley et al., 2010). 
Interestingly, children with ASD who possess the s allele also have more social and 
communication difficulties compared to ASD children with the l allele (Tordjman et 
al., 2001, Brune et al., 2006) and it has been shown that young adults with the s/s 
genotype have decreased metabolism in mPFC (Endo et al., 2010). However, it has 
been reported that children with the l/l genotype have more stereotyped behaviours, 
unusual sensory interest and increased aggression which is in line with the findings 
that lower levels of 5-HT are associated with aggression (Brune et al., 2006).  
 
Thus, although the SCL6A4 gene polymorphisms may not be associated with a 
risk for ASD, ASD is a heterogeneous condition so SCL6A4 polymorphisms such as 
those of 5-HTTLPR may be associated with particular structural and functional brain 
abnormalities that are present in some but not all individuals with ASD, and this may 
have led to mixed and insignificant results.   
 
4.6.2 – Biochemistry 
 
In 1961 a landmark paper by Schian and Freedman found that children and 
adolescents with ASD had higher levels of 5-HT in their blood (Schain and Freedman, 
1961). Since then, increased levels of platelet and whole blood 5-HT, known as 
hyperserotonemia, have been consistently reported in approximately 30% of 
individuals with ASD making this one of the most reproducible biological findings in 
Autism research (Ritvo et al., 1970, Anderson et al., 1987, Piven et al., 1991, Singh et 
al., 1997, Mulder et al., 2004, Hranilovic et al., 2009).  
 
This hyperserotonemia has been linked to Autistic behaviours such as speech 
and language difficulties, sensory interests and self-injurious behaviour, and 
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highlights the potentially important role that 5-HT dysregulation plays in ASD 
symptoms (Kuperman et al., 1987, Cuccaro et al., 1993, Hranilovic et al., 2007, 
Kolevzon et al., 2009). Furthermore, higher levels of 5-HT have been observed in 
individuals with ASD who have a sibling with ASD compared to individuals with 
ASD whose sibling does not have ASD, and this suggests that there may be a genetic 
component to the hyperserotonemia observed in ASD (Piven et al., 1991). 
 
A higher density of Paroxetine binding sites have been observed in the platelets 
of children and adolescents with ASD compared to controls suggesting an increased 
level of SERT (Marazziti et al., 2000, Croonenberghs et al., 2000). Lower plasma 
levels of tryptophan have also been reported in children with ASD compared to 
controls and this would be expected to lead to lower levels of 5-HT (Croonenberghs et 
al., 2000). A study investigating the effect of ATD in adults with ASD found that it 
increased ASD behaviours in 65% of the group and it was noted that patients with a 
higher 5-HT baseline responded worse to ATD (McDougle et al., 1996). An 
interesting study by Hranilovic et al separated a group of ASD adults into two groups, 
depending on whether hyperserotonemia was present. They then assessed the activity 
of SERT and MAO-B and found that individuals with ASD had significantly 
increased MAO-B activity compared to controls, and that this difference was more 
pronounced for ASD adults with hyperserotonemia (Hranilovic et al., 2009). 
 
Interestingly, it has been suggested that hyperserotonemia in pregnant women 
may lead to increased risk of their children developing Autism, which is in line with 
recent reviews highlighting the importance of prenatal 5-HT in neural development 
(Hadjikhani, 2010, Daubert and Condron, 2010, Lesch and Waider, 2012). 
 
4.6.3 – Neuroimaging 
 
Due to the wealth of genetic and biochemical evidence for serotonergic 
dysfunction in ASD, a number of neuroimaging studies have been conducted in order 





No fMRI study has investigated the effect of 5-HT manipulation in children 
with ASD. However, a SPECT study in children with ASD found decreased SERT 
binding in mPFC compared to their typically developing peers (Makkonen et al., 
2008). A PET study in children with ASD which investigated tryptophan uptake as an 
indicator of 5-HT synthesis found that 55% of Autistic children showed abnormal 
asymmetry in their uptake of tryptophan compared to their typically developing 
siblings and that this was driven mainly by the decreased tryptophan uptake in the 
frontal lobe of children with ASD. Interestingly, it was noted that autistic children 
with lower tryptophan uptake in the left cortex had higher levels of speech and 
language difficulties (Chandana et al., 2005). A similar PET study in children with 
ASD found age related differences in the trajectory of 5-HT synthesis capacity, as 
indicated by tryptophan uptake, compared to their typically developing siblings 
(Chugani et al., 1999). Another study from this group found abnormal asymmetry of 
5-HT in frontal cortex, thalamus and the denate nucleus of the cerebellum synthesis 
for children with ASD compared to their non-autistic siblings (Chugani et al., 1997). 
 
Adult studies have provided further evidence of serotonergic abnormalities in 
the brain of individuals with ASD. A recent study investigating the effects of ATD in 
adults with ASD during an emotional face processing task found that ATD had 
opposing effects in mPFC in adults with ASD compared to age matched controls 
(Daly et al., 2012). A case study on the neurofunctional and behavioural effect of a 12 
week course of Citalopram treatment on 2 HFA males found that the participant 
whose symptoms improved with treatment showed increased activation in left IFC, 
ACC and right postcentral gyrus during an oddball task (Dichter et al., 2010). 
 
A 16 week placebo controlled, cross-over trial of Fluoxetine in adults with ASD, 
in which PET scans were performed before and after Fluoxetine treatment, showed 
that Fluoxetine led to increased metabolic rates in right frontal lobe, ACC, OFC and 
striatum. This Fluoxetine induced increased metabolism was associated with 
behavioural improvement after Fluoxetine, showing that Fluoxetine has a positive 
behavioural and neurobiological effect in ASD (Buchsbaum et al., 2001).  
 
Furthermore, adult studies have found more wide reaching 5-HT receptor 
deficits, with one PET study finding reduced SERT binding in all 4 lobes of the brain 
119 
 
as well in the limbic system, basal ganglia and thalamus in a group of 20 young adult 
men with ASD compared to controls. In addition to this, reduced binding in the ACC 
and PCC was correlated with poor social interaction skills, while reduced thalamic 
binding was correlated with stereotyped and repetitive behaviours (Nakamura et al., 
2010).  
 
An adult study which used SPECT to assess 5-HT2A binding in young adult 
males with ASD found reduced binding in mPFC, ACC, PCC, bilateral frontal and 
superior temporal lobe and left parietal lobe. Reduced receptor binding was associated 
with abnormal social communication and this highlights the link between impaired 
serotonergic function and Autistic behaviours (Murphy et al., 2006). A recent PET 
study found no differences in 5-HT2A binding between ASD adults and controls 
(Girgis et al., 2011), but these conflicting findings may be due to the use of a different 
neuroimaging technique and radioligand. 
 
These studies provide strong evidence for the role of 5-HT in the abnormalities 
observed in the brains of individuals with ASD, and future research should focus on 
investigating the role of 5-HT in the neurofunctional ability of children with ASD.  
 
4.6.4 – Clinical Trials 
 
Research into the clinical efficacy of SSRIs in treating ASD has become quite 
popular due the evidence for serotonergic abnormalities in individuals with ASD and 
the effectiveness of Fluoxetine in treating Obsessive Compulsive Disorder and 
anxiety disorders which have similar symptoms to ASD (Masand and Gupta, 1999). 
 
Studies on the effect of Fluoxetine treatment in children with ASD have found 
that children showed improvements in language and social communication after 2-3 
years of taking 0.2mg-1.4mg/kg each day, with 50% of children being reported as 
having an overall good or excellent response (DeLong et al., 2002, DeLong et al., 
1998). Intriguingly, it was reported that positive treatment response was correlated 
with unusual intellectual achievement and familial history of affective disorder 
(DeLong et al., 2002). Similar improvements in social communication, stereotypies 
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and irritability has been reported in a study including children, adolescents and young 
adults on a dose range of 20-80mg daily for an average of 6-18 months (Cook et al., 
1992, Fatemi et al., 1998). A double-blind placebo controlled cross over trial of 
Fluoxetine, consisting of two 8 week phases with a 4 month washout period in 
between, found that a daily mean dose of 9.9mg was able to improve repetitive 
behaviours, as assessed by the Children’s Yale-Brown Obsessive Compulsive Scale, 
and was globally more effective than placebo (Hollander et al., 2005). A small, six 
month open label trial of Fluoxetine in young autistic children, with a peak dose of 
20mg, reported marked improvement on the Clinical Global Impression Scale, with 
decreased ritualistic tendencies and better social communication (Peral et al., 1999).  
 
Citalopram studies have found that a 12 week course of Citalopram with a mean 
dose of 16.5mg daily in children and adolescents with ASD led to a significant 
decrease in irritability, however it was also associated with increased energy levels as 
defined by Clincal Global Impressions Scale (King et al., 2009). Studies using long 
term courses of Citalopram, with a mean course duration of approximately 7 months 
and a mean dose of between 16.9-19.7mg daily, found that between 59%-73% of 
children were significantly improved in the domains of anxiety, aggression and mood 
using the Clinical Global Impressions Scale (Couturier and Nicolson, 2002, Namerow 
et al., 2003).  
 
There is a relatively large body of evidence to support the positive effect of 
Fluoxetine treatment in children with ASD and research focused on uncovering the 
neurobiological basis of this symptomatic improvement is very much needed.  
 
4.7 – Summary of Serotonergic Abnormalities in ADHD and 
ASD 
 
The only studies that have directly compared serotonergic function in children 
with ADHD and children with ASD are genetic studies, and results suggest that 
polymorphisms of the 5-HTTLPR may modulate ADHD and ASD severity alongside 
complex gene-environment interactions (Sinzig and Lehmkuhl, 2007, Nijmeijer et al., 
2009, Gadow et al., 2013). Genetic studies of ADHD (Gizer et al., 2009) and ASD 
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(Sugie et al., 2005, Wassink et al., 2007, Owley et al., 2010) individuals alone support 
the potential role of 5-HTTLPR polymorphisms in each disorder, and there is 
evidence that 5-HT1B may also be involved in both ADHD (McGough et al., 2009, 
Banerjee et al., 2012) and ASD (Orabona et al., 2009, Anderson et al., 2009, 
Hranilovic et al., 2010). However, many more studies that directly compare the role 
of key serotonergic genes in both ADHD and ASD are needed in order to assess 
whether there is any genetic overlap between the two disorders which may underlie 
their co-morbidity.  
 
Children with ADHD and children with ASD appear to have very different 
biochemical profiles with regards to 5-HT. While there is evidence for a link between 
decreased 5-HT and increased aggression, impulsivity, and ADHD severity in 
children with ADHD (Stadler et al., 2007, Zepf et al., 2009, Zepf et al., 2010, Zepf et 
al., 2008a, Zepf et al., 2008b), children with ASD have higher platelet and whole 
blood 5-HT levels, in addition to decreased SERT binding, and this appears to be 
linked to symptom severity (Ritvo et al., 1970, Anderson et al., 1987, Piven et al., 
1991, Singh et al., 1997, Mulder et al., 2004, Hranilovic et al., 2007). However, only 
30% of individuals with ASD have this hyperserotonemia, and it has been shown that 
ATD leads to an increase in Autistic symptoms (McDougle et al., 1996). Therefore, 
more research needs to be conducted to assess the level serotonergic dysfunction 
present in children with ADHD and children with ASD, separately as well as 
comparatively. 
 
To my knowledge, only two SPECT and no fMRI studies have been conducted 
on the effect of 5-HT manipulation on the brains of individuals with ADHD. 
Consequently, it is difficult to draw comparisons between the neurobiological 
differences observed in ADHD and ASD with regards to the serotonergic system. 
SPECT and PET studies in children with ASD have found decreased SERT binding in 
the mPFC as well as abnormal 5-HT synthesis and asymmetry in the brain (Chugani 
et al., 1999, Chugani et al., 1997, Chandana et al., 2005, Makkonen et al., 2008). No 
fMRI study has focused on the effects of an SSRI in children with ASD during an 
executive function task, but a case study in two young men with HFA have reported 
that Citalopram increases activation in left IFC and ACC during an oddball task 
(Dichter et al., 2010). This intriguing finding highlights the need for more research 
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focused on the neurofunctional effect of SSRIs in both children and adults with ASD, 
and it would be particularly interesting to directly compare the effect of an SSRI on 
brain activation in both ADHD and ASD. 
 
The need for research into the effect of SSRIs in both ADHD and ASD is further 
supported by the finding that SSRIs, particularly Fluoxetine, have a clinically 
significant effect in improving both ADHD (Barrickman et al., 1991, Gammon and 
Brown, 1993, Quintana et al., 2007) and ASD symptoms (DeLong et al., 2002, 
DeLong et al., 1998, Hollander et al., 2005). Therefore, based on the genetic, 
biochemical and neuroimaging evidence for serotonergic abnormalities in both 
children with ADHD and children with ASD, in addition to the positive clinical effect 
SSRIs have shown in these disorders, this PhD decided to focus on the 
neurofunctional effect of an acute dose of Fluoxetine in children with ADHD and 

















Chapter 5 – Disorder dissociated effects of Fluoxetine 
on areas of working memory in boys with ADHD and 
boys with ASD 
 
5.1 – Introduction 
 
ADHD is a neurodevelopmental disorder defined by age-inappropriate levels 
of inattention, impulsivity and hyperactivity (American et al., 1994). ASD is defined 
by impairments in communication, social interaction and by restricted, repetitive 
behaviours (American et al., 1994). However, there is increasing evidence for 
comorbidity between disorders (Rommelse et al., 2011), suggesting that ADHD and 
ASD may be part of a neurodevelopmental disorder spectrum (van der Meer et al., 
2012). For instance, both disorders share deficits in executive functions (Willcutt et 
al., 2005, Corbett et al., 2009), including WM (O'Hearn et al., 2008, Kasper et al., 
2012), and this is more pronounced at higher WM loads (Steele et al., 2007, Cui et al., 
2010, Kasper et al., 2012). The importance of this clinical and behavioural overlap is 
highlighted by recent changes to the DSM-V - which now allows the co-diagnosis of 
both ADHD and ASD (http://www.dsm5.org).  
 
WM is defined as the ability to temporarily store and manipulate information 
to guide and direct behaviour (Baddeley, 1996). A classic paradigm for measuring 
verbal WM is the parametric N-Back task in which subjects have to identify targets 
that were shown a few trials back (Baddeley, 2003).  In ADHD, fMRI studies of 
verbal N-Back tasks show underactivation compared to controls in DLPFC, parietal 
lobe and right cerebellum, with more pronounced behavioural and functional deficits 
during higher WM loads (Kobel et al., 2009, Cubillo et al., 2013). No fMRI study has 
tested verbal WM in children with ASD, but adult studies have shown decreased 
activation in left DLPFC, left IFC and left inferior parietal lobe in the highest WM 
load of a verbal N-Back task (Koshino et al., 2005). Therefore, fronto-parietal 
dysfunction appears to be present in both disorders during verbal WM tasks with high 
cognitive load (Koshino et al., 2005, Kobel et al., 2009, Cubillo et al., 2013), but an 




There is evidence that 5-HT is involved in verbal WM (Rose et al., 2006, 
Allen et al., 2006). Pharmaco-fMRI studies using the N-Back in healthy adults have 
shown that Escitalopram increases activation in left IFC (Rose et al., 2006) and that 
ATD decreases right middle/IFC activation and attenuates DMN deactivation during 
high WM loads (Allen et al., 2006). Despite evidence of WM deficits in both 
disorders (Rommelse et al., 2011) and serotonergic mediation of the neural correlates 
of verbal WM in healthy individuals (Rose et al., 2006, Allen et al., 2006), few 
studies have investigated the clinical efficacy of SSRIs in ADHD and ASD. 
Fluoxetine, for example, has been shown to improve aggression, irritability, 
inattentiveness and hyperactivity in children with ADHD (Barrickman et al., 1991, 
Gammon and Brown, 1993, Quintana et al., 2007) and to improve communication, 
social interaction and stereotyped behaviours in children with ASD (West et al., 
2009), although other SSRIs such as Citalopram have been shown to be ineffective 
(King et al., 2009). Nevertheless, an important question that may elucidate potential 
differential neurotransmitter underpinnings of cognitive abnormalities is whether 5-
HT modulates verbal WM networks in ADHD and ASD and whether this modulation 
differs between disorders. 
 
The aim of this fMRI study was therefore to investigate 1) disorder-specific 
brain dysfunctions in children with ADHD and children with ASD during a verbal N-
Back task, and 2) disorder-specific neurofunctional effects of an acute dose of 
Fluoxetine on these (dys)functions. Based on previous findings, we hypothesised that, 
under placebo, both disorders would show reduced left DLPFC and parietal 
activation, with ADHD patients exhibiting additional right DLPFC and cerebellar 
abnormalities (Kobel et al., 2009, Cubillo et al., 2013, Koshino et al., 2005), and that 










5.2 – Methods 
 
5.2.1 - Participants 
 
Thirty - two ADHD boys were recruited in total; however, seven boys dropped 
out of the study due to their dislike of the MRI scanner, three were excluded due to 
co-morbidities, one boy did not reach the diagnostic criteria for the combined subtype 
of ADHD, one boy was excluded due to poor task performance and three were 
excluded due to high levels of motion. Forty - four ASD boys were recruited in total. 
Of these, seven boys dropped out of the study due to their dislike of the MRI scanner, 
14 were excluded due to co-morbidities, one was excluded due to neurological 
abnormalities, two were excluded due to SSRI use, one was excluded due to poor task 
performance and two were excluded due to high levels of motion. Thirty - two 
controls were recruited in total however 10 were excluded due to high scores on the 
SDQ (Goodman and Scott, 1999)  and CPRS (Conners et al., 1998) . 
 
Fifty-six right handed boys (assessed with the Edinburgh Handedness 
Inventory (Oldfield, 1971)) (22 controls, 17 with ADHD and 17 with ASD) aged 10-
17 years old, with an IQ > 70 (assessed with the Wechsler Abbreviated Scale of 
Intelligence-Revised (Wechsler, 1999) participated. 
 
ADHD boys met DSM-IV diagnostic criteria for hyperactive-
impulsive/inattentive combined type ADHD and scored above clinical threshold for 
ADHD symptoms on the SDQ (Goodman and Scott, 1999) and the CPRS (Conners et 
al., 1998); one boy was below cut-off on SDQ but had diagnostic confirmation from a 
child psychiatrist. Three of the ADHD boys were medication-naïve, one had ceased 
taking MPH for three months and 13 received chronic stimulants, but had a 48hr 
medication washout prior to scanning.  
 
ASD diagnosis was made using ICD-10 (World et al., 1994) diagnostic criteria 
and confirmed by the ADI (Lord et al., 1994) and the ADOS (Lord et al., 2000). All 
ASD subjects were medication-naïve apart from one patient, who took melatonin but 
underwent two week medication washout. ASD exclusion criteria included a score 
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above 7 on the hyperactivity/inattention subscale of the SDQ. ADHD boys were 
excluded if they scored above 15 on the Social Communication Questionnaire (SCQ) 
(Rutter et al., 2003). Comorbidity with other psychiatric or neurological disorders, 
and drug/alcohol dependency were exclusion criteria for all patients. Patients were 
recruited from local clinical services and support groups. Written informed 
consent/assent was given for all participants and the study was approved by the local 
Ethical Committee. 
 
Patients were scanned twice in a double-blind, randomised, placebo-controlled 
design, using a Latin square randomisation design for counter-balanced effects. Due 
to the half-life of Fluoxetine (1-3 days), and its metabolite Norfluoxetine (5-16 days) 
(Wong et al., 1995), each scan was 3-4 weeks apart. To ensure that Fluoxetine had 
reached its peak plasma levels, which occurs after 5-8 hours (Wong et al., 1995), 
patients were scanned five hours after administration. Liquid Fluoxetine was titrated 
to age and weight in the following manner: boys between 10-13 years and less than 
30kg received 8mg, those greater than 30kg received 10mg; boys between 14-17 
years and less than 30kg received 10mg, those greater than 30kg received 15mg. 
Placebo was equivalent amounts of peppermint water which was similar in taste to 
Fluoxetine.   
 
Twenty-two healthy, age and handedness matched control boys were recruited 
locally by advertisement and scored below clinical thresholds on the SDQ, SCQ and 
CPRS. 
 
5.2.2 - fMRI N-Back Paradigm 
 
Subjects practiced the task once before scanning. The six minute block design 
WM task (Ginestet and Simmons, 2011) consists of four conditions. During “1-Back”, 
“2-Back” and “3-Back”conditions, subjects are presented with series of letters (A-Z) 
(1s duration, intertrial interval: 2 secs) and must respond with their right thumb using 
a button box whenever the letter presented is the same as one, two or three before it, 
respectively (e.g. 2-Back:B/J/A/J) (see Figure 4). This requires both storage and 
continuous updating of stimuli being held in WM. In the baseline vigilance “0-Back” 
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condition, subjects must respond to each X that appears on the screen. The task 
consists of 12 randomised blocks. Before each block, written instructions of a 3 
second duration are shown as to which condition is next (i.e., “0-Back”;”1-Back”; 
etc). In each of the WM blocks of 30 second duration only one WM condition is 
presented (i.e. 2-back), and contains fifteen stimuli: three targets and twelve non-
targets. Each condition is presented three times. Performance data were recorded 
during scanning. The dependent variable is accuracy (percentage of correctly 




Figure 4 – The N-Back task: The six minute WM task consists of four different 
conditions. In the control condition “0-Back” the subject is presented to series of 
letters, and the subject has to press for every X that appears on the screen. In the 
conditions “1-back”, “2-back” and “3-back”, the subject has to press the button 
whenever the letter presented is the same as one, two or three before it, respectively.  




5.2.3 - Data Analysis 
 
Analysis of performance data 
For the main performance measure of accuracy a repeated measures analysis 
of variance (ANOVA) within patients was conducted with drug condition (placebo, 
Fluoxetine) and WM-load (1-Back, 2-Back, 3-Back) as within-subject factors and 
group as between subjects factor. For case-control comparisons, two repeated 
measures ANOVAs (controls vs ADHD and ASD under placebo; controls vs ADHD 
and ASD under Fluoxetine) were conducted with WM-load as the within-subjects 
factor and group as the between-subjects factor.  
 
fMRI Image acquisition  
            Gradient-echo echoplanar MR imaging (EPI) data were acquired on a General 
Electric Signa 3T Horizon HDx system at the Centre for Neuroimaging Sciences, 
Institute of Psychiatry, King’s College London, UK. A semi-automated quality 
control procedure ensured consistent image quality (Simmons et al., 1999). A 
quadrature birdcage headcoil was used for radio frequency transmission and 
reception. In each of 39 non-contiguous planes parallel to the anterior-posterior 
commissure line, 186 T2*-weighted MR images depicting BOLD contrast covering 
the whole brain were acquired with TE=30ms, TR=2s, flip angle=75º, in-plane voxel 
size=3mm, slice thickness=3.5mm, slice-skip=0.5mm. This EPI dataset provided 
complete brain coverage. 
 
fMRI image analysis 
 Blocked fMRI data were acquired in randomised block presentation and 
analysed using the XBAM software package (http://www.brainmap.co.uk) (Brammer 
et al., 1997) which makes no normality assumptions (often violated in fMRI data), but 
instead uses median statistics to control outlier effects and permutation rather than 
normal theory-based inference (Thirion et al., 2007).  
 
Individual Analysis: fMRI data were first processed to minimise motion 
related artifacts (Bullmore et al., 1999). A 3D volume consisting of the average 
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intensity at each voxel over the whole experiment was calculated and used as a 
template. The 3D image volume at each time point was then realigned to this template 
by computing the combination of rotations (around the x y and z axes) and 
translations (in x y and z) that maximised the correlation between the image 
intensities of the volume in question and the template (rigid body registration). 
Following realignment, data were then smoothed using a Gaussian filter (FWHM, 
7.2mm) to improve the signal to noise characteristics of the images. After  
preprocessing,  time  series  analysis  for  each  subject  was  based  on  a wavelet-
based  data  resampling  method  for  functional  MRI  data (Bullmore et al., 2000, 
Bullmore et al., 1999).  At  the  individual  subject  level,  a  standard  general linear 
modelling approach was used to obtain estimates of the response size (beta) to each 
N-Back task condition (1-Back; 2-Back; 3-Back) against an implicit baseline (0-
Back). Briefly, we first convolved the main experimental conditions (1-Back; 2-Back; 
3-Back; contrasted with 0-Back) with two Poisson model functions (peaking at 4s and 
8s) after motion correction, global detrending and spin-excitation history correction. 
We then calculated the weighted sum of these two convolutions that gave the best fit 
(least-squares) to the time series at each voxel. A goodness-of-fit statistic (the SSQ-
ratio) was then computed at each voxel consisting of the ratio of the sum of squares of 
deviations from the mean intensity value due to the  model  (fitted  time  series)  
divided  by  the  sum  of  squares  due  to  the  residuals (original  time  series  minus  
model  time  series). The appropriate null distribution for assessing significance of 
any given SSQ-ratio was established using a wavelet-based data  re-sampling  method 
(Bullmore et al., 2000) and  applying  the  model-fitting process to the re-sampled 
data. This process was repeated 20 times at each voxel and the data combined over all 
voxels, resulting in 20 null parametric maps of SSQ-ratio for each subject, which 
were combined to give the overall null distribution of SSQ-ratio.  The  same  
permutation  strategy  was  applied  at  each  voxel  to  preserve  spatial correlation 
structure in the data. Activated voxels, at a <1 level of type I error, were identified 
through the appropriate critical value of the SSQ-ratio from the null distribution. 
Individual SSQ-ratio maps were then transformed into standard space, first by rigid 
body transformation of the fMRI data into a high-resolution inversion recovery image 
of the same subject, and then by affine transformation onto a Talairach template 




 Group Analysis: A group activation map was produced for each experimental 
condition (1-Back; 2-Back; 3-Back; contrasted with 0-Back) by calculating the 
median observed SSQ-ratio over all subjects at each voxel in standard space and 
testing them against the null distribution of median SSQ-ratios computed from the 
identically transformed wavelet re-sampled data(Brammer et al., 1997). The voxel-
level threshold was first set to 0.05 to give maximum sensitivity and to avoid type II 
errors. Next, a cluster-level threshold was computed for the resulting 3D voxel 
clusters. The necessary combination of voxel and cluster level thresholds was not 
assumed from theory but rather was determined by direct permutation for each data 
set, giving excellent Type II error control (Bullmore et al., 1999). Cluster mass rather 
than a cluster extent threshold was used, to minimise discrimination against possible 
small, strongly responding foci of activation (Bullmore et al., 1999). In all group 
activation analyses, less than one false positive activation locus was expected for 
p<0.05 at voxel level and p<0.01 at cluster level. 
 
Investigation for a group by WM load interaction effect on brain activation 
 To test for group by WM load interaction effects on brain activation, we 
conducted a repeated measures ANCOVA with rotational and translation movement 
in Euclidian 3-D space as covariate, group as between-subject variable and WM load 
as within-subject variable. For this purpose, we conducted randomisation-based tests 
for voxel or cluster-wise differences as described in detail elsewhere (Cubillo et al., 
2013). A significant WM load effect was shown in 12 clusters in: right DLPFC, left 
DLPFC/IFC, ACC/SMA, right IFC/basal ganglia/thalamus, left basal 
ganglia/thalamus, thalamus/midbrain, left precentral/postcentral gyri, right 
precentral/postcentral gyri, right precentral gyrus, precuneus/cuneus, left PCC and 
right PCC. BOLD response was extracted for each region and each group. This 
showed that for all 3 groups, activation in bilateral ACC/SMA, DLPFC, IFC, basal 
ganglia, thalamus, midbrain, precuneus and cuneus increased progressively with 
increasing WM load, while activation in precentral/postcentral gyri and PCC was 
progressively more deactivated with increasing WM load (see Figure 5). However, no 
group by WM load interaction was observed. Consequently, we focused on the 3-
Back vs 0-Back contrast in all subsequent analyses as this contrast elicited the 






Figure 5 – Brain activation for working memory load effect in controls, boys 
with ADHD under placebo and boys with ASD under placebo. Axial sections 
showing brain activation for increasing WM load in healthy control boys, boys with 
ADHD under placebo and boys with ASD under placebo. Shown underneath are the 
statistical measures of BOLD response each of the brain regions that showed a 
significant WM load effect in all three groups. Green = 1-Back; Red = 2-Back, Blue = 
3-Back. Talairach z co-ordinates are indicated for slice distance (in mm) from the 
intercommissural line. The right side corresponds to the right side of the image. 
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ANCOVA Between-Group Difference Analyses: For between-group 
comparisons between controls and patients under either placebo or Fluoxetine for the 
3-Back condition, one-way ANCOVA analyses with group as factor and rotational 
and translation movement in Euclidian 3-D space as covariate, were conducted. For 
these between-group comparisons, less than one false activated cluster was expected 
at p < 0.05 for voxel and p < 0.01 for cluster comparisons. The standardised BOLD 
response values (SSQ ratios) for each participant were then extracted for the mean 
activation of each of the significant clusters of the 3-group ANCOVA analyses and 
post-hoc t-tests (correcting for multiple comparisons using least significant difference 
(LSD)) were conducted to identify the direction of the group differences.  
 
ANCOVA Within-Patients Interaction Effects: In order to investigate group by 
drug interaction effects between placebo and Fluoxetine within the patient groups, a 
2x2 ANCOVA (2 medication conditions, 2 groups) with rotational and translation 
movement in Euclidian 3-D space as covariate was conducted using randomised-
based testing for voxel or cluster-wise differences. Less than one false positive 3D 
cluster was expected at p<0.05 at voxel and p<0.01 at the cluster level. Statistical 
measures of BOLD response for each participant were then extracted in each of the 
significant clusters and post-hoc t-tests (correcting for multiple comparisons with 
LSD) were conducted to identify the direction of the interaction effects.  
 
Normalisation Effects: To test for the statistical significance of any apparent 
normalisation effects of Fluoxetine on case-control activation differences observed 
under placebo, we used non-parametric Friedman two-way analysis of variance by 
ranks on the extracted BOLD responses during each medication condition for each of 
the clusters shown to be significantly different in the comparison between controls 
and patients during placebo. We conducted this test only within patients, given that 
controls were only tested once, and hence constant across comparisons. 
 
Correlations with Behaviour and IQ: To test whether group, or group by drug, 
interaction effects were related to clinical behaviour or IQ we correlated activation in 
clusters that differed between groups with the SDQ hyperactive/inattentive subscale 
and CPRS scores in the ADHD group. In the ASD group we correlated activation 
with the social and communication, and stereotyped behaviours, subscales of the 
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ADOS. Activation and full scale IQ was correlated in each group. For this purpose, 
the BOLD response was extracted for each subject and Pearson correlations were 
performed between these and behavioural and IQ scores. 
 
5.3 – Results 
 
5.3.1 - Participant Characteristics 
 
Group differences in age and IQ 
 ANOVAs showed no significant group differences in age, but did for IQ (F (df 
=2,55) = 15, p < 0.0001) which was significantly lower in ADHD relative to control 
and ASD boys (p < 0.0001), who did not differ. ADHD children have a typically 
lower IQ than their healthy peers(Bridgett and Walker, 2006). Therefore, IQ was not 
covaried, as covarying for a measure that is intrinsic to the condition, and hence 
differs between groups, which were not randomly selected, would violate ANCOVA 
assumptions (Dennis et al., 2009). Furthermore, WM is included in  the Wechsler 
Intelligence Scale for Children (4th version) (WISC-IV)(Wechsler, 2004) and  shares 
a common neurological correlate in DLPFC, which would mean that covarying for IQ 
would also covary for the function of interest (Conway et al., 2003).  
 
Group differences in clinical measurements 
Multivariate ANOVA showed a significant group effect for all SDQ measures 
(F(df =10,100)=21 p < 0.0001). Post-hoc analyses showed that controls scored 
significantly better on all subscales compared to patients (p < 0.01). ADHD boys 
scored significantly higher than ASD boys on the conduct and hyperactive/inattentive 
subscales of the SDQ (p < 0.0001). ASD boys scored significantly worse than ADHD 
boys on the peer relations subscale (p < 0.005) and significantly higher on the SCQ (F 
(df =2,50) = 112, p < 0.0001) than ADHD (p < 0.0001) and controls participants (p 
<0.0001),while ADHD participants scored significantly higher than controls (p 
<0.0001). ADHD boys scored higher on the CPRS (F (df =2,52) = 136, p< 0.0001) 
than ASD (p <0.0001) and controls (p <0.0001) and ASD participants scored higher 








5.3.2 - Performance Data  
 
  Case-controls comparisons showed that across all subjects there was a 
significant linear WM load effect under both placebo (F(df =2,52)=49, p < 0.0001) 
and Fluoxetine (F(df =2,31)=35, p < 0.0001) showing lower accuracy in the more 
difficult conditions. However, no group effect was observed. Within-patient repeated 
measures ANOVA showed a trend for a drug effect (F(df =1,32)=3, p < 0.1) due to 
both patient groups being more accurate under Fluoxetine than under placebo (p < 
0.08). No other effects were significant (Table 2). 






Age (years) 14.0 (2.6) 14.7 (1.9) 15.2 (1.8) 
IQ 111 (13) 93 (9) 114 (14) 
SDQ Hyperactive/Inattentive Subscale 2.0 (1.8) 8.9 (1.4) 4.7 (1.9) 
SDQ - Emotional Distress Subscale 0.9 (1.6) 3.2 (3.0) 4.3 (3.0) 
SDQ - Conduct Subscale 0.5 (0.9) 4.6 (2.1) 2.2 (2.1) 
SDQ – Peer Relations Subscale  .9 (1.2) 3.6 (2.3) 6.1 (2.4) 
SDQ – Prosocial Behaviour Subscale  8.7 (2.3) 6.3 (2.3) 4.8 (2.2) 
SDQ – Total scores  4.3 (4) 20.4 (4.9) 17.4 (5.9) 
SCQ Total 1.8 (2.8) 8.1 (4.1) 23.4 (5.6) 
CPRS Total T score 44 (4) 83 (8) 59 (9) 
ADOS Communication scores - - 2 (1) 
ADOS Social Interaction scores - - 7 (4) 
ADOS Social and Communication scores - - 9 (5) 
ADOS Stereotyped behaviour scores - - 1 (1) 
ADI Communication scores - - 15 (4) 
ADI Social Interaction scores - - 17 (4) 
ADI Stereotyped behaviour scores - - 5 (3) 
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ASD Fluoxetine  
Mean (SD) 
Accuracy 1-Back           96 (9)                95 (7)            94 (10)                  99 (4)                98 (6) 
Accuracy 2-Back          91 (11)                74 (24)             84 (15)                  88 (17)               95 (10) 
Accuracy 3-Back          70 (18)                65 (19)             68 (28)                  75 (24)               78 (19) 
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5.3.3 - fMRI Data 
 
Movement  
Repeated measures ANOVAs using group as an independent factor and 
maximum x, y z rotation and translation as repeated measures showed that there were 
no significant group by movement interaction effects in rotation (F(df =4,106)=1, 
p=n.s.) or translation (F(df =4,106)=2, p=n.s). Nevertheless, to eliminate any potential 
effects of even small, non-significant variance in motion, motion parameters were 
used as a covariate in the fMRI analyses. 
 
Group Brain Activation Maps  
 
3-Back – 0-Back 
Controls – During 3-Back – 0-Back controls activated a bilateral WM network 
consisting of inferior/middle/superior frontal cortices, ACC/SMA, basal ganglia, 
thalamus, parietal lobe, precuneus, cerebellum/midbrain and left middle temporal 
lobe. 
 
ADHD – While under placebo, the ADHD group activated bilateral 
inferior/middle frontal cortices, left precentral gyrus, ACC/SMA, bilateral basal 
ganglia and thalamus, right parietal lobe, precuneus, left middle/superior temporal 
lobe , left occipital lobe and midbrain/left cerebellum. While under Fluoxetine, they 
activated bilateral superior/inferior/middle frontal cortices, ACC/SMA, bilateral basal 
ganglia and thalamus, bilateral parietal lobe, precuneus, right inferior/middle temporal 
lobe, bilateral midbrain/cerebellar vermis. 
 
 ASD – While under placebo, the ASD group activated bilateral 
inferior/middle frontal cortices, left superior frontal cortex, left precentral gyrus, 
ACC/SMA, bilateral basal ganglia and thalamus, bilateral parietal lobe, precuneus, 
bilateral middle/superior temporal lobe, midbrain/cerebellar vermis and right 
cerebellum. While under Fluoxetine, the ASD group activated bilateral 
superior/inferior/middle frontal cortices, left precentral gyrus, ACC/SMA, bilateral 
basal ganglia and thalamus, bilateral insula, bilateral parietal lobe, precuneus, left 
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middle/superior temporal lobe, right inferior/middle temporal lobe, left middle 
occipital lobe, midbrain/cerebellar vermis and left cerebellum/fusiform gyrus (Figure 
6.A) 
 
Figure 6.A – Within-Group activation for controls, and patients under either 
placebo or Fluoxetine, for the contrast of 3-Back – 0-Back. Axial sections showing 
within-group brain activation for healthy control boys, boys with ADHD under either 
placebo or Fluoxetine and boys with ASD under either placebo or Fluoxetine for the 
contrast of 3-Back – 0-Back. Talairach z co-ordinates are indicated for slice distance 





0-Back – 3-Back 
Controls – During 0-Back – 3-Back controls activated DMN areas consisting 
bilaterally of mPFC, precentral and postcentral gyri, putamen and caudate, insula, 
middle/superior temporal lobe, PCC, cuneus, fusiform gyrus and right middle 
occipital lobe. 
 
ADHD – While under placebo, the ADHD group activated mPFC, left 
inferior/superior frontal cortex, bilateral precentral and postcentral gyri, left inferior 
parietal lobe, right middle/superior temporal lobe, bilateral insula/putamen, PCC, 
precuneus/cuneus, right lingual/fusiform gyrus and right cerebellum. While under 
Fluoxetine, they activated mPFC, left superior frontal cortex, bilateral IFC, bilateral 
precentral and postcentral gyri, bilateral inferior parietal lobe, right middle/superior 
temporal lobe, bilateral insula/putamen and thalamus, PCC and precuneus/cuneus. 
 
ASD – While under placebo, the ASD group activated mPFC, right superior 
frontal cortex, bilateral precentral and postcentral gyri, bilateral inferior parietal lobe, 
bilateral middle/superior temporal lobe, left putamen, right lentiform nucleus/insula, 
PCC, precuneus/cuneus, right fusiform gyrus and cerebellum. While under 
Fluoxetine, the ASD group activated mPFC, left inferior/superior frontal cortices, 
bilateral precentral and postcentral gyrus, , left putamen, right lentiform 
nucleus/insula, bilateral superior temporal lobe, left middle temporal lobe, PCC, 
precuneus/cuneus, bilateral occipital lobe, bilateral fusiform gyrus and cerebellum 






Figure 6.B –Within-Group activation for controls, and patients under either 
placebo or Fluoxetine, for the contrast of 0-Back – 3-Back. Axial sections showing 
within-group brain activation for healthy control boys, boys with ADHD under either 
placebo or Fluoxetine and boys with ASD under either placebo or Fluoxetine for the 
contrast of 0-Back – 3-Back. Talairach z co-ordinates are indicated for slice distance 
(in mm) from the intercommissural line. The right side corresponds to the right side of 
the image. The right side corresponds to the right side of the image. 
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Between-group differences between controls and patients under placebo for 3-
Back 
ANCOVA analysis between controls and patients under placebo for the 3-
Back condition showed a significant group effect in right DLPFC and PCC (Figure 
7.A, Table 3). Post-hoc analyses showed that the group effect in right DLPFC was 
due to significantly decreased activation in this region in the ASD (p < 0.0001) and 
ADHD (p <0.05) groups relative to controls, and there was a trend-wise difference for 
significantly decreased activation in ASD compared to ADHD boys (p < 0.08). In 
PCC, the ASD group had significantly increased deactivation compared to both 
controls (p < 0.0001) and ADHD participants (p < 0.005), who also deactivated this 
cluster, but did not differ from each other (Figure 7.A, Table 3). No significant 
correlations between brain activation and behaviour or brain activation and IQ were 
observed. 
 
Between-group differences between controls and patients under Fluoxetine for 
3Back 
ANCOVA analysis of controls and patients on Fluoxetine showed a significant 
group effect in PCC, as observed under placebo, but no longer in DLPFC (Figure 7.B, 
Table 3). Post-hoc analyses showed that both ADHD (p < 0.0001) and ASD boys (p = 
0.008) deactivated PCC more than controls. 
 
Friedman two-way analysis of variance by ranks to test for significant 
normalisation showed that Fluoxetine relative to placebo significantly increased 
activation in right DLPFC in the ASD group only χ2 (1,N=17) =7.12, p = 0.008), 
while in the ADHD group this was not significant, suggesting significant 
normalisation of this brain dysfunction in ASD only. There was a trend for Fluoxetine 
relative to placebo to increase deactivation of the PCC in ADHD χ2 (1,N=17) =2.88, p 
< 0.09).  
 
Correlations with behaviour showed that there was a positive correlation 
between PCC activation and scores on the hyperactive/inattentive subscale of the 
SDQ in the ADHD group (r=0.578, p <0.05) and PCC activation and scores on the 
social/communication subscale of the ADOS in the ASD group (r = 0.564, p < 0.05). 




Within-Patients group by medication interaction effects 
Within-patients ANCOVA analysis with group as dependent variable and drug 
as within-group variable showed a significant group by medication interaction effect 
in one cluster in PCC (74 voxels, peak Talairach coordinates (x;y;z): 11;-30;37; 
Brodmann area (BA): 31/24). This was due to Fluoxetine increasing deactivation of 
this area in the ADHD group and attenuating the deactivation in the ASD group (p < 
0.005) (Figure 7C). No significant correlations between brain activation and 








Figure 7.A. Working Memory Between-Group and Within-Patient Comparisons: 
Axial sections showing the between-group ANCOVA findings between controls and 
patients under placebo. Shown underneath are the statistical measures of BOLD 
response for each of the three groups for each of the brain regions that showed a 
significant group effect. B. Axial sections for the between-group ANCOVA 
comparison between controls and patients under Fluoxetine. Shown underneath are 
the statistical measures of BOLD response for each of the three groups for each of the 
brain regions that showed a significant group effect. C. Axial sections showing 
within-patient group by medication interaction effects. Shown underneath are the 
statistical measures of BOLD response for each of the brain regions that showed a 
significant group by medication interaction effect between patients. Talairach z co-
ordinates are indicated for slice distance (in mm) from the intercommissural line. The 
right side of the image corresponds to the right side of the brain. 
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Voxels   Cluster 
  p-value 
PLACEBO 
ADHD, ASD < C 
 

















ASD, ADHD < C PCC/Precuneus  31/7 -11;-37;37 49 0.003 
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5.4 – Discussion 
 
 This study shows that while performing a WM task under placebo, ADHD and 
ASD boys share brain underactivation relative to controls in right DLPFC, a key area 
for WM (Wager and Smith, 2003), which at a trend-level was more severe in ASD 
relative to ADHD. Furthermore, ASD boys showed disorder-specific increased 
deactivation of PCC compared to controls and ADHD boys. Fluoxetine at a trend-
level improved performance in both disorders relative to placebo, but had a disorder-
dissociated effect on task-positive and task-negative activation clusters. Fluoxetine, 
significantly normalised the right DLPFC deficit in ASD, while it only non-
significantly normalised it in ADHD. However, Fluoxetine significantly increased the 
deactivation of the PCC, a DMN region, in ADHD boys and within-patient analyses 
confirmed that Fluoxetine significantly enhanced PCC deactivation in ADHD, but 
attenuated deactivation in ASD. The findings thus show both shared (DLPFC 
underactivation) and disorder-specific (PCC deactivation in ASD) brain dysfunctions 
during WM in both disorders as well as disorder-dissociated drug-effects on task-
positive and task-negative activations, with Fluoxetine normalising task-positive right 
DLPFC underactivation in ASD, but enhancing task-negative PCC deactivation in 
ADHD, both leading to improved WM performance. 
 
 The shared underactivation relative to controls in right DLPFC, a key area of 
manipulation of information during WM (Wager and Smith, 2003), during a verbal N-
Back task replicates previous findings of DLPFC underactivation in ADHD children 
(Cubillo et al., 2013) and adults(Valera et al., 2010) during a verbal N-Back task and 
also echoes consistent DLPFC underactivation in a meta-analysis of attention tasks 
(Hart et al., 2013). The novelty is the finding of right DLPFC underactivation in ASD 
during a verbal WM task and that this was trend-wise more impaired than in ADHD. 
The finding extends previous findings of left DLPFC underactivation in adult ASD 
during a verbal N-Back task (Koshino et al., 2005). The findings of shared DLPFC 
deficits  extend prior evidence for shared reduction in left DLPFC activation during a 
parametric sustained attention task in ADHD and ASD (Christakou et al., 2013), 
suggesting that DLPFC dysfunction during attention tasks may be shared between the 
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two overlapping neurodevelopmental disorders and possibly play a role in the 
comorbidity reported between the two disorders (Rommelse et al., 2011). 
 
 The disorder-specific increased deactivation of PCC, a key region of the 
DMN, in the ASD group compared to controls and ADHD may have been a 
compensation for their DLPFC underactivation given that deactivation of the DMN is 
typically anti-correlated with task positive activation in DLPFC (Christakou et al., 
2013) and is associated with better task performance (Northoff et al., 2010).  
 
 Under Fluoxetine right DLPFC underactivation appeared normalised in both 
groups, but rigorous normalisation testing showed significance only for ASD. 
However, Fluoxetine led to increased deactivation of PCC in ADHD, which while not 
different from controls under placebo, was now significantly more pronounced 
relative to controls under Fluoxetine. This disorder differential effect of Fluoxetine on 
a task-positive area in ASD (DLPFC) and a task-negative DMN area in ADHD (PCC) 
is interesting given that Fluoxetine improved accuracy in both disorders, at a trend-
level. It suggests that Fluoxetine had a positive effect on performance and brain 
activation in both disorders but via different underlying mechanisms: namely, by 
decreasing task-unrelated thinking processes mediated by the DMN in ADHD, which 
has been shown to interfere with task-positive activation and lead to poor attention in 
the disorder (Christakou et al., 2013), and by enhancing a key task-positive area of 
WM in ASD.  
 
The disorder-specific effects on DLPFC activation and the inverse effects on 
PCC in both disorders may be due to differences in underlying biochemical 
abnormalities the two disorders. Approximately 30% of individuals with ASD have 
hyperserotonemia (Hranilovic et al., 2007). Reduced binding to the SERT and the 5-
HT2A transporter in the frontal lobe and PCC have also been reported, the latter of 
which has been linked to poor social communication (Murphy et al., 2006, Nakamura 
et al., 2010). Furthermore, abnormal 5-HT synthesis has been observed in children 
with ASD (Chandana et al., 2005, Chugani et al., 1999, Chugani et al., 1997). This 
suggests that hyperserotonemia may be an adaptation to counteract poor 5-HT 
receptor binding and abnormal 5-HT synthesis. The increase in 5-HT with Fluoxetine 
may have increased ligand-receptor binding sufficiently to enhance activation in areas 
147 
 
where 5-HT receptor density is typically low (Nakamura et al., 2010, Murphy et al., 
2006). This would be in line with, and extends prior evidence that, SSRIs increase 
metabolic and neurofunctional activity in prefrontal areas in adults with ASD which 
was associated with an improvement in ASD behaviour (Buchsbaum et al., 2001, 
Dichter et al., 2010).  
 
Conversely, in ADHD there is evidence for lower platelet 5-HT levels 
compared to controls (Spivak et al., 1999) as well as genetic (Gizer et al., 2009) and 
biochemical serotonergic dysfunction (Oades, 2007). Therefore, the increase in 5-HT 
induced by Fluoxetine may not have been sufficient to normalise their DLPFC deficit. 
The increased deactivation of PCC in ADHD under Fluoxetine may be due to the 
effect of an increase in 5-HT on the 5-HT2C receptors in this area which would lead to 
a decrease in dopamine (Di Matteo et al., 2008). There is consistent evidence for 
decreased dopamine levels in individuals with ADHD in the basal ganglia and 
cingulate gyrus (Volkow et al., 2005, del Campo et al., 2011) so an increase 5-HT 
may have decreased the already low dopamine levels in the ADHD group, leading to 
deactivation of this area. Interestingly, ATD in healthy adults during a verbal N-Back 
led to a decrease in right DLPFC activation and attenuation of PCC deactivation 
(Allen et al., 2006), which suggests that these brain regions are particularly sensitive 
to 5-HT manipulation during verbal WM and are often modulated in an inverse 
manner. 
 
The strengths of this study are the carefully selected, non-comorbid patient 
groups who were free of psychiatric co-morbidities and, in the case of the ASD group, 
medication naïve.  A limitation of this study is that the control group was only 
scanned once, while patients were scanned twice which could have accounted for the 
lack of performance differences. The significantly lower IQ in the ADHD group is 
another limitation. However, none of the brain activation effects were correlated with 
IQ, suggesting that IQ did not play a key role in the findings.  
 
In summary, ADHD and ASD patients showed shared underactivation in right 
DLPFC, a key area for WM, with ASD patients showing more pronounced 
deactivation of PCC relative to both groups. Fluoxetine had a disorder-dissociated 
region-specific effect of significantly normalising the DLPFC deficit in ASD, but 
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enhancing deactivation in PCC in ADHD, which at a trend-level was concomitant 
with better task performance. The region-specific disorder-dissociated effects of 


































Chapter 6 – Inverse effects of Fluoxetine on frontal 
inhibitory brain activation in boys with ADHD and 
boys with ASD 
 
6.1 – Introduction 
 
ADHD is a neurodevelopmental disorder defined by age-inappropriate levels 
of inattention, impulsivity and hyperactivity (American et al., 1994). In contrast ASD 
is defined by impairments in communication, social interaction and by restricted and 
repetitive behaviours (American et al., 1994). However, there is increasing evidence 
for comorbidity between disorders (Rommelse et al., 2011) suggesting that ADHD 
and ASD may be part of a neurodevelopmental disorder spectrum (van der Meer et 
al., 2012). For instance, both disorders share executive function deficits (Willcutt et 
al., 2005, Corbett et al., 2009), in particular in motor response inhibition (Willcutt et 
al., 2005, Robinson et al., 2009) which furthermore has been associated with 
impulsiveness in ADHD and motor stereotypies in ASD (DSM-IV,(Langen et al., 
2011). This overlap was highlighted by recent changes to the DSM-V - which now 
allows the co-diagnosis of both ADHD and ASD (http://www.dsm5.org).  
 
In ADHD, the neurofunctional correlates of inhibition are well established 
with consistent evidence of underactivation compared to controls in IFC, SMA and 
caudate/thalamus (Rubia et al., 1999, Rubia et al., 2005b, Hart et al., 2012b). In 
children with ASD, however, no study has investigated the neurofunctional 
underpinnings of inhibition. In adults with ASD, fMRI studies report inconsistent 
findings of increased activation in left IFC and decreased activation in right IFC and 
ACC (Schmitz et al., 2006, Kana et al., 2007). Therefore, a key question to elucidate 
the pathophysiology of these two disorders, is whether the underlying neurobiology of 
shared cognitive phenotypes is shared or disorder-specific. 
 
There is evidence that 5-HT is involved in impulsiveness and motor inhibition 
(Robbins et al., 2010). Pharmacological fMRI studies in healthy adults show that 
SSRIs and ATD enhance and decrease activation in IFC and striatal inhibition areas, 
respectively (Del-Ben et al., 2005, Rubia et al., 2005a). Despite evidence for 
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inhibitory deficits in both disorders (Rommelse et al., 2011) and serotonergic 
mediation of inhibitory control in healthy individuals (Del-Ben et al., 2005, Rubia et 
al., 2005a, Robbins et al., 2010), few studies have investigated the clinical efficacy of 
SSRIs in ADHD and ASD. Those that have, have used Fluoxetine and it has been 
shown to improve aggression, irritability, inattentiveness and hyperactivity in children 
with ADHD (Quintana et al., 2007) and to improve communication, social interaction 
and stereotyped behaviours in children with ASD (Hollander et al., 2005), although 
other SSRIs like Citalopram have been shown to be ineffective (King et al., 2009). 
Nevertheless, an important question that may elucidate potential neurotransmitter 
underpinnings of cognitive abnormalities, is whether 5-HT modulates the inhibitory 
network in both ADHD and ASD and whether this modulation differs between 
disorders. 
 
The aim of this fMRI study was therefore to investigate 1) shared and 
disorder-specific brain dysfunctions in children with ADHD and children with ASD 
during a Stop Signal task and 2) shared and disorder-specific neurofunctional effects 
of an acute dose of Fluoxetine on these inhibitory (dys)functions in both disorders. 
Based on our previous findings we hypothesised that, under placebo, ADHD boys 
would show decreased activation in IFC and caudate compared to controls (Rubia et 
al., 1999, Hart et al., 2012b, Rubia et al., 2005b), whereas ASD boys would show 
increased left frontal activation (Schmitz et al., 2006). We further hypothesised that 
Fluoxetine would increase the reduced fronto-striatal activation in ADHD, but reduce 
the increased left frontal abnormalities in ASD. 
 
6.2 – Methods 
 
6.2.1 - Participants 
 
Thirty - two ADHD boys were recruited in total; however, seven boys dropped 
out of the study due to their dislike of the MRI scanner, three were excluded due to 
co-morbidities, one boy did not reach the diagnostic criteria for the combined subtype 
of ADHD, one boy was excluded due to poor task performance and two were 
excluded due to high levels of motion. Forty - four ASD boys were recruited in total. 
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Of these, seven boys dropped out of the study due to their dislike of the MRI scanner, 
14 were excluded due to co-morbidities, one was excluded due to neurological 
abnormalities, two were excluded due to SSRI use and one was excluded due to poor 
task performance. Thirty - four controls were recruited in total butnine were excluded 
due to high scores on the SDQ and CPRS. 
 
Sixty - two right handed boys (assessed with the Edinburgh Handedness 
Inventory (Oldfield, 1971)) (25 controls, 18 with ADHD and 19 with ASD) aged 10-
17 years old, with an IQ > 70 (assessed with the Wechsler Abbreviated Scale of 
Intelligence-Revised (Wechsler, 1999) participated. 
 
ADHD boys met DSM-IV diagnostic criteria for hyperactive-
impulsive/inattentive combined type ADHD and scored above clinical threshold for 
ADHD symptoms on the SDQ (Goodman and Scott, 1999) and CPRS (Conners et al., 
1998). Four of the ADHD boys were medication-naïve, three had ceased taking MPH 
for a year (one), or 3 months (two) and 11 received chronic stimulants, but had a 48hr 
medication washout prior to scanning.  
 
ASD diagnosis was made using ICD-10 diagnostic criteria (Organization, 
1993) and confirmed by the ADI (Lord et al., 1994) ADOS (Lord et al., 2000). All 
ASD subjects were medication-naïve apart from one patient, who took melatonin (but 
underwent two week medication washout). ASD exclusion criteria included a score 
above 7 on the hyperactivity/inattention subscale of the SDQ or a t-score above 70 on 
the DSM-IV subscale of the CPRS. ADHD boys were excluded if they scored above 
15 on the SCQ (Rutter et al., 2003). Comorbidity with other psychiatric or 
neurological disorders, and drug/alcohol dependency were exclusion criteria for all 
patients. Patients were recruited from local clinical services and support groups. 
Written informed consent/assent was given for all participants and the study was 
approved by the local Ethical Committee. 
 
Patients were scanned twice in a double-blind, randomised, placebo-controlled 
design, using a Latin square randomisation design for counter-balanced effects. Due 
to the half-life of Fluoxetine (1-3 days), and its metabolite Norfluoxetine (5-16 days) 
(Wong et al., 1995), each scan was 3-4 weeks apart. To ensure that Fluoxetine had 
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reached its peak plasma levels, which occurs after 5-8 hours (Wong et al., 1995), 
patients were scanned five hours after administration. Liquid Fluoxetine was titrated 
to age and weight in the following manner.  Boys between 10-13 years and less than 
30kg received 8mg, those greater than 30kg received 10mg. Boys between 14-17 
years and less than 30kg received 10mg, those greater than 30kg received 15mg. 
Placebo was equivalent amounts of peppermint water with similar taste to Fluoxetine. 
 
Twenty-five healthy, handedness, and age-matched control boys were 
recruited locally by advertisement and scored below clinical thresholds on the SDQ, 
SCQ and CPRS.  
 
6.2.2 - fMRI Stop Signal Paradigm 
 
Subjects practised the task once prior to each scan. The nine minute visual 
tracking Stop Signal task requires withholding of an already triggered motor response 
to a go stimulus when it is followed unpredictably by a stop signal (Rubia et al., 
1999). Subjects have to respond as quickly as possible to left or right pointing “go” 
arrows (500ms duration; 80% of trials) with a left or right (thumb) button press, 
followed by a gap of 1100 to 1500ms (mean ITI: 1.8s; jittered between 1.6 and 2 
seconds to optimize statistical efficiency). In 20% of trials, pseudo-randomly 
interspersed, and at least three repetition times apart for adequate separation of the 
hemodynamic response, go signals are followed (about 250ms later) by arrows 
pointing upwards (stop signals), and subjects have to inhibit their motor response. A 
tracking algorithm changes the time interval between go and stop-signal onsets 
according to each subject’s inhibitory performance, which is recalculated after each 
stop signal based on the average percentage of inhibition over previous stop trials to 
provide 50% successful and 50% unsuccessful inhibition trials (see Figure 8). In the 
fMRI analysis, brain activation to the 50% unsuccessful stop trials is subtracted from 
the 50% successful stop trials, controlling for the attentional oddball effect of the 
infrequent stop signal appearance. 
 
The main dependent variable of the task is the SSRT, calculated by subtracting 
the mean stop signal delay (SSD: the average time between go and stop signal, at 
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which the subject managed to inhibit to 50% of trials) from the mean reaction time 
(MRT) to go trials, i.e. MRT-SSD (Logan et al., 1997). MRT, intrasubject Standard 
Deviation of MRT (SD MRT), and omission error percentage measure the executive 




Figure 8 – The Stop Signal task. Subjects have to respond to go arrows that point 
either right or left with a right/left button response. In 20% of trials (the go-signals 
were followed (about 250ms later) by stop signals and subjects had to inhibit their 
motor responses. A tracking algorithm changed the time interval between go-signals 
and stop-signals according to each subject’s performance on previous trials (average 
percentage of inhibition over previous stop trials, recalculated after each stop trial), 
resulting in 50% successful and 50% unsuccessful inhibition trials. 
 
6.6.3 - Data Analysis 
 
Analysis of performance data 
 Multiple ANOVAs compared the main performance variables between 
controls and patients under placebo and Fluoxetine. Multiple repeated-measures 
ANOVAs within the patient groups with group as independent factor and 
placebo/Fluoxetine as repeated measure were conducted to test for group by 





fMRI Image acquisition  
            Gradient-echo echoplanar MR imaging (EPI) data were acquired on a General 
Electric Signa 3T Horizon HDx system at the Centre for Neuroimaging Sciences, 
Institute of Psychiatry, King’s College London, UK. A semi-automated quality 
control procedure ensured consistent image quality. A quadrature birdcage headcoil 
was used for RF transmission and reception. In each of 28 non-contiguous planes 
parallel to the anterior-posterior commissure, 296 T2*-weighted MR images depicting 
BOLD contrast covering the whole brain were acquired with TE=30ms, TR=1.8s, flip 
angle=75°, in-plane voxel-size=3mm, slice thickness=5.5mm, slice-skip=0.5mm. A 
whole-brain high resolution structural scan (inversion recovery gradient echo planar 
image) on which to superimpose the individual activation maps, was also acquired in 
the inter-commissural plane with TE=30 ms, TR=3s, flip angle = 90
o
, 43 slices, slice 
thickness=3.0mm, slice skip=0.3mm, in-plane voxel-size = 1.875mm. 
 
fMRI image analysis 
 The XBAM software package was used (http://www.brainmap.co.uk) 
(Brammer et al., 1997) which makes no normality assumptions (often violated in 
fMRI data), but instead uses median statistics to control outlier effects and 
permutation rather than normal theory-based inference (Thirion et al., 2007).  
 
Individual Analysis: fMRI data were first processed to minimise motion 
related artifacts (Bullmore et al., 1999). A 3D volume consisting of the average 
intensity at each voxel over the whole experiment was calculated and used as a 
template. The 3D image volume at each time point was then realigned to this template 
by computing the combination of rotations (around the x y and z axes) and 
translations (in x y and z) that maximised the correlation between the image 
intensities of the volume in question and the template (rigid body registration). 
Following realignment, data were then smoothed using a Gaussian filter (FWHM, 
7.2mm) to improve the signal to noise characteristics of the images. After  
preprocessing,  time  series  analysis  for  each  subject  was  based  on  a wavelet-
based  data  resampling  method  for  functional  MRI  data (Bullmore et al., 1999, 
Bullmore et al., 2000).  At  the  individual  subject  level,  a  standard  general linear 
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modelling approach was used to obtain estimates of the response size (beta) to the 
Stop Signal task conditions (successful and failed stop trials) against an implicit 
baseline (go trials) and then again for the higher level contrast of successful-go trials 
minus unsuccessful-go trials. Briefly, we first convolved the main experimental 
condition (successful and failed inhibitory trials, each separately contrasted with Go 
trials) and the higher level contrast (successful-go trials minus unsuccessful-go trials) 
with two Poisson model functions (peaking at 4s and 8s) after motion correction, 
global detrending and spin-excitation history correction. We then calculated the 
weighted sum of these two convolutions that gave the best fit (least-squares) to the 
time series at each voxel. A goodness-of-fit statistic (the SSQ-ratio) was then 
computed at each voxel consisting of the ratio of the sum of squares of deviations 
from the mean intensity value due to the  model  (fitted  time  series)  divided  by  the  
sum  of  squares  due  to  the  residuals (original  time  series  minus  model  time  
series). The appropriate null  distribution  for assessing significance of any given 
SSQ-ratio was established using a wavelet-based data  re-sampling  method 
(Bullmore et al., 2000) and  applying  the  model-fitting process to the re-sampled 
data. This process was repeated 20 times at each voxel and the data combined over all 
voxels, resulting in 20 null parametric maps of SSQ-ratio for each subject, which 
were combined to give the overall null distribution of SSQ-ratio.  The  same  
permutation  strategy  was  applied  at  each  voxel  to  preserve  spatial correlation 
structure in the data. Activated voxels, at a <1 level of type I error, were identified 
through the appropriate critical value of the SSQ-ratio from the null distribution. 
Individual SSQ-ratio maps were then transformed into standard space, first by rigid 
body transformation of the fMRI data into a high-resolution inversion recovery image 
of the same subject, and then by affine transformation onto a Talairach template 
(Talairach and Tournoux, 1988). 
 
 Group Analysis: A group activation map was produced for the experimental 
condition (Successful Stop—Unsuccessful Stop) by calculating the median observed 
SSQ-ratio over all subjects at each voxel in standard space and testing them against 
the null distribution of median SSQ-ratios computed from the identically transformed 
wavelet re-sampled data (Brammer et al., 1997). The voxel-level threshold was first 
set to 0.05 to give maximum sensitivity and to avoid type II errors. Next, a cluster-
level threshold was computed for the resulting 3D voxel clusters. The necessary 
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combination of voxel and cluster level thresholds was not assumed from theory but 
rather was determined by direct permutation for each data set, giving excellent Type 
II error control (Bullmore et al., 1999). Cluster mass rather than a cluster extent 
threshold was used, to minimise discrimination against possible small, strongly 
responding foci of activation(Bullmore et al., 1999). In all group activation analyses, 
less than one false positive activation locus was expected for p<0.05 at voxel level 
and p<0.01 at cluster level. 
 
 ANCOVA Between-Group Difference Analyses: For between-group 
comparisons between controls and patients under either placebo or Fluoxetine, one-
way ANCOVA analyses with group as factor and rotational and translation movement 
in Euclidian 3-D space as covariate, were conducted using randomisation-based tests 
for voxel or cluster-wise differences as described in detail(Bullmore et al., 1999, 
Bullmore et al., 2000). For these between-group comparisons, less than 1 false 
activated cluster was expected at p < 0.05 for voxel and p < 0.01 for cluster 
comparisons. Given that right IFC was an apriori hypothesised region, we used a 
more lenient cluster p < 0.05. Then the standardised BOLD response values (SSQ 
ratios) for each participant were extracted for the mean activation of each of the 
significant clusters of the 3-group ANCOVA analyses and post-hoc t-tests (correcting 
for multiple comparisons using least significant difference (LSD)) were conducted to 
identify the direction of the group differences. 
 
 ANCOVA Within-Patients Interaction Effects: In order to investigate group by 
drug interaction effects between placebo and Fluoxetine within the patient groups, a 
2x2 ANCOVA (2 medication conditions, 2 groups) with rotational and translation 
movement in Euclidian 3-D space as covariate was conducted using randomised-
based testing for voxel or cluster-wise differences as described elsewhere(Bullmore et 
al., 2000). Less than one false positive activation cluster was expected at p<0.05 at 
voxel and p<0.01 at cluster level. For our apriori hypothesised region in right IFC, a 
more lenient p < 0.05 was used. Statistical measures of BOLD response for each 
participant were then extracted in each of the significant clusters and post-hoc t-tests 
(correcting for multiple comparisons with LSD) were conducted to identify the 




 Normalisation Effects: To test for the statistical significance of any apparent 
normalisation effects of Fluoxetine on case-control activation differences observed 
under placebo, we used non-parametric Friedman two-way analysis of variance by 
ranks on the extracted BOLD responses during each medication condition for each of 
the clusters shown to be significantly different in the comparison between controls 
and patients during placebo. We conducted this test only within patients, given that 
controls were only tested once, and hence constant across comparisons. 
 
Correlations with Behaviour: To test whether group, or group by drug, 
interaction effects were related to task performance or clinical behaviour we 
correlated all clusters with the main inhibitory variable of SSRT as well as with 
omission errors, since they were lower in ADHD patients relative to controls and 
ASD, in each group.  The SDQ hyperactive/inattentive subscale and CPRS scores in 
the ADHD group, and the social and communication, and stereotyped behaviours, 
subscales of the ADOS in the ASD group, were correlated with activation. For this 
purpose, the BOLD responses in these clusters were extracted for each subject and 
Pearson correlations were performed between these and performance and behaviour 
within each group. 
 
6.3 – Results 
 
6.3.1 - Participant Characteristics 
 
Group differences in age and IQ 
Univariate ANOVAs showed no significant group differences in age, but did 
for IQ (F (df =2,61) = 10, p < 0.001) which was significantly lower in ADHD relative 
to control and ASD boys (p < 0.005), who did not differ. ADHD children have 
typically lower IQ than their healthy peers (Bridgett and Walker, 2006). Therefore, 
we did not covary for IQ, as covarying for a measure that is intrinsic to the condition, 
and hence differs between groups, that were not randomly selected, would violate 
ANCOVA assumptions (Dennis et al., 2009). Nonetheless, to assess the potential 
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impact of IQ on group differences and group by medication interaction effects, 
analyses were repeated with IQ as covariate.  
 
Group differences in clinical questionnaire measures 
Multivariate ANOVA showed a significant group effect for all SDQ measures 
(F(df =10,112)=30 p < 0.0001). Post-hoc analyses are shown in the supplement. Post-
hoc analyses showed that controls scored significantly better on all subscales 
compared to patients (p < 0.001). ADHD boys scored significantly higher than ASD 
boys on the conduct and hyperactive/inattentive subscales of the SDQ (p < 0.0001) 
while ASD boys scored significantly worse than ADHD boys on the peer relations 
and prosocial subscales (p < 0.05) and significantly higher on the SCQ than ADHD 
and controls participants, while ADHD participants scored significantly higher than 
controls (F (df =2,55) = 152, p < 0.0001). ADHD boys scored higher on the CPRS 
than ASD and controls and ASD participants scored higher than controls (F (df =2,56) 





















Table 4. Sample characteristics for control boys, boys with ADHD and boys with 
ASD 
 






Age (years) 13.4 (2.4) 14.3 (1.8) 14.7 (2.0) 
IQ 109 (13) 95 (11) 112 (15) 
SDQ Hyperactive/Inattentive Subscale 1.8 (1.6) 9.2 (0.9) 4.5 (1.8) 
SDQ - Emotional Distress Subscale 0.5 (0.8) 3.6 (3.0) 4.2 (3.0) 
SDQ - Conduct Subscale 0.3 (0.7) 5.0 (2.4) 2.1 (2.0) 
SDQ – Peer Relations Subscale  .6 (1.1) 3.4 (2.5) 6.1 (2.4) 
SDQ – Prosocial Behaviour Subscale  9.1 (1.3) 6.7 (2.3) 5.1 (2.3) 
SDQ – Total scores  3.3 (2.9) 21.2 (4.9) 16.8 (5.7) 
SCQ Total 1.6 (2.7) 7.0 (3.4) 23.5 (5.5) 
CPRS-R Total T score 44 (3) 83 (7) 57 (8) 
ADOS Communication scores - - 2 (1) 
ADOS Social Interaction scores - - 7 (4) 
ADOS Social and Communication scores - - 9 (5) 
ADOS Stereotyped behaviour scores - - 1 (1) 
ADI Communication scores - - 14 (4) 
ADI Social Interaction scores - - 17 (5) 
ADI Stereotyped behaviours scores - - 6 (3) 
 
6.3.2 - Performance Data  
 
 All subjects achieved a comparable mean probability of inhibition of 
approximately 50% in the Stop Signal task (F(df =2,61)=1 p=0.3), demonstrating that 
the Stop algorithm was successful. ANOVA between controls and patients under 
placebo showed a significant group effect for omission errors (F(df =2,61)=4 p<0.05). 
Post-hoc analysis showed that this was due to the ADHD group making significantly 
more omission errors than controls (p < 0.05) and the ASD group (p < 0.01). ANOVA 
between controls and patients under Fluoxetine showed a significant group effect for 
omission errors (F(df =2,61)=5 p<0.05). Post hoc analysis showed that this was due to 
the ADHD group making significantly more omission errors than controls (p < 0.05) 
and the ASD group (p < 0.01) (see Table 5). There were no other significant group 




Table 5. Performance measures for the Stop Signal task for controls, boys with ADHD and boys with ASD 
 
 
Abbreviations: PI = Percentage Inhibition, SSRT = Stop Signal Reaction Time; MRT = Mean Reaction Time (in ms); SD = intrasubject 



























SSRT  161 (107) 132 (81)         142 (109) 140 (125) 142 (103) 
PI  51 50      49 50 49 
MRT to go trials  623 (104) 629 (86)       632 (109) 618 (102) 622 (113) 
SD for MRT to go trials  174 (39) 194 (44)       194 (60) 168 (39) 166 (43) 
Omission errors 5 (5) 9 (8)*       9 (9)* 3 (5) 3 (3) 
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6.3.3 - fMRI Data 
 
Movement  
Repeated measures ANOVAs using group as an independent factor and 
maximum x, y z rotation and translation as repeated measures showed that there were 
no significant group by movement interaction effects in rotation (F(df =4,118)=2, 
p=0.14.) or translation (F(df =4,118)=1, p=0.58). Nevertheless, to eliminate any 
potential effects of even small, non-significant variance in motion, motion parameters 
were used as a covariate in the fMRI analyses. 
 
Group Brain Activation Maps 
Successful- Failed Inhibition 
Controls – During successful - failed inhibition controls activated a typical 
inhibition network consisting of right inferior and middle frontal cortex, right caudate, 
bilateral putamen/globus pallidus, right middle/superior temporal lobe, right inferior 
parietal lobe, occipital lobe and left cerebellum.  
ADHD – While under placebo, the ADHD group activated bilateral occipital 
lobe. While under Fluoxetine, they activated right middle and superior frontal cortex, 
bilateral precentral and postcentral gyri, right caudate, putamen, insula and thalamus, 
right temporal lobe, bilateral parietal lobe, PCC, bilateral occipital lobe and 
cerebellum/midbrain. 
ASD – While under placebo, the ASD group activated bilateral middle and 
superior frontal cortex, right IFC, right caudate, putamen, thalamus and precuneus, 
bilateral occipital lobe and cerebellum. While under Fluoxetine, the ASD group 
activated right precentral and postcentral gyri, right parietal lobe, right middle 





Figure 9.A – Within-group activation for controls, boys with ADHD under either 
placebo or Fluoxetine and boys with ASD under either placebo or Fluoxetine for 
the contrast of successful – failed inhibition. Axial sections showing within-group 
brain activation for healthy control boys, boys with ADHD under either placebo or 
Fluoxetine and boys with ASD under either placebo or Fluoxetine for the contrast of 
successful – failed inhibition. Talairach z co-ordinates are indicated for slice distance 




Failed - Successful inhibition 
Controls – During failed – successful inhibition controls activated a single 
cluster in right precentral and postcentral gyri. 
ADHD – While under placebo, the ADHD group activated a single cluster in 
left precentral and postcentral gyri reaching into parietal lobe. While under 
Fluoxetine, the ADHD group activated mPFC/pre-SMA reaching into left superior 
frontal cortex and left inferior parietal lobe. 
ASD – While under placebo, the ASD group activated mPFC, including ACC, 
PCC and a left hemispheric network consisting of IFC, post insula, putamen and 
premotor and postcentral gyri. While under Fluoxetine, they activated ACC and left 




Figure 9.B –Within-group activation for controls, boys with ADHD under either 
placebo or Fluoxetine and boys with ASD under either placebo or Fluoxetine for 
the contrast of failed – successful inhibition. Axial sections showing within-group 
brain activation for healthy control boys, boys with ADHD under either placebo or 
Fluoxetine and boys with ASD under either placebo or Fluoxetine for the contrast of 
failed – successful inhibition. Talairach z co-ordinates are indicated for slice distance 
(in mm) from the intercommissural line. The right side corresponds to the right side of 
the image. The right side corresponds to the right side of the image.  
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Between-group differences between controls and patients under placebo 
ANCOVA between controls and patients on placebo showed significant group 
differences in left middle/IFC, left VLPFC/superior temporal lobe reaching into 
putamen and globus pallidus, and in left inferior parietal lobe. The right IFC was 
observed at a more lenient p < 0.05 (Figure 10.A, Table 6). 
 
Post-hoc analyses showed that the group effect in right IFC was due to 
significantly increased activation in this region in the ASD group relative to controls 
(p < 0.005) and trend-wise compared to ADHD boys (p = 0.08). In left middle/IFC, 
the ASD group had significantly increased activation compared to both controls and 
ADHD participants (p < 0.005) who activated this region during failed inhibition and 
had a trend-wise reduction relative to controls (p = 0.08). In left VLPFC/superior 
temporal lobe/basal ganglia both controls and ASD boys, who did not differ, showed 
increased activation relative to ADHD boys who activated this area during failed 
inhibition (p < 0.005). Left inferior parietal lobe was significantly reduced in both 
patient groups relative to controls (p < 0.05), with ASD patients activating this area 
significantly more during failed inhibition than ADHD (p < 0.05).  
 
In order to test whether group effects were related to task performance we 
correlated all clusters with the main inhibitory variable of SSRT as well as with 
omission errors, since they were lower in ADHD patients relative to controls and 
ASD. For this purpose, the BOLD responses in these clusters were extracted for each 
subject and Pearson correlations were performed between these and performance 
within each group. The (reduced) activation in left VLPFC/basal ganglia in ADHD 
was significantly negatively correlated with omission errors (r = -0.506, p < 0.05). No 
other correlations were significant.  
 
Between-group differences between controls and patients under Fluoxetine 
There were significant group differences in left and right pre-SMA/superior 
frontal cortex, SMA proper, left inferior parietal lobe/middle temporal lobe, right 
inferior parietal lobe and precuneus (Figure 10.B, Table 6). Post-hoc analyses showed 
that controls and the ASD group, who did not differ, activated pre-SMA/superior 
frontal cortex significantly more than ADHD boys who activated this cluster during 
failed inhibition (p < 0.0001). SMA proper was significantly more activated in 
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patients, who did not differ, relative to controls who activated this region during failed 
inhibition (p < 0.05). In left and right inferior parietal lobe, controls and ASD boys 
had increased activation relative to ADHD boys who activated this region during 
failed inhibition (p < 0.05). In right inferior parietal lobe, ASD also had increased 
activation relative to controls (p < 0.05). In precuneus, the ADHD group showed 
significantly enhanced activation relative to both ASD (p < 0.05) and controls who 
activated this region during failed inhibition and differed relative to ASD (p < 0.05).  
 
Friedman two-way analysis of variance by ranks showed that Fluoxetine 
relative to placebo significantly increased activation in left superior temporal 
lobe/VLPFC/putamen in the ADHD group and in left inferior parietal lobe in the ASD 
group, as well as reducing activation in right and left IFC in the ASD group, leading 
to normalisation of these deficits that were observed in patients relative to controls 
under placebo.  
 
Correlations with performance showed that activation in pre-SMA/superior 
frontal cortex during successful inhibition was negatively correlated with SSRT in the 
ASD group (r = -0.532, p < 0.05). Activation in precuneus was negatively correlated 
with SSRT in the ADHD group (r = -0.493, p < 0.05). No other correlations were 
significant.    
 
To assess the potential impact of IQ on case-control group differences, all 
analyses were repeated with IQ as a covariate. All clusters remained at a p < 0.01, 
apart from left VLPFC in the placebo between-group ANCOVA and right inferior 
parietal lobe in the fluoxetine between-group ANCOVA, which survived at a more 











Within-Patients group by medication interaction effects 
ANCOVA analysis with group as dependent variable and drug as within-group 
variable showed a significant group by medication interaction effect in five clusters. 
1) Fluoxetine reduced pre-SMA activation in the ADHD group, whereas it increased 
it in the ASD group during successful inhibition (p < 0.005). 2) Fluoxetine increased a 
cluster in left VLPFC/superior temporal lobe/putamen/globus pallidus in ADHD 
during successful inhibition relative to placebo, but reduced it in ASD (p < 0.05). 3) 
Both patient groups activated left inferior parietal lobe during failed inhibition while 
on placebo, but the ADHD group activated this region more during failed inhibition 
and the ASD group more during successful inhibition on Fluoxetine (p < 0.0001). 4) 
Right cerebellum activation was increased under Fluoxetine in ADHD relative to 
placebo for successful stop trials, while ASD boys activated this area during failed 
inhibition on both placebo and Fluoxetine (p <0.05). 5) A right IFC cluster was 
present at a more lenient p < 0.05, due to Fluoxetine increasing this activation in 
ADHD during successful inhibition relative to placebo while decreasing it in the ASD 
group relative to placebo (p < 0.05) (Figure 10.C, Table 7). No significant correlations 
with performance were observed. All findings remained significant at p < 0.01 when 











Figure 10.A Stop Signal Task Between-Group and Within-Patient Comparisons: 
Axial sections showing the between-group ANCOVA findings between controls and 
patients under placebo. Shown underneath are the statistical measures of BOLD 
response for each of the 3 groups for each of the brain regions that showed a 
significant group effect. B. Axial sections for the between-group ANCOVA 
comparison between controls and patients under Fluoxetine. Shown underneath are 
the statistical measures of BOLD response for each of the 3 groups for each of the 
brain regions that showed a significant group effect. C. Axial sections showing 
within-patient group by medication interaction effects. Shown underneath are the 
statistical measures of BOLD response for each of the brain regions that showed a 
significant group by medication interaction effect between patients. Talairach z co-
ordinates are indicated for slice distance (in mm) from the intercommissural line. The 
right side of the image corresponds to the right side of the brain. 
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Voxels   Cluster 
  p-value 
PLACEBO 
C < ASD 
 
C, ADHD < ASD 
 
C, ASD > ADHD  
 
C > ADHD > ASD 
R Inferior frontal cortex 
 
L Inferior/middle frontal cortex 
 
L Superior temporal lobe/VLPFC/putamen/globus pallidus 
 




























   0.002 
FLUOXETINE 
C, ASD > ADHD 
 
 
C < ADHD, ASD 
 
ADHD < C < ASD 
 
C, ASD > ADHD 
 
C < ASD < ADHD 
 L + R pre-SMA/premotor/superior frontal cortex 
 
 
 SMA proper 
 
 R Inferior parietal lobe/angular gyrus 
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R pre-SMA/premotor/superior frontal cortex 
 
L Superior temporal lobe/VLPFC/putamen/globus pallidus 
 








































6.4 – Discussion 
 
 This study shows inverse brain dysfunction patterns in inhibitory brain regions 
in ADHD and ASD as well as inverse disorder-dissociated modulation effects of 
Fluoxetine on these neurofunctional abnormalities. Relative to controls, ADHD 
patients showed reduced left VLPFC/basal ganglia activation whereas ASD patients 
showed enhanced left and right IFC activation relative to ADHD and controls. 
Fluoxetine significantly normalised these disorder-dissociated brain abnormalities 
relative to controls, via disorder-dissociated inverse effects within patients: Fluoxetine 
enhanced the abnormally reduced VLPFC/basal ganglia activation in ADHD, but 
reduced it in ASD. In contrast, it reduced the abnormally enhanced IFC activation in 
ASD, but enhanced it in ADHD. Furthermore, Fluoxetine also inverse disorder-
dissociated effects on other inhibition areas such as pre-SMA and cerebellum: these 
were, respectively, enhanced (SMA) and reduced (cerebellum) in ADHD with 
Fluoxetine relative to placebo, but reduced (SMA) and enhanced (cerebellum) in 
ASD.  
 The finding of disorder-specific increased activation in ASD relative to 
controls and ADHD in left IFC and in right IFC (where it was only trend-wise 
different to ADHD) extends our previous finding of increased left IFC activation in 
young adults with Asperger syndrome compared to controls during a Go/No-Go 
task(Schmitz et al., 2006)by showing that this hyperactivation is disorder-specific 
relative to ADHD. Predominantly right(Rubia et al., 2003) but also left IFC(Rubia et 
al., 2001a) are crucial areas mediating response inhibition. ADHD patients had no 
underactivation in these areas relative to controls as observed previously (Rubia et al., 
1999, Rubia et al., 2005b), but did relative to ASD. Potential practice effects (may 
have overshadowed deficits in both IFC activation and inhibitory performance since 
ADHD patients performed the task twice. The deficits in ADHD adolescents in left 
VLPFC/basal ganglia relative to controls extends prior findings of VLPFC-striatal 
deficits in ADHD(Rubia et al., 1999, Rubia et al., 2005b, Hart et al., 2012b) (albeit in 
a more ventral location). Therefore, our results show disorder-dissociated frontal lobe 
dysfunctions in ADHD and ASD boys during inhibitory performance relative to 
controls: with ASD patients showing significantly enhanced bilateral IFC activation 




Fluoxetine significantly normalised all disorder-dissociated frontal brain 
dysfunctions due to inverse modulation effects in both disorders. Fluoxetine 
significantly reduced right IFC and left VLPFC activation in the ASD group but 
enhanced it in ADHD. Fluoxetine also had an inverse upregulation/downregulation 
effect on another key inhibition region of pre-SMA: this was upregulated in ASD and 
hence increased relative to controls and ADHD, but downregulated in ADHD and 
hence reduced relative to controls and ASD. The upregulation effect of Fluoxetine on 
right IFC and VLPFC-striatal regions in ADHD extends prior evidence on 5-HT 
modulation of these areas in healthy adults during inhibitory control (Del-Ben et al., 
2005) to the ADHD population. Most intriguing, however, are the consistently inverse 
reduction effects of Fluoxetine on these frontal activations in the ASD group. Inverse 
activation effects could possibly reflect group differences in baseline 5-HT levels. 
There is evidence for lower platelet 5-HT levels in ADHD children compared to 
controls (Spivak et al., 1999). Conversely, there is consistent evidence for increased 
baseline platelet and blood 5-HT levels in 30% of individuals with ASD (Hranilovic 
et al., 2007) and in prefrontal regions, relative to controls (Nakamura et al., 2010). 
  
Furthermore, during emotion processing, serotonergic modulation with ATD 
in adults with ASD compared to controls has shown inverse patterns of 
neurofunctional modulation, suggesting abnormal 5-HT baseline levels in ASD (Daly 
et al., 2012). Therefore, Fluoxetine may increase the low baseline of 5-HT in children 
with ADHD to normal levels, leading to normalised activation in fronto-striatal areas. 
Whereas in children in ASD, the increase in 5-HT in an already hyperserotonemic 
system may activate a negative feedback mechanism via activation of 5-HT1A 
autoreceptors (Sibley et al., 2007), leading to a decrease in 5-HT and in fronto-striatal 
activation. 
  
A limitation of this study is that the control group was only scanned once, 
while patients were scanned twice which could have accounted for the lack of 
performance differences. The significantly lower IQ in the ADHD group is another 
limitation. However, covariance analysis showed that findings were not affected by 
IQ. The strengths of this study are the carefully selected and non-comorbid patient 
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groups who were free of psychiatric co-morbidities and, in the case of the ASD group, 
medication naïve.   
 
To summarise, ADHD and ASD patients showed inverse brain activation 
abnormalities, with reduced frontal activations in ADHD and enhanced frontal 
activation in ASD relative to controls. Importantly, Fluoxetine had a disorder-
dissociated inverse effect on frontal brain dysfunctions, enhancing frontal activation 
in ADHD and reducing it in ASD which could suggest differential underlying 5-HT 




























Chapter 7 – Inverse effect of Fluoxetine on medial 
prefrontal cortex activation during reward reversal 
learning in ADHD and ASD 
 
7.1 – Introduction 
 
 ADHD is a neurodevelopmental disorder characterized by age-inappropriate 
levels of impulsiveness, inattention and hyperactivity (American et al., 1994). ASD is 
also a neurodevelopmental disorder, and is defined by impairments in communication 
and social interaction, as well as restricted and repetitive behaviours (American et al., 
1994). ADHD and ASD are highly comorbid with recent studies reporting an overlap 
of up to 30% (Simonoff et al., 2008, Kochhar et al., 2011, Rommelse et al., 2011). 
However, the underlying cause of this high risk for co-morbidity, and the shared and 
disorder-specific biological profiles of these disorders, are still unknown. Both 
disorders share executive function deficits (Willcutt et al., 2005, Rommelse et al., 
2011, Corbett et al., 2009) including poor cognitive flexibility (Hill, 2004, Willcutt et 
al., 2005, Sanders et al., 2008) which has been linked to repetitive behaviours in ASD 
(Yerys et al., 2009). The clinical importance of this behavioural and cognitive overlap 
has been highlighted by changes to the upcoming DSM-V which allows co-diagnosis 
of both ADHD and ASD (http://www.dsm5.org). 
 
 Cognitive flexibility can be measured in switching and reversal tasks, where 
stimulus-response associations need to be either changed to new, or reversed to 
previous stimulus-response associations, respectively. fMRI studies of switch tasks 
have found decreased activation in ADHD compared to controls in IFC, the temporo-
parietal junction and striatum (Smith et al., 2006, Rubia et al., 2010b, Rubia et al., 
2010a, Hart et al., 2013), and reversal studies have found  abnormal medial frontal 
and precuneus activation (Finger et al., 2008). No fMRI study has investigated 
cognitive flexibility in ASD children, with two adult ASD studies reporting 
conflicting evidence of decreased activation in DLPFC, ACC and basal ganglia 
(Shafritz et al., 2008), and increased activation in IFC and parietal lobe relative to 




 There is evidence that manipulation of 5-HT modulates reward reversal 
learning (Roberts, 2011, Murphy et al., 2002, Evers et al., 2005). Polymorphisms of 
serotonergic genes have been associated with both ADHD and ASD (Rommelse et al., 
2010, Sinzig and Lehmkuhl, 2007) and there is evidence that a polymorphism of the 
5-HTLPR may play a role in the ADHD symptoms observed in ASD (Gadow et al., 
2013). Furthermore, biochemical serotonergic dysfunction has been implicated in 
both ADHD (Oades, 2007) and ASD (Zafeiriou et al., 2009), with evidence for 
decreased platelet 5-HT levels in ADHD (Spivak et al., 1999) and increased platelet 
5-HT levels in one third of individuals with ASD (Piven et al., 1991, Mulder et al., 
2004, Hranilovic et al., 2007). In ASD abnormal 5-HT synthesis (Chugani et al., 
1999, Chugani et al., 1997), SERT binding (Makkonen et al., 2008, Nakamura et al., 
2010) and 5-HT2A receptor binding (Murphy et al., 2006) has also been reported. 
Fluoxetine has been shown to increase metabolic and neurofunctional activity in 
adults with ASD in areas mediating reward reversal learning such as OFC and mPFC, 
ACC and striatum (Mitchell et al., 2008, Freyer et al., 2009), which was associated 
with reduced obsessive behaviour (Buchsbaum et al., 2001, Dichter et al., 2010). 
Clinical trials of Fluoxetine in children with ASD have shown  improvement in 
communication, social interaction and stereotyped behaviours (DeLong et al., 2002, 
DeLong et al., 1998, Hollander et al., 2005, Carrasco et al., 2012), although effects 
are small (Williams et al., 2010) and studies using Citalopram have found no effects 
(King et al., 2009). In children with ADHD, Fluoxetine has been shown to improve 
irritability, inattentiveness and hyperactivity (Gammon and Brown, 1993, Barrickman 
et al., 1991, Quintana et al., 2007).  
 
 Despite the cognitive and neurofunctional evidence for impaired cognitive 
flexibility in ADHD (Willcutt et al., 2005, Smith et al., 2006, Rubia et al., 2010b, 
Rubia et al., 2010a, Finger et al., 2008) and ASD (Hill, 2004, Sanders et al., 2008, 
Shafritz et al., 2008, Schmitz et al., 2006), for 5-HT abnormalities in both disorders 
(Rommelse et al., 2010, Sinzig and Lehmkuhl, 2007, Gadow et al., 2013, Oades, 
2007, Zafeiriou et al., 2009, Spivak et al., 1999, Piven et al., 1991, Mulder et al., 
2004, Hranilovic et al., 2007, Chugani et al., 1999, Chugani et al., 1997, Makkonen et 
al., 2008, Nakamura et al., 2010, Murphy et al., 2006, Buchsbaum et al., 2001, 
Dichter et al., 2010), the positive effect of 5-HT upregulation on cognitive flexibility 
(Roberts, 2011) and the ameliorative effect of Fluoxetine on behaviour in these two 
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disorders (DeLong et al., 2002, DeLong et al., 1998, Hollander et al., 2005, Carrasco 
et al., 2012, Gammon and Brown, 1993, Barrickman et al., 1991, Quintana et al., 
2007), no study has as yet compared the shared and disorder-specific neurofunctional 
abnormalities of this executive function, nor the modulatory effects of Fluoxetine.   
 
 The aim of this fMRI study was therefore to investigate 1) shared and 
disorder-specific brain abnormalities in adolescents with ADHD and adolescents with 
ASD during reward reversal learning and 2) shared and disorder-specific 
neurofunctional effects of an acute dose of Fluoxetine on this function in both 
disorders. Based on prior evidence (Smith et al., 2006, Rubia et al., 2010a, Rubia et 
al., 2010b, Hart et al., 2013, Shafritz et al., 2008) we hypothesised that under placebo, 
both disorders would show abnormal activation in IFC, mPFC and striatum compared 
to controls, with disorder-dissociated abnormalities in these regions. We hypothesised 
that Fluoxetine would normalise these neurofunctional abnormalities in both 
disorders.  
 
7.2 - Methods  
 
7.2.1 – Participants 
 
Thirty - two ADHD boys were recruited in total, however; 10 dropped out of 
the study due to their dislike of the MRI scanner, three were excluded due to co-
morbidities, one boy did not reach the diagnostic criteria for the combined subtype of 
ADHD, one boy was excluded due to poor task performance and two were excluded 
due to high levels of motion. Forty - four ASD boys were recruited in total. Of these, 
seven boys dropped out of the study due to their dislike of the MRI scanner, 14 were 
excluded due to co-morbidities, one was excluded due to neurological abnormalities, 
two were excluded due to SSRI use and two were excluded due to high levels of 
motion. Twenty - two controls were recruited in total however one was excluded due 
to high scores on the SDQ. 
 
Fifty-four right handed males (assessed with the Edinburgh Handedness 
Inventory) (Oldfield, 1971) (21 controls, 15 with ADHD and 18 with ASD) aged 10-
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17 years old, with an IQ > 70 (assessed with the Wechsler Abbreviated Scale of 
Intelligence-Revised (Wechsler, 1999) participated. 
 
ADHD boys met the diagnostic DSM-IV criteria for hyperactive-
impulsive/inattentive combined type ADHD and scored above clinical threshold for 
ADHD on both the SDQ (Goodman and Scott, 1999) and the CPRS (Conners et al., 
1998) (one boy was below cut-off on SDQ but had diagnostic confirmation from a 
child psychiatrist). Three ADHD boys were medication-naïve, one ceased taking 
MPH for three months prior to the study and 11 were on chronic stimulants, but all 
had a 48hr medication washout prior to scanning.  
 
ASD diagnosis was made using ICD-10 diagnostic criteria (World et al., 1994) 
and confirmed by the ADI-R (Lord et al., 1994) and the ADOS (Lord et al., 2000). All 
ASD subjects were medication-naïve apart from one patient, who took melatonin, but 
underwent two week medication washout. ASD exclusion criteria included a score 
above seven on the hyperactivity/inattention subscale of the SDQ. ADHD boys were 
excluded if they scored above 15 on the SCQ (Rutter et al., 2003). Comorbidity with 
other psychiatric or neurological disorders and drug/alcohol dependency were 
exclusion criteria for all patients. Patients were recruited from local clinical services 
and support groups. Written informed consent/assent was given for all participants 
and the study was approved by the local Ethical Committee. 
 
Patients were scanned twice in a double-blind, randomised, placebo-controlled 
design, using a Latin square randomisation design for counter-balanced effects. Due 
to the half-life of Fluoxetine, (1-3 days), and its metabolite Norfluoxetine (5-16 days) 
(Wong et al., 1995) each scan was 3-4 weeks apart. To ensure that Fluoxetine had 
reached its peak plasma levels, which occur after 5-8 hours (Wong et al., 1995), 
patients were scanned five hours after administration. Liquid Fluoxetine was titrated 
to age and weight in the following manner.  Boys between 10-13 years and less than 
30kg received 8mg, those greater than 30kg received 10mg. Boys between 14-17 
years and less than 30kg received 10mg, those greater than 30kg received 15mg. 
Placebo was equivalent amounts of peppermint water which was similar in taste to 




Twenty-one age and handedness matched control boys were recruited locally 
by advertisement. They all scored below clinical thresholds on the SDQ, SCQ and 
CPRS.  
 
7.2.2 - fMRI Reward Reversal Learning Paradigm 
 
Subjects practised the task once prior to each scan. Our fMRI adaptation is 
similar to the probabilistic reward reversal learning task employed by Cools et al 2002 
(Cools et al., 2002). The semi self-paced reward reversal learning task requires 
subjects to reverse their response and select a previously unrewarded stimulus after 
learning a particular stimulus-reward association. Images of a car and a spaceship are 
displayed simultaneously on the left and right side (randomised) of a black screen for 
1950ms, and the subject has to choose the correct choice with a left and right button 
press, indicated by feedback which is a photo of a 50 pence piece and a green happy 
smiley. The incorrect choice is indicated by a photo of a crossed-out 50 pence piece 
and a red unhappy smiley, both displayed after the choice for 950ms. There is a 
100ms gap between each trial leading to an inter-trial interval of 3s. Reversal of the 
stimulus-reward association occurs after 4-6 consecutive correct responses, allowing 
adequate separation of the haemodynamic response curves. The task ends after 20 
reversal trials or after 20 minutes, whichever condition is met first. Zero to 2 
probabilistic error trials (PET), where negative feedback is given for a correct 
response, are randomly interspersed between reversal trials to prevent subjects from 
predicting an upcoming reversal trial. PET trials are at least 3 trials apart from other 
PETs and reversal trials for adequate separation of haemodynamic response curve 
(Figure 11). The main dependent variable of this task is the number of perservative 






Figure 11 – Reward Reversal Learning Task: Subjects select an image (right/left) 
by pressing the corresponding button (right/left). If is the choice is correct/incorrect, 
positive/negative feedback is given. Once the subject has made 4-6 correct responses, 
the stimulus reward contingency is reversed. Probabilistic Error Trials (PET), where 
incorrect feedback is given for a correct response, are included to prevent subjects 
from predicting an upcoming reversal trial. The task contains on average 20 reversal 









7.2.3 - Data Analysis 
 
Analysis of performance data 
 Two ANOVAs compared perseverative errors between controls and patients 
under either placebo or Fluoxetine. A repeated-measures ANOVA was conducted 
within the patient groups with group as an independent factor and drug 
(placebo/Fluoxetine) as a repeated measure to test for group by medication interaction 
effects on performance.  
 
fMRI Image acquisition  
            Gradient-echo  echoplanar  MR  imaging  (EPI)  data  were  acquired  on  a  
General Electric Signa 3T Horizon HDx system at the Centre For Neuroimaging 
Sciences, Institute of Psychiatry, King’s College London, UK. A semi-automated 
quality control procedure ensured consistent image quality (Simmons et al., 1999). A 
quadrature birdcage headcoil was used for radio frequency transmission and 
reception. In each of 23 non-contiguous planes parallel to the anterior-posterior 
commissure, 800 T2*-weighted MR images depicting BOLD contrast covering the 
whole brain were acquired with TE=30ms, TR=1.5s, flip angle=70°, in-plane voxel 
size=3mm, slice thickness=5.5mm (including slice-skip=0.5mm). This EPI dataset 
provided almost complete brain coverage. A whole-brain high resolution structural 
scan (inversion recovery gradient echo planar image) on which to superimpose the 
individual activation maps, was also acquired in the inter-commissural plane with 
TE=30 ms, TR=3s, flip angle = 90
o
, 43 slices, slice thickness=3.0mm, slice 
skip=0.3mm, in-plane voxel-size = 1.875mm. 
 
fMRI image analysis 
 The XBAM software package was used (http://www.brainmap.co.uk) 
(Brammer et al., 1997) which makes no normality assumptions (often violated in 
fMRI data), but instead uses median statistics to control outlier effects and 
permutation rather than normal theory-based inference (Thirion et al., 2007). In the 
fMRI analysis, brain activation to PETs are subtracted from brain activation to the 
final reversal error before a correct response. This stringent contrast captures the point 
at which subjects learn to reverse their response, and controls for the brain response to 
the punishment given in the negative feedback in both trials. This contrast has been 
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used in previous fMRI studies of reward reversal learning (Cools et al., 2002, 
Remijnse et al., 2005).  
 
Individual Analysis: fMRI data were first processed to minimise motion 
related artifacts (Bullmore et al., 1999). A 3D volume consisting of the average 
intensity at each voxel over the whole experiment was calculated and used as a 
template. The 3D image volume at each time point was then realigned to this template 
by computing the combination of rotations (around the x y and z axes) and 
translations (in x y and z) that maximised the correlation between the image 
intensities of the volume in question and the template (rigid body registration). 
Following realignment, data were then smoothed using a Gaussian filter (FWHM, 
7.2mm) to improve the signal to noise characteristics of the images. After  
preprocessing,  time  series  analysis  for  each  subject  was  based  on  a wavelet-
based  data  resampling  method  for  functional  MRI  data (Bullmore et al., 2000, 
Bullmore et al., 1999).  At the individual subject level, a standard general linear 
modelling approach was used to obtain estimates of the response size (beta) to the 
reward reversal task condition final reversal error against probabilistic error trials. 
Briefly, we first convolved the main experimental conditions (final reversal error 
versus repeat trials; probabilistic error trials versus repeat trials) with two Poisson 
model functions (peaking at 4s and 8s) after motion correction, global detrending and 
spin-excitation history correction. We also calculated the difference between the two 
(i.e. final reversal error versus probabilistic error trials). We then calculated the 
weighted sum of these two convolutions that gave the best fit (least-squares) to the 
time series at each voxel. A goodness-of-fit statistic (the SSQ-ratio) was then 
computed at each voxel consisting of the ratio of the sum of squares of deviations 
from the mean intensity value due to the  model  (fitted  time  series)  divided  by  the  
sum  of  squares  due  to  the  residuals (original  time  series  minus  model  time  
series). The appropriate null  distribution  for assessing significance of any given 
SSQ-ratio was established using a wavelet-based data  re-sampling  method 
(Bullmore et al., 2000) and  applying  the  model-fitting process to the re-sampled 
data. This process was repeated 20 times at each voxel and the data combined over all 
voxels, resulting in 20 null parametric maps of SSQ-ratio for each subject, which 
were combined to give the overall null distribution of SSQ-ratio.  The  same  
permutation  strategy  was  applied  at  each  voxel  to  preserve  spatial correlation 
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structure in the data. Activated voxels, at a <1 level of type I error, were identified 
through the appropriate critical value of the SSQ-ratio from the null distribution. 
Individual SSQ-ratio maps were then transformed into standard space, first by rigid 
body transformation of the fMRI data into a high-resolution inversion recovery image 
of the same subject, and then by affine transformation onto a Talairach template 
(Talairach and Tournoux, 1988). 
 
 Group Analysis: A group activation map was produced for the key 
experimental condition (final reversal error – probabilistic error trials) by calculating 
the median observed SSQ-ratio over all subjects at each voxel in standard space and 
testing them against the null distribution of median SSQ-ratios computed from the 
identically transformed wavelet re-sampled data (Brammer et al., 1997). The voxel-
level threshold was first set to 0.05 to give maximum sensitivity and to avoid type II 
errors. Next, a cluster-level threshold was computed for the resulting 3D voxel 
clusters. The necessary combination of voxel and cluster level thresholds was not 
assumed from theory but rather was determined by direct permutation for each data 
set, giving excellent Type II error control (Bullmore et al., 1999). Cluster mass rather 
than a cluster extent threshold was used, to minimise discrimination against possible 
small, strongly responding foci of activation (Bullmore et al., 1999). In all group 
activation analyses, less than one false positive activation locus was expected for 
p<0.05 at voxel level and p<0.01 at cluster level. 
 
 ANCOVA Between-Group Difference Analyses: For the between-group 
comparisons between controls and patients under either placebo or Fluoxetine, one-
way ANCOVA analyses, with group as an independent factor and rotational and 
translation movement in Euclidian 3-D space as a covariate, were conducted using 
randomisation-based tests for voxel or cluster-wise differences as described in detail 
elsewhere (Bullmore et al., 2000, Bullmore et al., 1999). For these between-group 
comparisons, a p-value of p < 0.05 was used for voxel and p < 0.02 for cluster 
comparisons to achieve an optimal balance between type II and type I error. Then the 
standardised BOLD response values (SSQ ratios) for each participant were extracted 
for each of the significant clusters of the 3-group ANCOVA analyses and post-hoc t-
tests (correcting for multiple comparisons using least significant difference (LSD)) 




 ANCOVA Within-Patient Interaction Effects: In order to investigate the group 
by drug interaction effects between placebo and Fluoxetine within-patient groups, a 
2x2 ANCOVA (2 medication conditions, 2 groups) with rotational and translation 
movement in Euclidian 3-D space as covariate was conducted using randomisation-
based testing for voxel or cluster-wise differences as described elsewhere (Bullmore 
et al., 2000). Less than one false positive 3D cluster was expected at p<0.05 at voxel 
level and p<0.01 at the cluster level. Statistical measures of BOLD response for each 
participant were then extracted in each of the significant clusters and post-hoc t-tests 
(correcting for multiple comparisons with LSD) were conducted to identify the 
direction of the interaction effects. 
 
 Normalisation Effects: To test for the statistical significance of any apparent 
normalisation effects of Fluoxetine on case-control activation differences observed 
under placebo, we used non-parametric Friedman two-way analysis of variance by 
ranks on the extracted BOLD responses during each medication condition for each of 
the clusters shown to be significantly different in the comparison between controls 
and patients during placebo. We conducted this test within patients only, given that 
controls were tested once.  
 
Correlations with Behaviour: To test whether group, or group by drug, 
interaction effects were related to task performance or clinical behaviour we 
correlated all clusters with perservative errors in each group.  The SDQ 
hyperactive/inattentive subscale and CPRS scores in the ADHD group, and the social 
and communication, and stereotyped behaviours, subscales of the ADOS, and the 
social interaction subscale of the ADI, in the ASD group, were correlated with 
activation. For this purpose, the BOLD responses in these clusters were extracted for 
each subject and Pearson correlations were performed between these and performance 







7.3 – Results 
 
7.3.1 - Participant Characteristics 
 
Group Differences in age and IQ 
ANOVAs showed no significant group differences in age, but did for IQ (F (df 
=2,53) = 7, p < 0.002), which was significantly lower in ADHD relative to control and 
ASD boys (p < 0.005), who did not differ from each other. ADHD children typically 
have lower IQ than their healthy peers (Bridgett and Walker, 2006). Therefore, IQ 
was not covaried, as when the covariate is intrinsic to the condition, and differs 
between groups who were not randomly selected, it violates ANCOVA assumptions 
(Dennis et al., 2009). Nonetheless, to assess the potential impact of IQ on group 
differences and group by medication interaction effects, the analyses were repeated 
with IQ as covariate.  
 
Group Differences in clinical questionnaires 
Multivariate ANOVA showed a significant group effect for all SDQ measures 
(F(df =10,94)=18 p < 0.0001). Post-hoc analyses showed that controls scored 
significantly better on all subscales compared to patients (p < 0.05), apart from the 
conduct subscale where ASD boys scored equally as low as controls. ADHD boys 
scored significantly higher than ASD boys on the conduct and hyperactive/inattentive 
subscales of the SDQ (p < 0.005), while the ASD boys scored significantly worse 
than the ADHD boys on the peer relation subscale (p < 0.0001). ASD boys scored 
significantly higher on the SCQ than ADHD and controls participants, while ADHD 
participants scored significantly higher than controls (F (df =2,50) = 134, p < 0.0001). 
ADHD boys scored higher on the CPRS than ASD and controls participants and the 








Table 8. Sample characteristics for control boys, boys with ADHD and boys 
with ASD 
 






Age (years) 14.2 (2.6) 14.6 (1.8) 14.6 (1.9) 
IQ 107 (14) 96 (12) 114 (16) 
SDQ Hyperactive/Inattentive Subscale 2.9 (1.8) 8.9 (1.4) 4.8 (1.6) 
SDQ - Emotional Distress Subscale 0.8 (1.4) 3.1 (3.2) 4.3 (3.0) 
SDQ - Conduct Subscale 1.0 (1.7) 4.4 (2.3) 2.1 (2.0) 
SDQ – Peer Relations Subscale  1.2 (1.1) 3.1 (2.2) 6.3 (2.4) 
SDQ – Prosocial Behaviour Subscale  8.6 (1.7) 6.3 (2.3) 5.1 (2.3) 
SDQ – Total scores  5.9 (3.9) 19.5 (5.1) 17.6 (5.3) 
SCQ Total 2.1 (2.9) 7.2 (3.8) 23.8 (5.3) 
CPRS-R Total T score 44 (3) 82 (7) 58 (8) 
ADOS Communication scores - - 2 (1) 
ADOS Social Interaction scores - - 7 (4) 
ADOS Social and Communication scores - - 10 (5) 
ADOS Stereotyped behaviour scores - - 1 (1) 
ADI Communication scores - - 15 (4) 
ADI Social Interaction scores - - 17 (5) 




7.3.2 - Performance Data  
 
ANOVA between controls and patients under placebo showed no significant 
group effect (F(df =2,53)=2, p=0.170), although both patient groups made 
numerically more errors with a relatively large effect size of  0.12 for ADHD and a 
medium effect size of 0.05 for ASD. Fluoxetine showed a significant group effect for 
perseverative errors (F(df =2,53)=4, p<0.05) which were significantly higher in 
ADHD relative to controls (p < 0.005). (Mean perseverative errors: Controls: 1.4 (SD 
= 0.3); ADHD placebo: 1.7 (SD = 0.5); ADHD Fluoxetine: 1.8 (SD = 0.4); ASD 
placebo: 1.7 (SD = 0.6); ASD Fluoxetine: 1.6 (0.4)). There were no group by 
medication interaction effects.  
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7.3.3 - fMRI Data 
 
Movement  
Repeated measures ANOVAs using group as an independent factor and 
maximum x, y and z rotation or maximum x, y and z translation as repeated measures 
showed that there were no significant group by movement interaction effects in 
rotation (F(df =4,102)=2, p=n.s.) or translation (F(df =4,102)=2, p=n.s). Nevertheless, 
to eliminate any potential effects of non-significant variance in motion, motion 
parameters were used as covariates in fMRI analysis. 
 
Group Brain Activation Maps 
 
Final Reversal Error – Probabilistic Error 
Control – At the point of deciding to reverse their response compared to 
probabilistic errors, control activated mPFC, SMA, ACC, and a bilateral network 
involving precentral/postcentral gyri, inferior/middle/superior frontal cortices, basal 
ganglia, thalamus, midbrain and PCC/precuneus, 
ADHD – Under placebo, at the point of deciding to reverse their response, 
ADHD subjects activated mPFC/ACC, left precentral/postcentral gyri, right middle 
frontal cortex, bilateral IFC/insula, putamen and left inferior, and right superior, 
parietal cortices. Under Fluoxetine, ADHD subjects activated SMA, left superior 
parietal lobe and right hippocampal gyrus. 
ASD – Under placebo, at the point of deciding to reverse their response, ASD 
subjects activated bilateral IFC/caudate/putamen and a right hemispheric network 
comprising precentral/postcentral gyrus, inferior/superior parietal lobe, precuneus and 
fusiform gyrus/cerebellum. Under Fluoxetine, ASD subjects activated a right 
hemispheric network consisting of middle/superior frontal cortex, superior parietal 






Figure 12– Within-group activation for controls, boys with ADHD under either 
placebo or Fluoxetine and boys with ASD under either placebo or Fluoxetine for 
the contrast of Final Reversal Error – Probabilistic Error. Axial sections showing 
within-group brain activation for healthy control boys, boys with ADHD under either 
placebo or Fluoxetine and boys with ASD under either placebo or Fluoxetine for the 
contrast of final reversal error – probabilistic error. Talairach z co-ordinates are 
indicated for slice distance (in mm) from the intercommissural line. The right side 
corresponds to the right side of the image. 
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Between-Group differences between controls and patients under placebo 
ANCOVA between controls and patients under placebo showed significant 
group effects in mPFC and precuneus reaching into PCC (Figure 13.A Table 9). Post-
hoc analyses showed that the group effect in mPFC was due to significantly decreased 
activation in ASD compared to controls (p < 0.0001) and ADHD (p < 0.0001), who 
did not differ from each other. In precuneus both ADHD (p < 0.005) and ASD (p < 
0.05) groups, who did not differ from each other, had significantly decreased 
activation compared to controls.  
 
In order to test whether group effects were related to performance or 
behaviour we correlated the statistical BOLD response in group difference clusters 
with perseverative errors and behavioural scores within each group. For this purpose, 
the statistical BOLD response measures in these clusters were extracted for each 
subject and Pearson correlations were performed between these, performance and 
behaviorual scores. The activation in precuneus in ASD was positively correlated with 
perservative errors (r = 0.5, p < 0.05). No other correlations were significant.  
 
Between-Group differences between controls and ADHD and ASD patients 
under Fluoxetine 
 ANCOVA between controls and patients under Fluoxetine showed a 
significant group effect in left insula reaching into putamen (Figure 13.B, Table 9). 
Post-hoc analyses showed that this difference was due to significantly reduced 
activation in the ASD group compared to controls (p < 0.005), who did not differ 
from ADHD.  
 
Friedman two-way ANOVA by ranks showed a significant effect of drug 
condition in mPFC χ2 (1,N=18) =5.56, p <0.05) which was due to significantly 
increased activation in mPFC in the ASD group under Fluoxetine relative to placebo. 
No other significant normalisation effects were observed.  
 
Correlation analyses showed that the (reduced) activation in left insula in ASD 
was negatively correlated with scores on the social domain of the ADI (r = -0.5, p < 




To assess the potential impact of IQ on case-control group differences, all 
analyses were repeated with IQ as covariate. All clusters remained at p < 0.05 for 
placebo and at p < 0.02 for Fluoxetine  
 
Within-Patients group by medication interaction effects 
 Repeated measures ANCOVA analysis showed a significant group by 
medication interaction effect in mPFC (41 voxels, peak Talairach coordinates (x;y;z): 
0;63;15; BA10/9), due to Fluoxetine increasing activation in this area in the ASD 
group and decreasing it in the ADHD group (Figure 13.C).  This remained significant 










Figure 13.A. Reward Reversal Learning Between-Group and Within-Patient 
Comparisons: Axial sections showing the between-group ANCOVA findings 
between controls and patients under placebo. Shown underneath are the statistical 
measures of BOLD response for each of the 3 groups for each of the brain regions that 
showed a significant group effect. B. Axial sections for the between-group ANCOVA 
comparison between controls and patients under Fluoxetine. Shown underneath are 
the statistical measures of BOLD response for each of the 3 groups for each of the 
brain regions that showed a significant group effect. C. Axial sections showing 
within-patient group by medication interaction effects. Shown underneath are the 
statistical measures of BOLD response for each of the brain regions that showed a 
significant group by medication interaction effect within-patients. Talairach z co-
ordinates are indicated for slice distance (in mm) from the intercommissural line. The 




Table 9. Brain activation differences during reward reversal learning between controls and patients on either placebo or Fluoxetine 
Post-Hoc Group 
Differences 





Voxels   Cluster 
  p-value 
PLACEBO 
ASD < C, ADHD 
 
ADHD, ASD < C 

















ASD < C Left Insula/Putamen  13 -33;19;4 23 0.007 
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7.4 – Discussion 
 
 
 This study shows that during the final stage of reward reversal, contrasted with 
probabilistic errors, ASD boys have disorder-specific underactivation in mPFC, a key 
region of reward-related decision making, relative to ADHD and control boys, as well 
as shared underactivation with ADHD boys, relative to controls, in precuneus, a key 
region of error processing. Fluoxetine had an inverse, disorder-specific effect in 
mPFC as it increased activation in ASD boys, leading to normalisation of their 
dysfunction relative to controls, but decreased activation in ADHD boys, concomitant 
with deteriorated task performance relative to controls. The findings suggest that 
Fluoxetine has disorder-dissociative, inverse modulatory effects on a key region of 
reward reversal learning, potentially reflecting differential baseline 5-HT levels in 
both disorders.   
 
 ASD boys compared to the other two groups showed disorder-specific 
underactivation in a key region of reward reversal (Finger et al., 2008, Remijnse et al., 
2005, Mitchell et al., 2009a) and reward-related decision making (Euston et al., 2012) 
that is particularly sensitive to negative feedback, mediating shifting away from 
disadvantageous responses after negative feedback (Christakou et al., 2009a, 
Ghahremani et al., 2010). Dysfunction in mPFC in ASD may be related to evidence 
for abnormally increased grey matter in the mPFC in adolescent boys with ASD 
compared to controls (Bonilha et al., 2008), indicative of poor synaptic pruning, and 
of poor SERT binding in mPFC in ASD (Makkonen et al., 2008). Although ASD 
patients were not significantly impaired in the task they had numerically more 
perseverative errors with a medium effect size (0.5) which may have reached 
significance in a larger cohort.  The disorder-specificity of the brain dysfunction to 
ASD was unexpected. However, the only previous fMRI study that used a very 
similar reward reversal task and contrast found normal mPFC activation in ADHD 
relative to controls (Finger et al., 2008). Together, the findings of these two studies 
suggest that mPFC underactivation may not be a neurofunctional feature of ADHD in 
the context of reward reversal learning. This contrasts with consistent evidence for 
lateral prefrontal underactivation in ADHD patients relative to controls during other 
cognitive control tasks that are mediated by more lateral prefrontal regions (Hart et 
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al., 2013, Smith et al., 2006, Rubia et al., 2010a, Rubia, 2011, Rubia et al., 2010b, 
Rubia et al., 2009d, Rubia et al., 2005b).  
 
The shared dysfunction in precuneus is interesting as precuneus is closely 
interconnected with mPFC (Small et al., 2003) and plays a role in reversal learning 
(Dodds et al., 2008, Ghahremani et al., 2009), reward evaluation (McCoy and Platt, 
2005, Liu et al., 2011) and visual-spatial attention to saliency, in particular error 
processing (Kravitz et al., 2011, Rubia et al., 2003, Rubia et al., 2007c, Small et al., 
2003, Ridderinkhof et al., 2004). Findings of precuneus dysfunction in ADHD during 
reward reversal extends prior evidence for precuneus dysfunction in response to 
salient events such as errors and rewarded trials in other tasks (Rubia et al., 2009d, 
Rubia et al., 2005b, Rubia, 2011), presumably reflecting poor saliency and error 
processing. In ASD, the precuneus has been found to be underactivated during 
interference (Solomon et al., 2009) and motor inhibition (Kana et al., 2007). The 
association in ASD between precuneus dysfunction and perseverative errors supports 
the notion that this dysfunction may reflect poor error processing, even if these did 
not reach significance relative to controls.  
 
 The most intriguing finding is the inverse effect of Fluoxetine on mPFC 
activation in the two disorders, upregulating and normalising it in ASD but decreasing 
it in ADHD. This inverse effect could potentially reflect disorder differences in 
baseline 5-HT levels. Approximately 30% of individuals with ASD have 
hyperserotonemia (Piven et al., 1991, Mulder et al., 2004, Hranilovic et al., 2007). 
There is evidence for reduced binding to SERT in the mPFC of individuals with ASD 
(Makkonen et al., 2008, Nakamura et al., 2010) as well as reduced 5-HT2A receptor 
binding (Murphy et al., 2006) and altered 5-HT synthesis (Chugani et al., 1999, 
Chugani et al., 1997). This suggests that hyperserotonemia may be an adaptation to 
counteract poor 5-HT receptor binding and abnormal 5-HT synthesis. The increase in 
5-HT with Fluoxetine may have increased ligand-receptor binding sufficiently to 
enhance activation in areas where 5-HT receptor density is particularly low. In 
addition, Fluoxetine may have amended an abnormal “balance” of 5-HT, therefore 
improving the homeostatic role of this key neurotransmitter and potentially leading to 
an increase in mPFC activation in ASD (Murano et al., 2011, Di Pietro and Seamans, 
2011).  Furthermore, each brain region has a distinct serotonergic profile, with limbic 
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and more medial structures receiving dense serotonergic innervation (Varnäs et al., 
2004, Jacobs and Azmitia, 1992). This therefore makes regions such as the mPFC 
highly susceptible to serotonergic manipulation, particularly in a patient group which 
have shown structural (Bonilha et al., 2008) and biochemical (Makkonen et al., 2008, 
Nakamura et al., 2010, Murphy et al., 2006) abnormalities in this region . It is also 
plausible that an increase in 5-HT may be modulating primary 5-HT abnormalities in 
transporter function (Makkonen et al., 2008, Nakamura et al., 2010) or 5-HT2A 
receptor binding (Murphy et al., 2006), which have been reported to be impaired in 
the mPFC of ASD individuals (Makkonen et al., 2008, Nakamura et al., 2010, 
Murphy et al., 2006), and may have led to the increased activation in mPFC observed 
in the ASD group. Our finding of an upregulation and normalisation in the mPFC of 
adolescents with ASD under Fluoxetine extends prior evidence that SSRIs increase 
metabolic and neurofunctional activity in prefrontal areas in adults with ASD 
(Buchsbaum et al., 2001, Dichter et al., 2010).  
 
 Fluoxetine also decreased insula activation in ASD relative to controls. The 
insula forms part of a mPFC-limbic network for reward-related decision making, and 
like mPFC, is particularly sensitive to negative feedback and mediates shifting away 
from disadvantageous choices (Christakou et al., 2009a).  The normalisation of mPFC 
with Fluoxetine may have resulted in the impairment of a limbic part of the reversal 
network, suggesting that brain function was not entirely normalised. 
 
The inverse reduction of activation in mPFC in ADHD with Fluoxetine was 
unexpected. However, ADHD boys, unlike ASD boys, showed no underactivation in 
this region and hence the 5-HT modulation may have interfered with normal 
prefrontal activation. This is further supported by the finding of performance 
impairment with 5-HT in ADHD. While ADHD patients have shown lateral 
prefronto-striatal underactivation during switching tasks (Smith et al., 2006, Rubia et 
al., 2010b, Rubia et al., 2010a, Hart et al., 2013), the only previous fMRI study on a 
similar contrast in a reward reversal task found normal mPFC activation in ADHD 
relative to controls (Finger et al., 2008).  Hence, reward reversal learning tasks may 
not elicit underactivation in key areas of reversal processes and consequently not tap 
into the dysfunctional brain mechanisms of ADHD. Furthermore, although there is 
evidence of serotonergic dysfunction in ADHD, the direction and implications of 
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these abnormalities are still unclear (Oades, 2007). In ASD, however, there is a 
wealth of research supporting the presence of genetic and biochemical serotonergic 
abnormalities (Zafeiriou et al., 2009, Piven et al., 1991, Mulder et al., 2004, 
Hranilovic et al., 2007, Chugani et al., 1999, Chugani et al., 1997, Makkonen et al., 
2008, Nakamura et al., 2010, Murphy et al., 2006, Buchsbaum et al., 2001, Dichter et 
al., 2010) which may have accounted for the positive upregulation effect of 
Fluoxetine on ASD mPFC activation and its negative downregulating effect on mPFC 
activation in ADHD. Interestingly, a decrease in 5-HT with ATD has been shown to 
lead to increased activation in the mPFC in healthy individuals during a task of 
reward reversal learning (Evers et al., 2005). Therefore, it appears as if ADHD 
children are exhibiting a similar pattern of serotonergic neurofunctional modulation to 
healthy controls in a brain region which is not impaired in the disorder. Consequently, 
Fluoxetine may interfere with this normal brain function in ADHD in this task 
context, leading to decreased activation.  
 
The strengths of this study are the carefully selected, non-comorbid patient 
groups and the medication-naivety of the ASD group. A limitation is the lower IQ in 
the ADHD group. However covariance analysis showed that this did not affect the 
main findings.  
 
 To summarise, we found disorder-specific underactivation in ASD boys in 
mPFC, a key region of reversal learning, as well as disorder-dissociated inverse 
effects of Fluoxetine on this region, with upregulated and normalised dysfunction in 
ASD but downregulated activation in ADHD, concomitant with worsening their task 
performance. The findings may indicate dissociated underlying 5-HT abnormalities in 













Chapter 8 – General Discussion 
 
8.1 – Summary 
 
 
ADHD and ASD are two neurodevelopmental disorders which are frequently 
co-morbid (Rommelse et al., 2011, van der Meer et al., 2012) and share executive 
function impairments (Willcutt et al., 2005, Corbett et al., 2009). In addition, there is 
evidence of serotonergic dysfunction, and a positive effect of the SSRI Fluoxetine, in 
both ADHD (Oades, 2007, Barrickman et al., 1991, Quintana et al., 2007) and ASD 
(Zafeiriou et al., 2009, West et al., 2009). However, the shared and disorder-specific 
neural underpinnings of the cognitive impairments in these disorders, as well as the 
modulating effect of Fluoxetine on these potential neurofunctional abnormalities, has 
yet to be investigated. This thesis has, for the first time, 1) used fMRI to compare 
boys with ADHD and boys with ASD during tasks of working memory, motor 
response inhibition and cognitive flexibility and 2) investigated the shared and 
disorder-specific effects of an acute clinical dose of Fluoxetine on these neural 
substrates in a double-blind, placebo controlled, randomised design. The results show 
both disorder-specific and shared dysfunctions in boys with ADHD and boys with 
ASD under placebo, compared to controls. Most importantly, an acute dose of 
Fluoxetine appears to have mainly inverse effects on the regulation of prefrontal brain 
activation in the two disorders, although there is also evidence for shared effects.  
 
During WM, behavioural case-control comparisons showed no group 
differences under placebo, but the within-group analysis showed a trend for increased 
accuracy in patients under Fluoxetine, relative to placebo. fMRI data showed that 
under placebo, both ADHD and ASD boys exhibited shared reduced activation in 
right DLPFC compared to controls, with a trend for the ASD group to be more 
impaired than the ADHD group. ASD boys exhibited disorder-specific increased 
deactivation of PCC compared to control and ADHD boys. Under Fluoxetine, case-
control comparisons showed that the DLPFC underactivation was normalised in both 
disorders relative to controls, but only significantly so in the ASD group. The within-
patient analysis showed that Fluoxetine relative to placebo had an inverse effect in 
both disorders on the task negative PCC deactivation, as it increased deactivation in 
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the ADHD group, making it significantly different from controls, and attenuated it in 
the ASD group, who were still significantly different from controls in this activation 
cluster, but no longer significantly different from ADHD. Therefore, during WM 
Fluoxetine had disorder-dissociated effects in the regulation of brain function as it 
significantly upregulated and normalised task-positive DLPFC activation in the ASD 
group, whereas it increased task negative deactivation of a DMN area in the ADHD 
group. Both of these dissociated brain modulation effects appear to be associated with 
better performance as both patient groups were more accurate, at a trend-level, 
relative to placebo. 
 
During motor response inhibition, performance data showed no group 
differences for inhibition measures and no effect of Fluoxetine on these measures. 
However, boys with ADHD made more omission errors compared to controls and 
ASD boys under both placebo and Fluoxetine. fMRI data showed that under placebo, 
boys with ADHD exhibited disorder-specific underactivation of left VLPFC/basal 
ganglia compared to controls and ASD boys, while ASD boys exhibited disorder-
specific increased bilateral IFC activation compared to controls and ADHD boys. 
Shared underactivation of left inferior parietal lobe was observed in both disorders 
compared to controls. Fluoxetine relative to placebo modified brain activation in an 
inverse manner in the two disorders, leading to significant normalisation of all frontal 
abnormalities in both disorders relative to controls. This was confirmed by the within-
patient analysis which showed that Fluoxetine relative to placebo increased left 
VLPFC activation in ADHD, while decreasing this activation in ASD, and decreased 
the right IFC activation in ASD, while increasing it in ADHD. Fluoxetine relative to 
placebo also had an inverse effect in left inferior parietal activation as it significantly 
increased activation in the ASD group, leading to significant normalisation, but 
decreased activation in this area in the ADHD group. An inverse effect was also noted 
in pre-SMA/mPFC extending into left middle/superior frontal cortex as Fluoxetine 
compared to placebo increased activation in these regions in the ASD group, which 
correlated with shorter SSRTs, while decreasing activation in these regions in the 
ADHD group. The findings show that during motor response inhibition, Fluoxetine 
normalises frontal lobe dysfunctions in both disorders via inverse effects, 
downregulating abnormally high frontal activation in ASD and upregulating 




During reward reversal learning, performance data showed that under placebo, 
the patient groups did not differ from controls, but under Fluoxetine boys with ADHD 
made significantly more perservative errors than controls. Case-control comparisons 
showed that under placebo, ASD boys had disorder-specific underactivation of mPFC 
compared to controls and ADHD, and that both patient groups significantly 
underactivated precuneus compared to controls. Under Fluoxetine the mPFC deficit in 
ASD compared to controls and ADHD was significantly normalised. This was 
confirmed by within-patient analyses which showed that Fluoxetine relative to 
placebo increased activation in mPFC in ASD patients. However, Fluoxetine had the 
inverse effect in ADHD as it reduced activation in this region relative to placebo. 
Precuneus activation was increased in both disorders under Fluoxetine relative to 
placebo. However it did not significantly normalise the deficit in either disorder 
relative to controls. A further disorder-specific effect of Fluoxetine was observed in 
the ASD group, under Fluoxetine, but not under placebo, the insula activation was 
reduced in ASD relative to controls. The findings show disorder-specific 
underactivation in ASD boys in mPFC, as well as disorder-dissociated inverse effects 
of Fluoxetine on this region, which upregulated and normalised dysfunction in ASD 
but downregulated activation in ADHD, concomitant with worsening their task 
performance. 
 
     The findings of each of these studies will be discussed in detail below in order 
to assess the shared and disorder-specific dysfunctions in boys with ADHD and ASD, 
and the shared and disorder-specific modulating effect of Fluoxetine on brain 
activation in these two overlapping disorders.    
 
8.2 – Disorder-Specific Dysfunction 
 
 This section will focus on the disorder-specific findings for each patient group 
under placebo.  
 
 In the ADHD group, the only disorder-specific brain dysfunction across all 
tasks relative to ASD was observed in a left hemispheric, ventrolateral fronto-striatal 
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activation cluster during motor response inhibition, and this neurofunctional 
abnormality was observed alongside poor task performance, in the form of increased 
omission errors. This finding of underactivation in VLPFC is in line with previous 
findings, as it has been consistently reported that children with ADHD have reduced 
ventrolateral frontal and striatal  activation during tasks of motor response inhibition 
(Rubia et al., 1999, Rubia et al., 2010a, Tamm et al., 2004, Rubia et al., 2011a, 
Durston et al., 2003, Durston et al., 2006, Booth et al., 2005, Smith et al., 2006, 
Epstein et al., 2007), and this neural dysfunction has been confirmed by a  meta-
analysis of all whole brain fMRI studies (Hart et al., 2013). However, the location of 
the underactivation observed in this study was more ventral than the typically reported 
IFC location. Also, although we hypothesised right IFC underactivation in the ADHD 
group there have been previous findings of left IFC underactivation in children with 
ADHD during motor response inhibition, and there is evidence that left, as well as 
right, IFC is involved in motor response inhibition (Rubia et al., 2001a, Tamm et al., 
2002, Swick et al., 2008). Furthermore, progressively increased left VLPFC and 
striatal activation during motor response inhibition has been reported to correlate 
positively with age (Tamm et al., 2002, Rubia et al., 2007c). Therefore, 
underactivation in this region in the ADHD group relative to their age-matched peers 
is suggestive of an immature pattern of brain activation. Consequently, this finding 
not only replicated the consistent evidence for fronto-striatal underactivation in 
ADHD during motor response inhibition (Cubillo et al., 2012), but showed for the 
first time that this abnormality is disorder-specific when compared to ASD.   
 
Conversely, in ASD, increased activation was observed in bilateral IFC during 
motor response inhibition, compared to controls and ADHD boys. Increased left IFC 
activation has been previously reported in adults with ASD during a Go/No-Go task 
(Schmitz et al., 2006). However, this is the first time this abnormality has been 
reported in children. It is also the first time this overactivation has also been observed 
in the right IFC. This increased bilateral IFC activation may be due to children with 
ASD having to exert more effort in these key areas of inhibition (Rubia et al., 2001a, 
Rubia et al., 2003, Rubia et al., 2006, Rubia et al., 2007c) to successfully inhibit their 
motor response, as they are prone to becoming locked in to the repetitive motor action 




These disorder-specific abnormalities in the neural substrates of inhibition 
may play a role in the different inhibition associated behaviours observed in the two 
disorders. Impaired inhibition in ADHD is exhibited by impulsive behaviour such as 
blurting out answers and interrupting conversations (American et al., 1994). However, 
in ASD impaired inhibition is thought to be associated with the inability to inhibit 
particular actions, leading to repetitive behaviours (American et al., 1994). Therefore, 
decreased activation in ventrolateral fronto-striatal areas in ADHD may lead to 
reduced ability to inhibit responses, resulting in the impulsive behaviours that are 
characteristic of this disorder. Conversely, increased IFC activation in ASD may have 
a different effect on inhibition, resulting in different behavioural manifestations such 
as repetitive and stereotyped actions. However, as this thesis found no performance 
differences in SSRT, another potential explanation for these different neurofunctional 
abnormalities is that unlike the children with ASD, the children with ADHD were not 
at risk of becoming locked into the repetitive action of button pressing. Therefore, 
normal right IFC activation, potentially compensating for VLPFC underactivation, 
may have been sufficient for normal task performance, with regards to inhibitory 
measures, in the ADHD group. However, due to their propensity for repetitive 
behaviours, boys in the ASD group may have had to exert more effort in these key 
regions of inhibition in order to successfully inhibit their motor response. 
 
In addition, during the Stop Signal task left inferior parietal cortex was 
underactivated in ASD boys compared to controls. Therefore, one can postulate that 
in the ASD group, during inhibition, the increased activation in IFC may also have 
been a compensation for reduced activation in left inferior parietal lobe. There is 
evidence that inferior parietal lobe is involved in attention to salient stimuli and this is 
integral to successful Stop Signal task performance (Rubia et al., 2001a, Simmonds et 
al., 2008). Consequently, in the ASD group more neurofunctional activity may have 
been required in IFC in order to compensate for reduced activation in attention areas. 
 
Although there is neuropsychological evidence for poor motor response 
inhibition in children with ADHD (Willcutt et al., 2005) and children with ASD (Hill, 
2004, O'Hearn et al., 2008, Sanders et al., 2008), in this study no performance 
differences were observed for the inhibitory measure of SSRT. This may be due to the 
size of the sample in this study as although the number of subjects in each group is 
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adequate for fMRI, it is relatively small for a neuropsychological study (Thirion et al., 
2007). Furthermore, practice effects in the patient groups may have prevented 
significant between-group differences in inhibitory measures as controls were only 
scanned once, but patients twice. This may also account for the lack of significant 
between-group performance differences during WM.   
 
During WM, disorder-specific increased deactivation of the PCC was reported 
in the ASD group relative to controls and ADHD. It is known that PCC is part of the 
DMN and that deactivation of these task-negative DMN regions is associated with 
better task performance and less mind wandering, in particular during attention-
demanding tasks, (Fox et al., 2005, Raichle and Snyder, 2007, Northoff et al., 2010). 
Therefore, the increased deactivation of PCC in the ASD group may be compensating 
for underactivation in the key task positive WM region of DLPFC, and the trend-wise 
more severe deficit in this area in ASD compared to ADHD may further explain the 
disorder-specificity of this finding.   
 
 During reward reversal learning, the only disorder-specific abnormality 
reported was underactivation of mPFC in the ASD group as compared to controls and 
ADHD boys. There is consistent evidence to support the role of mPFC in reward 
reversal learning (Finger et al., 2008, Remijnse et al., 2005, Mitchell et al., 2009a), 
reward related decision making (Euston et al., 2012) and shifting away from poor 
choices after negative feedback (Christakou et al., 2009a, Ghahremani et al., 2010). 
Decreased activation in ACC, an anatomically and functionally related area to mPFC 
(Ridderinkhof et al., 2004), has been reported in adults with ASD during a switch task 
and this underactivation was correlated with stereotyped behaviours (Shafritz et al., 
2008). Atypical activation of mPFC has also been observed in individuals with ASD 
during an executive function task focusing on stimulus-orientated and stimulus-
independent thought (Gilbert et al., 2008). Interestingly, a meta-analysis of executive 
functions in ASD found decreased activation of dorsal ACC compared to controls (Di 
Martino et al., 2009). Structural studies have found increased grey matter in the mPFC 
of adolescents with ASD (Bonilha et al., 2008). These findings, along with our own, 
tentatively suggest that mPFC abnormality may be a defining neurofunctional deficit 
of ASD during tasks of executive functions, particularly those targeted at cognitive 
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flexibility. Furthermore, our findings extend this evidence by showing that mPFC 
underactivation may be a disorder-specific feature of ASD relative to ADHD. 
 
So to summarise, there appeared to be disorder-specific, and task-specific, 
dysfunctions present between boys with ADHD and boys with ASD. Ventrolateral 
fronto-striatal abnormalities appeared to be specific for boys with ADHD during 
motor response inhibition, whereas IFC overactivation appeared to be specific for 
boys with ASD during the same task. Increased PCC deactivation, presumably 
compensatory for the more severe DLPFC underactivation, was disorder-specific for 
ASD boys during WM. mPFC underactivation during reward reversal learning was an 
abnormality which was specific to ASD, compared to controls and ADHD, and 
structural (Bonilha et al., 2008) and functional studies (Shafritz et al., 2008, Gilbert et 
al., 2008, Di Martino et al., 2009) are beginning to show that mPFC/ACC may be a 
key area of structural and functional abnormality in ASD. The disorder-specificity of 
the findings from this thesis are highly intriguing and potentially suggest that 
(ventrolateral) fronto-striatal underactivation in ADHD during tasks motor response 
inhibition, and mPFC underactivation in ASD  during reward reversal learning, could 
potentially be disorder-specific neurofunctional biomarkers of the two disorders and 
could therefore be used to differentiate between ADHD and ASD. However, further 
research is needed to confirm or refute these novel findings.   
 
VLPFC was negatively correlated with omission errors in the ADHD group, 
suggesting that this deficit was associated with poor attention to the Stop Signal task. 
This ventrolateral fronto-striatal underactivation was specific to ADHD and this may 
be due to the inhibition deficits that are present in this disorder (Willcutt et al., 2005, 
Lijffijt et al., 2005, Alderson et al., 2007, Adams et al., 2008). Despite the lack of 
performance differences in inhibitory measures in this study, it is known that 
impulsivity and poor inhibition are key diagnostic features of ADHD (American et al., 
1994), and there is neuropsychological evidence that ADHD children are more 
impaired in motor response inhibition than both controls and ASD children (Happe et 
al., 2006, Sinzig et al., 2008). In this study, patients performed the task twice while 
controls did so only once and this may have diminished performance differences. 
Furthermore, ventrolateral fronto-striatal regions are involved in motor response 
inhibition in healthy individuals (Rubia et al., 2001a, Rubia et al., 2003, Rubia et al., 
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2007c, Rubia et al., 2006, Chambers et al., 2009). Therefore, it is reasonable to 
suggest that in a patient group which is characterised by impaired inhibition, disorder-
specific underactivation, compared to controls and ASD, would be observed in 
inhibition areas during a task of motor response inhibition.    
 
Disorder-specific underactivation in mPFC in boys with ASD, compared to 
controls and ADHD, is also in line with the key cognitive and behavioural 
impairments reported in this disorder. Stereotyped and repetitive behaviours are part 
of the ASD diagnostic triad (American et al., 1994)(APA 1994) and despite the lack 
of performance deficits in ASD boys in this thesis, there is evidence for poor 
cognitive flexibility in this disorder (Geurts et al., 2004, Ozonoff et al., 2004, Verte et 
al., 2005, Sanders et al., 2008) with some studies finding that this impairment is 
specific to ASD compared to both controls and ADHD (Ozonoff and Jensen, 1999, 
Geurts et al., 2004). Moreover, mPFC is involved in reversal learning and decision 
making in healthy individuals (Remijnse et al., 2005, Finger et al., 2008, Mitchell et 
al., 2009a, Euston et al., 2012). Consequently, disorder-specific reduced activation in 
this key area of cognitive flexibility in ASD, a disorder that is significantly impaired 
in this executive function, albeit not in this thesis, could reflect more severe 
abnormalities in neural substrates underlying this function. 
 
8.3 – Shared Dysfunction 
 
This section will focus on the shared abnormalities between boys with ADHD 
and boys with ASD under placebo. 
 
During WM, both boys with ADHD and boys with ASD showed decreased 
activation in right DLPFC compared to controls, with ASD boys being more impaired 
than ADHD boys, at a trend-level. DLPFC is a key area for the storage and 
manipulation of information during WM (Wager and Smith, 2003) and there is prior 
evidence for decreased activation in this area in male children (Cubillo et al., 2013) 
and adults (Valera et al., 2010) with ADHD, and in adults with ASD during similar 
WM tasks (Luna et al., 2002, Koshino et al., 2005). Furthermore, it has been reported 
that during a parametric sustained attention task, boys with ADHD and boys with 
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ASD show shared decreased activation in left DLPFC (Christakou et al., 2013). 
Therefore, the findings of the current study support the presence of DLPFC 
underactivation in children with ADHD, and find for the first time that right DLPFC 
is underactivated in children with ASD, during WM compared to controls.  
 
In addition, these findings, alongside those of Christakou et al, 2013, suggest 
that DLPFC underactivation may be shared by both children with ADHD and children 
with ASD during tasks of attention and WM. Right DLPFC underactivation was a key 
finding in a meta-analysis of whole brain imaging studies of attention in ADHD (Hart 
et al., 2013), and it is known that WM paradigms tap into attention functions as 
attention needs to be sustained in order to perform the task. There is behavioural and 
neuropsychological evidence for impaired attention in both ADHD (American et al., 
1994, Willcutt et al., 2005, Rubia et al., 2007a) and ASD (Sturm et al., 2004, Corbett 
and Constantine, 2006, Corbett et al., 2009, Simonoff et al., 2008). Therefore, deficits 
in DLPFC, a key area of attention, may explain the shared difficulties in sustained 
attention that are commonly observed in both ADHD and ASD.   
 
 During motor response inhibition, reduced activation was observed in left 
inferior parietal lobe in both boys with ADHD and boys with ASD, relative to 
controls. Although the inferior parietal lobe is considered an area of visual-spatial 
attention (Bisley and Goldberg, 2010), this function is essential for a visual Stop task, 
and inferior parietal lobe has therefore consistently been found to be relevant for 
motor response inhibition in a recent meta-analysis of Go/No-Go tasks (Criaud and 
Boulinguez, 2012) . The only previous fMRI study to directly compare boys with 
ADHD and boys with ASD is from our group, and found shared decreased activation 
in right DLPFC and left superior parietal lobe during a parametric sustained attention 
task (Christakou et al., 2013). Interestingly, a comparative sMRI study of children 
with ADHD and children with ASD found shared reduced grey matter in left inferior 
parietal lobe compared to controls, although this did not survive testing for multiple 
comparisons (Brieber et al., 2007). Furthermore, a recent study of cerebral blood flow 
in adults with ASD found that an increase in ADHD traits was correlated with 
increased blood flow in inferior parietal lobe (Manouilenko et al., 2013). The inferior 
parietal lobe is involved in orientation of attention (Bisley and Goldberg, 2010) and as 
previously discussed, both children with ADHD (American et al., 1994, Willcutt et 
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al., 2005, Rubia, 2007) and children with ASD (Sturm et al., 2004, Corbett and 
Constantine, 2006, Corbett et al., 2009, Simonoff et al., 2008) have behavioural and 
cognitive impairments in attention. Consequently, decreased activation in this key 
region of visuo-spatial attention in both ADHD and ASD may be due to both groups 
struggling with the attentional demands of the task and suggests that attention 
difficulties in both disorders may be mediated by common neural substrates.   
 
 During reward reversal learning reduced activation was observed in precuneus 
in both ADHD and ASD boys compared to controls. There is evidence for the role of 
precuneus in reversal learning (Dodds et al., 2008, Ghahremani et al., 2010) and 
reward evaluation (McCoy and Platt, 2005, Liu et al., 2011) as well as attentional 
orientation and  allocation (Kravitz et al., 2011). Decreased precuneus activation has 
been observed in boys with ADHD during error processing (Rubia et al., 2005b, 
Rubia et al., 2010a)(Rubia et al 2005, 2009, 2010), as well as attention allocation to 
rare stimuli, (Rubia et al., 2007b, Rubia et al., 2009c, Rubia et al., 2009b), and in 
individuals with ASD during interference and motor response inhibition (Solomon et 
al., 2009, Kana et al., 2007). However, it was observed that precuneus activation 
correlated positively with perservative errors in the ASD group. This may be because 
an increase in activation in this area would increase attention, potentially causing the 
ASD boys to hyper-focus on the stimuli, and this, in addition to reduced activation in 
mPFC, a key area for reversal learning, may lead to more repetitive and perservative 
responses. Moreover, there is evidence that attentional over-selectivity is linked to 
repetitive behaviours in ASD (Liss et al., 2006). Therefore, although both ADHD and 
ASD boys exhibit decreased activation in precuneus, this may be positive for the ASD 
group, in the context of mPFC underactivation, due to their propensity to hyper-focus 
(Liss et al., 2006), and negative in the ADHD due to their poor ability to sustain 
attention (Willcutt et al., 2005). 
 
 The findings from this thesis, as well the limited neuroimaging research 
focused on direct comparsions between ADHD and ASD, suggest that dorsolateral 
frontal and inferior parietal underactivation are shared between the disorders. A 
shared neurofunctional activation deficit in areas that are crucial for attention could 
possibly explain why both disorders have deficits in attention functions, both 
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behaviourally as well as in cognitive task performance (American et al., 1994, 
Willcutt et al., 2005, Rubia et al., 2007a, Sturm et al., 2004, Corbett and Constantine, 
2006, Corbett et al., 2009, Simonoff et al., 2008). While the patients of this study 
were non-comorbid, the shared underactivation in these key areas of attention could 
possibly underlie the comorbidity that some children have with both disorders. Future 
research should focus on the inferior parietal lobe as a potential key area for co-
morbidity between ADHD and ASD as both functional (Christakou et al., 2013) 
structural (Brieber et al., 2007) and metabolic (Manouilenko et al., 2013) 
abnormalities appear to be shared between these two disorder in this key region of 
attention. 
 
8.4 – Disorder Dissociated Fluoxetine Effects 
 
 This section will focus on the disorder-dissociated effects of Fluoxetine on 
brain activation in boys with ADHD and boys with ASD. 
 
Interestingly, Fluoxetine consistently had inverse, disorder-dissociated effects 
in mostly prefrontal brain regions where disorder-specific deficits were observed 
under placebo. Thus, within patients, Fluoxetine relative to placebo increased 
activation in left ventrolateral fronto-striatal regions in ADHD during motor response 
inhibition, leading to significant normalisation of this deficit in ADHD relative to 
controls, while it enhanced activation in this region in ASD. The inverse effect was 
observed for the enhanced IFC activation in ASD relative to ADHD and controls, 
which was downregulated in ASD but upregulated in ADHD.  
 
There is evidence for serotonergic dysfunction in ADHD (Oades, 2007) and 
although the direction of this dysfunction is unclear, there is evidence for decreased 
platelet 5-HT levels in boys with ADHD (Spivak et al., 1999). Furthermore, it has 
been observed that ATD, which diminishes 5-HT levels in the brain, leads to poorer 
performance on a Go/No-Go task (Zepf et al., 2008a), and increased impulsive 
aggression, in children with ADHD (Zepf et al., 2009, Zepf et al., 2008c, Stadler et 
al., 2007). It has also been consistently reported that lower levels of 5-HT are 
associated with impulsivity in both animals and healthy individuals (Robbins et al., 
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2010). Moreover, fMRI studies on healthy adults during a Go/No-Go task have shown 
that ATD leads to decreased activation in VLPFC (Rubia et al., 2005a), and that 
administration of Citalopram leads to increased VLPFC activation (Del-Ben et al., 
2005). Therefore, one could postulate that the ADHD cohort in this study may have 
had low baseline levels of 5-HT, which may have led to underactivation in 
ventrolateral fronto-striatal areas under placebo. This could explain why an increase 
in 5-HT, induced by Fluoxetine, increased activation in this area leading to 
normalisation of the underactivation relative to controls. This is of particular interest 
as it suggests that 5-HT may play a role in the fronto-striatal underactivation that has 
consistently been reported in ADHD during motor response inhibition. As mentioned 
in the introduction, due to the low  levels of dopamine in fronto-striatal regions in 
ADHD patients (Volkow et al., 2009, del Campo et al., 2011), fronto-striatal 
underactivation in ADHD during inhibition (Cubillo et al., 2012) and the positive 
effect of MPH on behaviour (Greenhill et al., 2001), performance (Gnagy et al., 2001) 
and fronto-striatal regions in the disorder (Rubia et al., 2009b, Rubia et al., 2011b, 
Rubia et al., 2011c) , research in ADHD has focused on dopamine, at the expense of 
other key neurotransmitters such as 5-HT.  
 
5-HT is one of the most wide reaching neurotransmitters in the brain and, like 
dopamine, is found in both frontal and striatal regions (Feldman et al., 1997, Tork, 
1990). Akin to dopamine, there is evidence that 5-HT plays an integral role in VLPFC 
activation during motor response inhibition, with an increase/decrease in 5-HT 
leading to an increase/decrease in activation, respectively (Rubia et al., 2005a, Del-
Ben et al., 2005). It has also been shown that Fluoxetine alone (Barrickman et al., 
1991, Quintana et al., 2007), or in conjunction with MPH (Gammon and Brown, 
1993) can improve hyperactivity and impulsivity in children with ADHD. Therefore, 
much like dopamine, there is behavioural and neurofunctional evidence that 5-HT 
may play a role in ADHD. This thesis provides evidence that 5-HT appears to be 
involved in ventrolateral fronto-striatal deficits in ADHD, because Fluoxetine can 
upregulate and normalise these deficits. This is the first time that this has been 
reported and shows that 5-HT may be as equally involved as dopamine in the key 
fronto-striatal pathophysiology of ADHD as dopamine. Furthermore, it is known that 
serotonergic neurons innervate the ventral tegmental area and modulate both phasic 
and tonic dopamine release (Feldman et al., 1997, Tork, 1990). Therefore, the 
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interaction between dopamine-serotonin, as well as the absolute levels of these two 




This normalising effect of Fluoxetine appears to be region-specific as although 
Fluoxetine in ADHD patients increased activation in DLPFC, and increased 
deactivation of PCC, during WM, and increased activation of precuneus during 
reward reversal learning, rigourous normalisation testing showed that these positive 
neurofunctional modulations were not significant. The region-specificity of the 
normalisation effects of Fluoxetine, on VLPFC but not DLPFC or medial parietal 
regions, may be due to the dense serotonergic innervation in VLPFC regions (Roberts, 
2011), resulting in high levels of sensitivity to 5-HT manipulation in these areas, 
particularly during motor response inhibition (Rubia et al., 2005a, Del-Ben et al., 
2005). Moreover, there is more evidence for the role of 5-HT in impulsivity and 
inhibition compared to WM (Anderson et al 2008, Silber et al 2009), which is thought 
to be mediated more by dopaminergic and noradrenergic systems (Cools and 
D'Esposito, 2011) . It has been observed that Atomoxetine is able to significantly 
normalise right DLPFC underactivation in boys with ADHD during the same N-Back 
task (Cubillo et al., 2013). Therefore, it appears as if Fluoxetine not only has disorder-
specific effects in ADHD on VLPFC, but also region-specific effects as it normalised 
deficits in serotonergically innervated VLPFC-striatal inhibition networks in ADHD, 
but did not do so in DLPFC mediated WM networks, and this may potentially be 
because noradrenergic/dopaminergic abnormalities play a larger role in these deficits.   
 
In the ASD group, however, the opposite effect was observed in this region as 
the within patient interaction analysis showed that Fluoxetine decreased activation in 
VLPFC/basal ganglia compared to placebo. Fluoxetine also decreased the IFC 
overactivation that was present in the ASD group under placebo, relative to controls 
and ADHD, leading to significant normalisation of this deficit. The opposite effect 
was observed in right IFC in the ADHD group in the within patient interaction 
analysis as Fluoxetine increased activation in this area relative to placebo. The 
opposite effect of Fluoxetine in these lateral prefrontal brain regions may be due to 
the differential serotonergic abnormalities that have been reported in these two 
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neurodevelopmental disorders. As previously mentioned, there is evidence for low 5-
HT levels in individuals with ADHD (Spivak et al., 1999) and increased impulsivity 
in children with ADHD after ATD (Stadler et al., 2007, Zepf et al., 2008a, Zepf et al., 
2008c). However, the converse has been reported in ASD as there is consistent 
evidence for hyperserotonemia in one third of individuals with ASD (Piven et al., 
1991, Mulder et al., 2004, Hranilovic et al., 2007). Therefore, Fluoxetine may have 
increased the low baseline of 5-HT in children with ADHD to normal levels, leading 
to normal activation in ventrolateral fronto-striatal areas. Whereas in children with 
ASD, the increase in 5-HT in an already hyperserotonemic system may have activated 
a negative feedback mechanism via activation of 5-HT1A autoreceptors (Di Matteo et 
al., 2008), leading to a decrease in 5-HT and resulting in a reduction of lateral 
prefrontal activation. Therefore, it appears as if Fluoxetine increased activation in 
ventrolateral prefrontal and striatal areas of underactivation in ADHD, whereas it 
decreased activation in these same areas in ASD. 
 
Interestingly, in other frontal regions, Fluoxetine, relative to placebo, had 
inverse upregulation-downregulation effects. Fluoxetine relative to placebo increased 
activation in pre-SMA/mPFC extending into left superior/middle frontal cortex in 
ASD, while decreasing activation in this area in ADHD. This increased pre-
SMA/mPFC activation in the ASD group was correlated with better SSRTs which is 
in line with the key role of pre-SMA in motor response inhibition (Simmonds et al., 
2008). This increased pre-SMA activation may have been a compensation for the 
reduction in IFC activation, another key area of inhibition. Alternatively, the increase 
in pre-SMA activation under Fluoxetine may have reduced the need for IFC 
overactivation, and this is in line with the association between increased pre-SMA 
activation and shorter SSRTs.    
  
During another task, the reward reversal learning task, and in other frontal 
brain regions, different upregulation/downregulation effects were observed with 
Fluoxetine. Disorder-specific mPFC underactivation in ASD relative to placebo was 
normalised under Fluoxetine. Whereas in ADHD, under Fluoxetine, relative to 
placebo, mPFC activation was downregulated and this presumably led to the 
increased number of perservative errors made by the ADHD group under Fluoxetine, 
relative to controls. As previously stated, there is a growing body of research to 
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suggest that mPFC underactivation during executive function may be a key 
impairment in ASD (Shafritz et al., 2008, Di Martino et al., 2009, Gilbert et al., 2008), 
and when taking into account the current findings,  may in fact be disorder-specific to 
ASD when compared to ADHD. Interestingly, compared to other brain regions, there 
is quite a large amount of evidence for serotonergic abnormality in the mPFC of 
individuals with ASD. Decreased 5-HT transporter binding in mPFC has been 
reported in both adolescents (Makkonen et al., 2008) and adults (Nakamura et al., 
2010) with ASD, as has decreased binding to 5-HT2A receptors in mPFC in adults 
with ASD (Murphy et al., 2006). Impaired metabolism in the right mPFC of ASD 
individuals with the s/s genotype of 5-HTTLPR has also been observed (Endo et al., 
2010) and metabolic activity in mPFC has been associated with better response to 
Fluoxetine (Buchsbaum et al., 2001). Furthermore, ATD in ASD adults during 
processing of a happy face led to decreased activation in dmPFC (Daly et al., 2012). 
This suggests that hyperserotonemia may be an adaptation to counteract serotonergic 
abnormalities in mPFC, which may possibly be the result of genetic polymorphisms. 
The increase in 5-HT induced by Fluoxetine may have increased ligand-receptor 
binding sufficiently to enhance activation in areas where serotonergic functioning is 
particularly low, such as mPFC. 
 
The inverse effect of Fluoxetine in reducing mPFC activation in ADHD boys 
during reward reversal learning may be due to the fact that ADHD boys showed no 
underactivation in this region under placebo and hence Fluoxetine may have 
interfered with normal prefrontal activation. Furthermore, although there is evidence 
of serotonergic dysfunction in ADHD, the direction and implications of these 
abnormalities are still unclear (Oades, 2007). Interestingly, a decrease in 5-HT with 
ATD has been shown to lead to increased activation in the mPFC in healthy 
individuals during a task of reward reversal learning (Evers et al., 2005). Therefore, it 
appears as if ADHD children are exhibiting a similar pattern of serotonergic 
neurofunctional modulation to healthy controls in a brain region which is not impaired 
in the task. Consequently, Fluoxetine may interfere with this normal brain function in 
ADHD in this task, leading to decreased activation and poor task performance.  
  Fluoxetine also had an inverse effect on the activation of posterior medial 
brain regions that are involved in the DMN, namely PCC, during WM. Fluoxetine, 
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relative to placebo, attenuated the disorder-specific enhanced PCC deactivation in the 
ASD group, whereas it increased PCC deactivation in the ADHD group. The 
increased deactivation of PCC in ADHD under Fluoxetine may be due to the effect of 
an increase in 5-HT on the 5-HT2C receptors in this area which would lead to a 
decrease in dopamine (Di Matteo et al., 2008). There is consistent evidence for 
decreased dopamine levels in individuals with ADHD in the basal ganglia and 
cingulate gyrus (Volkow et al., 2009, del Campo et al., 2011) and a further 5-HT 
enhancement-dependent decrease in dopamine may have decreased the already low 
dopamine levels in the ADHD group, leading to deactivation of this area. 
Interestingly, ATD in healthy adults during a verbal N-Back task led to an attenuation 
of PCC deactivation (Allen et al., 2006), suggesting once again that in a medial region 
of the brain ADHD children exhibit a similar pattern of serotonergic neurofunctional 
modulation to healthy controls. This increased deactivation of a task-negative area is 
advantageous as it has been shown to reduce task irrelevant thoughts and improve 
attention performance (Sonuga-Barke and Castellanos, 2007, Northoff et al., 2010, 
Christakou et al., 2013) and may therefore play a role in the increased accuracy 
observed under Fluoxetine. Furthermore, this decreased DMN activation was 
associated with lower scores on the SDQ hyperactive/inattentive subscale, suggesting 
that Fluoxetine is more effective at modulating PCC activation in boys with less 
severe ADHD symptoms.   
 
The attenuation of PCC deactivation in the ASD group during WM may be 
due to the serotonergic abnormalities reported in this medial region, as both decreased 
SERT (Nakamura et al., 2010) and 5-HT2A receptor (Murphy et al., 2006) binding 
have been observed in this DMN area in individuals with ASD. Therefore, Fluoxetine 
may be increasing activation in this posterior medial brain region via the same 
mechanism by which mPFC activation was increased. This attenuation of PCC 
deactivation may also be due to the increased activation in DLPFC in the ASD group 
under Fluoxetine relative to placebo, as task-positive and task negative regions are 
often anti-correlated (Fox et al., 2005, Raichle and Snyder, 2007, Northoff et al., 
2010). Therefore, the increased PCC deactivation in the ASD group under placebo 
may have been a compensation for the reduced activation in a key task-positive area 
of WM, particularly as the ASD deficit in this region was worse than that of the 
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ADHD boys, at a trend-level. Hence, the increased activation in DLPFC under 
Fluoxetine may have reduced the need for compensatory deactivation of the PCC, 
leading to attenuation in this region. There is evidence that the poor SERT binding in 
this region is associated with higher levels of social impairment in ASD (Murphy et 
al., 2006, Nakamura et al., 2010). This PhD found that Fluoxetine had the most 
pronounced effect in PCC in ASD individuals who scored highly on the social and 
communication domain of the ADOS. This suggests that Fluoxetine may work best at 
reducing self-referential thoughts in ASD individuals who are poor at social 
interaction, and are therefore more likely to mind wander or focus on self, as opposed 
to engage with external tasks. This extends the interesting body of literature that is 
developing regarding the role of 5-HT in the PCC and its link to poor social 
communication in ASD and is an area which warrants further research. 
 
Interestingly, the only area of shared deficit that exhibited a disorder-
dissociated effect under Fluoxetine was left inferior parietal lobe during motor 
response inhibition. Fluoxetine, relative to placebo, increased activation in this area in 
children with ASD which led to normalisation of their deficit during inhibition, 
whereas it further decreased activation in children with ADHD. As previously stated, 
there is evidence for decreased dopamine levels in ADHD (Volkow et al., 2009, del 
Campo et al., 2011) and it is known that dopamine is involved in attention processes 
which involve the parietal lobe (Nieoullon, 2002). Furthermore, there is consistent 
evidence that during sustained attention (Rubia et al 2009), interference inhibition 
(Rubia et al., 2011b), timing (Rubia et al., 2009a) and failed inhibition (Rubia et al., 
2011c) MPH, which increases dopamine in cortical and striatal regions (Volkow et 
al., 1998), also increases activation in inferior parietal lobe in boys with ADHD 
compared to placebo. Therefore, the increase in 5-HT, induced by Fluoxetine, may 
have led to increased activation of the 5-HT2C receptors in this area which would lead 
to a further decrease in dopamine and decreased activation in this area (Di Matteo et 
al., 2008). The increased activation in left inferior parietal lobe in the ASD group may 
be due the positive effect of an increase in 5-HT in a patient population where there is 
consistent evidence for serotonergic abnormalities (Zafeiriou et al., 2009), as has been 
described previously. This finding suggests that the shared dysfunction in left inferior 
parietal cortex in boys with ADHD and boys with ASD had a different biochemical 
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basis in each disorder and although this needs further research the clinical 
implications of this observation are intriguing.  
Finally, under Fluoxetine insula activation was decreased in boys with ASD, 
relative to controls, during reward reversal learning. There is consistent evidence for 
underactivation of the insula in individuals with ASD (Uddin and Menon, 2009). 
However, this is found during tasks of emotion processing and there is evidence that 
this underactivation is associated with alexithymia in ASD, as opposed to social 
interaction deficits (Bird et al., 2010). During tasks of gambling, which are more 
relevant to the current thesis, it has been shown that insula activation is associated 
with shifting from disadvantageous choices after negative feedback (Christakou et al., 
2009a). As the insula, along with mPFC, is part of the fronto-limbic network for 
reward-related decision making, the increase in mPFC activation under Fluoxetine 
may have adversely effected activation in the limbic aspect of this network. This is in 
line with the association between this decreased insula activation and increased scores 
on the social interaction domain of the ADI. Alternatively, insula activation has been 
observed in uncertain conditions during probabilistic tasks (Huettel et al., 2005) and is 
associated with anxiety to the anticipation of aversive stimuli (Simmons et al., 2006, 
Paulus and Stein, 2006). Therefore, the decreased activation in this area in ASD may 
have been a reflection of a reduction in their anxiety to the negative feedback they 
received when they reversed their response.     
 
Although there is evidence for lower levels of 5-HT in children with ADHD 
(Spivak et al., 1999), there is also evidence that their 5-HT levels do not differ from 
controls (Novkovic et al., 2009). Similarly, although hyperserotonemia is a consistent 
finding in ASD, it is only present in 30% of individuals (Piven et al., 1991, Mulder et 
al., 2004, Hranilovic et al., 2007). Consequently, it is plausible that the platelet/whole 
blood 5-HT level in each patient group in this study was normal. However, peripheral 
measures of 5-HT can be an inaccurate reflection of central activity. There is no 
knowledge on the serotoninergic abnormalities that may be present in the brains of 
children with ADHD, making interpretation of the results somewhat challenging. In 
ASD, there is large body of evidence to support the presence of brain based 
serotonergic abnormalities (Chugani et al., 1999, Chugani et al., 1997, Buchsbaum et 
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al., 2001, Chandana et al., 2005, Murphy et al., 2006, Makkonen et al., 2008, Dichter 
et al., 2010, Nakamura et al., 2010). Therefore, one can postulate that even if 
hyperserotonemia is not present in the cohort recruited in this thesis, Fluoxetine may 
still be having an effect due to the other serotonergic abnormalities present in the 
brains of ASD individuals. Alternatively, in absence of hyperserotonemia, the effect 
of Fluoxetine would also have been due to its effect on other neurotransmitter systems 
such as GABA and glutamate which have been linked with the serotonergic system 
(Liu et al., 2000, Sanacora et al., 2002, Murano et al., 2011) and are reported to be 
abnormal in ASD (Hussman, 2001, Purcell et al., 2001, Fatemi et al., 2009).  
 
Assuming that normal 5-HT levels were present in this ADHD cohort, then 
one can propose that the effects of 5-HT in ADHD are in line with those of healthy 
adults as an increase 5-HT has been shown to increase activation in VLPFC during a 
motor response inhibition task (Del-Ben et al., 2005) and increase IFC activation 
during a WM task (Rose et al., 2006). Furthermore, a decrease in 5-HT has been 
shown to decrease activation in VLPFC during motor response inhibition (Rubia et 
al., 2005a), decrease right DLPFC activation and attenuate PCC deactivation during 
WM (Allen et al., 2006) and increase mPFC activation during reward reversal 
learning (Evers et al., 2005). All of this would suggest that effects of Fluoxetine on 
ADHD brain activation may be similar to the effects on healthy brain activation. 
However, as both VLPFC and DLPFC were underactivated in ADHD compared to 
controls during inhibition and WM, respectively, and upregulated under Fluoxetine, 
this suggests that 5-HT abnormalities may have been underlying these lateral 
prefrontal deficits, and that serotonergic dysfunction may in fact have been present in 
these regions in the brains of boys with ADHD. Hence, Fluoxetine had a normalising 
effect on ventrolateral fronto-striatal dysfunction in boys with ADHD during motor 
response inhibition  likely due to the increase in 5-HT increasing activation in these 
regions. During motor response inhibition, Fluoxetine also normalised IFC 
overactivation in boys with ASD, potentially via negative feedback mechanisms, and 
normalised left inferior parietal lobe underactivation. In addition, in ASD boys, during 
reward reversal learning, Fluoxetine normalised underactivation in mPFC and 
decreased activation in the insula, and it attenuated PCC deactivation during WM. 
There is evidence that the nerofunctional effect of 5-HT is task-specific (Anderson et 
al., 2008) and that each brain region has a distinct serotonergic profile (Jacobs and 
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Azmitia, 1992, Varnäs et al., 2004) and consequently responds differently to 
serotonergic challenge. Therefore, task and region-specific effects of Fluoxetine were 
expected and are in line with this. Fluoxetine had a mainly inverse pattern of 
modulation in prefrontal regions in ADHD and ASD and this may have been due to 
the potentially inverse serotonergic abnormalities present in the two disorders, with 
low levels of 5-HT being associated with ADHD behaviours (Spivak et al., 1999, 
Stadler et al., 2007, Zepf et al., 2008a, Zepf et al., 2008c) and high levels of 5-HT 
being present in ASD individuals (Zafeiriou et al., 2009).  
 
An increase in 5-HT had a significantly normalising effect in the key 
abnormalities of each disorder during tasks in which they are typically most impaired 
in, albeit poor task performance under placebo was not observed in the main 
behavioural measures in this particular thesis.  The disorder-specific underactivation 
in the VLPFC of boys with ADHD during inhibition was normalised under 
Fluoxetine, whereas in ASD mPFC underactivation during reward reversal learning, 
and DLPFC underactivation during WM, were normalised under Fluoxetine. This 
shows for the first time that key areas of dysfunction in ADHD and ASD may 
bemediated by 5-HT, and that an increase in 5-HT had a significantly ameliorative 
effect on these dysfunctions in both disorders. This suggests that 5-HT plays a role in 
the pathophysiology of both ADHD and ASD, and that possible region-specific 5-HT 
dysfunction, leading to region-specific brain dysfunction,  may lead to the differential 
behavioural impairments that are characteristic of each disorder. 
 
8.5 – Shared Fluoxetine Effects 
 
This section will focus on the brain areas where Fluoxetine modulated 
activation in the same way in both ADHD and ASD.  
 
Apart from left inferior parietal lobe, Fluoxetine had the same effect in both 
ADHD and ASD in areas where a shared deficit was observed under placebo. 
Fluoxetine increased activation in precuneus during reversal learning, which was 
decreased in both disorders, and in right DLPFC during WM, which was also 
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decreased in both disorders. It was observed that while under Fluoxetine, activation in 
these brain regions no longer differed from controls in either disorder. However, 
rigorous normalisation testing showed that significant normalisation only occurred in 
the ASD group in right DLPFC. This suggests that these shared abnormalities may 
have a serotonergic basis in each disorder and that an increase in 5-HT has a shared 
positive effect on the activation of these areas.   
 
This shared neurofunctional effect of Fluoxetine in both ADHD and ASD in 
key brain regions, such as DLPFC during WM, is particularly interesting considering 
the evidence for potentially contrasting serotonergic abnormalities in both ADHD 
(Oades, 2007) and ASD (Zafeiriou et al., 2009). However, this may be explained by 
the fact that neurotransmitters often have an inverted-U shaped pattern of 
effectiveness where there is an optimum neurotransmitter level, which if surpassed, 
can cease to be beneficial and become impairing (Cools and D'Esposito, 2011). Due 
to the potentially different serotonergic abnormalities present in ADHD and ASD, the 
levels at which 5-HT might elicit its peak effectiveness may differ. Therefore, even 
though there is evidence that there is reduced platelet 5-HT levels in ADHD (Spivak 
et al., 1999) and increased platelet 5-HT levels in ASD (Piven et al., 1991, Mulder et 
al., 2004, Hranilovic et al., 2007), compared to controls, this level could still be a sub-
optimal amount of 5-HT for each disorder. Therefore, an increase in 5-HT in both 
ADHD and ASD could still elicit increased activation in a particular brain region for 
each disorder despite their different serotonergic profiles.  
 
Although this may seem incongruent with the disorder-dissociated findings 
mentioned above, it is known that the effect of 5-HT is task-specific (Anderson et al., 
2008) and that each brain region has a distinct serotonergic profile (Jacobs and 
Azmitia, 1992, Varnäs et al., 2004). Therefore it is not surprising that the effect of 5-
HT in each disorder varies somewhat depending on the task and the brain regions 
involved. Furthermore, it is known that 5-HT is able to modulate the activity of other 
neurotransmitters such as dopamine and it has been argued that the interactions 
between 5-HT and other neurotransmitters play a role in the aetiology of ADHD 
(Oades, 2002, Oades, 2008). Consequently, one can speculate that it may be the 
balance of 5-HT in relation to other neurotransmitters, in addition to the absolute level 
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of 5-HT, which may lead to the observation of both differential and shared effects of 
Fluoxetine in the two disorders.  
 
8.6 – Conclusions 
 
 In conclusion, during motor response inhibition, under placebo, disorder-
specific left ventrolateral prefrontal and striatal underactivation was observed in 
ADHD boys, whereas disorder-specific bilateral IFC overactivation was observed in 
ASD boys. Shared underactivation of left inferior parietal lobe was also observed 
under placebo in both ADHD and ASD. This shows that specific prefrontal and 
subcortical inhibitory brain regions exhibit inverse patterns of abnormality in each 
disorder during motor response inhibition, and that shared parietal underactivation 
may be due to both patient groups struggling with the attentional demands of the task.  
Disorder-specific mPFC underactivation was observed in boys with ASD during 
reward reversal learning under placebo and this shows an ASD specific impairment in 
a key region of reward related decision making which has previously been shown to 
be underactivated in individuals with ASD during executive function tasks. The 
fronto-striatal underactivation in ADHD during motor response inhibition and mPFC 
underactivation in ASD during reward reversal learning are in line with previous 
findings of regional abnormalities in the two disorders. Moreover, this study shows 
for the first time ever that these neurofunctional abnormalities are disorder-specific in 
ADHD and ASD when compared to each other. Shared underactivation in right 
DLPFC was observed during WM under placebo and extends prior research which 
has found reduced activation in this area in individuals with ADHD and individuals 
with ASD during sustained attention by showing for the first time that this deficit is 
shared between disorders during WM also. 
 
 Disorder-specific VLPFC deficits in motor response inhibition in ADHD, and 
disorder-specific mPFC deficits in ASD during reward reversal learning showed that 
each disorder exhibited underactivation during a task in which they are typically 
impaired in, albeit not in this thesis, and tentatively suggests that this dysfunction may 
be associated with impulsivity in ADHD and repetitive behaviours in ASD. The 
shared underactivation in DLPFC during WM, and left inferior parietal lobe during 
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inhibition, suggests that ADHD and ASD may share a deficit in dorsolateral fronto-
parietal regions of attention and that this common neural substrate may underlie the 
deficits in attention reported in both disorders. 
 
The inverse effects on frontal lobe activation in the two disorders may be due 
to inverse serotonergic abnormalities in the two disorders as there is evidence that 
children with ADHD have low levels of 5-HT, whereas children with ASD have 
increased levels. In right DLPFC, which was an area of shared underactivation, 
Fluoxetine increased activation in both disorders, but it only significantly normalised 
activation in the ASD group. This positive effect of Fluoxetine may be due to it 
increasing 5-HT to an optimum level in right DLPFC for each disorder during WM. 
One can further postulate that the ASD-specific normalisation was due to the fact that 
there is more evidence for serotonergic dysfunction in this disorder so the 
serotonergic modulation induced by Fluoxetine was more efficacious in this patient 
population. However, Fluoxetine also modulated activation in left inferior parietal 
lobe, a region of shared deficit, in a disorder-dissociated manner. The increased 
activation in ASD, and decreased activation in ADHD, in left inferior parietal lobe 
under Fluoxetine, relative to placebo, suggests that the ASD deficit in this region was 
serotonergically mediated, whereas the ADHD deficit may have been 
dopaminergically mediated.  
 
However, there are also alternative explanations. There is evidence that 5-HT 
levels are normal in ADHD (Novkovic et al., 2009), and hyperserotonemia is present 
in only 30% of ASD individuals. Therefore, the inverse effect of Fluoxetine on these 
two disorders could also have been due to the effect of Fluoxetine on other 
neurotransmitter systems that are abnormal in each disorder such as dopamine in 
ADHD (Volkow et al., 2009, del Campo et al., 2011) and GABA and glutamate in 
ASD (Hussman, 2001, Purcell et al., 2001, Fatemi et al., 2009). Alternatively, the 
disorder-dissociated effect in ADHD and ASD may not be due to abnormalities in the 
circulating levels of 5-HT, but due to brain based abnormalities in 5-HT synthesis 
(Chugani et al., 1999, Chugani et al., 1997), SERT (Makkonen et al., 2008, Nakamura 
et al., 2010) and 5-HT2A receptor binding (Murphy et al., 2006), that are present in 
ASD, but not in ADHD. However, the lack of these findings in ADHD is mainly due 
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to the lack of research in this field and therefore one cannot make strong statements 
with respect to 5-HT abnormalities in ADHD.   
 
These findings tentatively suggest that ventrolateral fronto-striatal 
underactivation during inhibition, and mPFC underactivation during reward reversal 
learning, may be ADHD and ASD specific neurofunctional biomarkers, respectively, 
when compared to each other, and that normalisation of these disorder-specific 
deficits may underlie the clinical effect of Fluoxetine that has been reported in these 
two disorders. 
 
8.7 – Strengths and Limitations 
 
 This study has a number of strengths and weaknesses which will be discussed 
in this section.  
 
One of the main strengths of this study is the use of homogenous patient 
groups as both the ADHD and ASD cohort were all right handed males aged between 
10-17 who were free of psychiatric comorbidites. It has been reported that handedness 
effects brain laterality (Knecht et al., 2000) so by including only right handed boys we 
were able to attribute any significant laterality effects to differences between the 
disorders as opposed to differences in handedness. There is evidence for sexual 
dimorphism in the brain (Sacher et al., 2012) and it has been shown in adult ADHD 
that the inclusion of both males and females reduces the neurofunctional differences 
observed between the groups (Valera et al., 2010). Furthermore, it is known that there 
is a higher prevalence of ADHD and ASD in males (Ramtekkar et al., 2010, Rivet and 
Matson, 2011). Therefore, by recruiting only males we increased the homogeneity of 
our sample. One of the most significant strengths of this study is the lack of 
psychiatric co-morbidities in each patient group as it is known that CD, which is often 
comorbid with ADHD, and anxiety/depression, which are often comorbid with ASD, 
present with particular neurofunctional impairments (Forbes and Dahl, 2005, Rubia, 
2011, Chantiluke et al., 2012) and biochemical abnormalities (Mann, 1999).  
Furthermore, the careful selection and stratification of the patient groups ensured that 
the ADHD group was non-comorbid with ASD and that the ASD group was non-
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comorbid with ADHD. This was verified by a child psychiatrist and corroborated by 
well-established parent rated questionnaires. Thus, the exclusion of psychiatric 
comorbidities, with particular attention to ASD traits in the ADHD group and ADHD 
traits in the ASD group, ensured that any neurofunctional abnormalities observed in 
each patient group were specific to that disorder.  The medication naivety of the ASD 
group is another strength of this study as children with ASD are occasionally  
prescribed psychotropics such as Risperidone and SSRIs (Benvenuto et al., 2012), 
which can have long term structural and functional effects (Navari and Dazzan, 2009, 
Murphy S.E, 2010). Therefore, by using a medication naïve ASD sample we removed 
this potential confound and enhanced the purity and homogeneity of this group.  
 
Nonetheless, this study is not without its limitations. The homogeneity of the 
patient groups unfortunately reduces the generalisability and direct clinical 
application of these findings. Due to ethical constraints, controls were scanned only 
once. Therefore, the modulating effect of Fluoxetine on healthy adolescents could not 
be compared to its effect on ADHD and ASD adolescents. As mentioned throughout 
the empirical chapters of the thesis, IQ was significantly lower in the ADHD group 
compared to controls and ASD, who did not differ in IQ. However, this limitation was 
addressed by repeating the analyses with IQ as a covariate in order to assess the 
potential impact of IQ on our results. During motor response inhibition and reward 
reversal learning, the findings remained at slightly more lenient cluster p-values and 
in the WM task, brain activation did not correlate with IQ. This shows that although 
IQ was a potential cofound in this thesis, it did not significantly alter the results 
obtained. Furthermore, due to the anxiety inducing environment of the scanner and 
the cognitive demands of the tasks, only boys who were verbal and had a full scale IQ 
greater than 70, were included and this adds to the difficulty of generalising the 
findings of this thesis to clinical populations. Another limitation is that the 
platelet/whole blood 5-HT level of the ADHD and ASD boys in the study was 
unknown. This therefore made it difficult to elucidate the mechanism by which 
Fluoxetine was inducing an effect on these two disorders. As a result, the discussion 
of the ASD findings focused mainly on the hyperserotonemia which is reported in this 
disorder (Piven et al., 1991, Mulder et al., 2004, Hranilovic et al., 2007). However, 
this biochemical abnormality is reported in only one third of individuals with ASD. 
Therefore, my particular ASD cohort could have had relatively normal or only 
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slightly elevated 5-HT levels. Furthermore, the fact that a large proportion of the 
ADHD group were medicated is another limitation as it is known that stimulants have 
long term structural and functional effects (Schweren et al., 2012, Nakao et al., 2011, 
Hart et al., 2013, Hart et al., 2012a) and this may account for the lack of ADHD 
disorder-specific findings under placebo during the reward reversal learning and WM. 
 
8.8 – Future Studies 
 
As this is only the second study to use fMRI to investigate the shared and 
disorder-specific abnormalities present in ADHD and ASD, and the first to investigate 
the modulatory effect of Fluoxetine in these two disorders, there is still a large amount 
of research that needs to be conducted in this highly topical area.  
 
This thesis has also provided intriguing evidence for the role of 5-HT 
modulation in both ADHD and ASD and this is an area of research which should be 
expanded further. This study has produced preliminary evidence for the positive 
neurofunctional effect of an acute dose of Fluoxetine on areas of disorder-specific 
dysfunction. The highly novel finding of VLPFC underactivation normalisation under 
Fluoxetine in ADHD strongly suggests that the role of 5-HT in ADHD be revisited. 
Future fMRI research should investigate the effect of an acute dose of Fluoxetine in 
tasks that are known to activate VLPFC, such as switching tasks, to see if this region-
specific effect is observed in other cognitive functions that are mediated by this area. 
Medication-naïve boys with ADHD should be recruited as the long-terms effects of 
stimulant medication may prevent the full ameliorative effect of Fluoxetine from 
being observed.  
 
Future fMRI research in ASD should assess the effect of an acute dose of 
Fluoxetine on emotion processing, and social cognition as there is a wealth of 
evidence that 5-HT plays a role in these functions (Silber and Schmitt, 2009, 
Mendelsohn et al., 2009) and that individuals with ASD are impaired in these 
domains (Harms et al., 2010). This field of research would shed light on the neural 
underpinnings of the improvement in social interaction that is reported in individuals 




Due to the use of an acute dose of Fluoxetine in this thesis, it is still unknown 
whether the modulatory effects of Fluoxetine on brain activation translate into clinical 
improvement. Therefore, studies on chronic administration should be conducted in 
order to ascertain the long-term effects of Fluoxetine in ADHD and ASD. Both 
neurofunctional, cognitive and behavioural data should be collected as this would 
enable a direct association to be made between neurofunctional changes and 
behaviour. This may also elucidate the baseline pattern of neurofunctional activity in 
each disorder that is associated with the best response to Fluoxetine treatment and 
therefore has the potential to aid the development of more tailored treatments. 
 
Neuroimaging studies investigating the effect of Fluoxetine in ADHD and 
ASD should aim to ascertain the platelet 5-HT level in each disorder as this would 
enable better interpretation of the results obtained. In addition to this, SPECT/PET 
studies should be conducted in adult forms of the disorder to investigate the level of 
5-HT and dopamine transporters present in these patient groups as this too will aid the 
understanding of the pharmaco-fMRI data obtained. 
 
Focusing on the shared and disorder-specific abnormalities in ADHD and 
ASD, further fMRI studies comparing between the two groups should be conducted in 
order to confirm or refute the findings of this thesis. These studies should employ 
tasks which are known to elicit activation in VLPFC, mPFC and DMN regions, such 
as gambling task, as this would enable one to test the hypothesis that VLPFC 
underactivation is specific to ADHD and mPFC underactivation is specific to ASD. 
Behavioural and cognitive data should be collected and correlated with imaging data 
to confirm the hypothesis that these disorder-specific dysfunctions are associated with 
disorder-specific behaviours.  
 
The fact that the only two studies, including this thesis, to directly compare 
neurofunctional activity in boys with ADHD and boys with ASD during tasks of 
executive functions both found shared decreased activation in DLPFC and parietal 
lobe in both disorders (Christakou et al., 2013) suggests that dorsolateral frontal and 
parietal underactivation may be a common neurobiological substrates for both 
disorders. Therefore, future research should scan boys with ADHD and boys with 
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ASD during tasks of selective attention and visuo-spatial working memory, which are 
known to elicit dorsolateral fronto-parietal activation (Pugh et al., 1996, D'Esposito et 
al., 1998), to clarify whether dorsolateral fronto-parietal underactivation is common to 
both ADHD and ASD. In addition, boys who are comorbid for both ADHD and ASD 
should also be scanned as this would enable one to uncover whether dorsolateral 
fronto-parietal dysfunction is in fact present in comorbid individuals.  
 
sMRI studies comparing non-comorbid groups of boys with ASD and boys 
with ADHD should also be conducted to confirm whether shared structural 
abnormalities are present in these regions as the only study to find shared 
neuroanatomical differences in parietal lobe in these disorders used an ASD group 
with clinical levels of ADHD traits and found no significant results which survived 
multiple corrections (Brieber et al., 2007). An understanding of the shared and 
disorder-specific neuroanatomical abnormalities in these two disorders will 
complement neurofunctional findings and aid the formation of a holistic 
neurobiological understanding of the common and distinct neural correlates of ADHD 
and ASD.  
 
8.9 – Final Conclusions and Final Remarks 
 
 In conclusion, this PhD has provided the first evidence of shared and disorder-
specific abnormalities in boys with ADHD and boys with ASD during a WM task, a 
motor response inhibition task and a reward reversal learning task. It has also 
provided the first evidence of the effect of Fluoxetine on these abnormalities, 
specifically, that Fluoxetine has mainly inverse effects on prefrontal regions in the 
two disorders.  
 
The main conclusions of this thesis can be summarised as follows: 
 
1) Under placebo, boys with ADHD exhibited disorder-specific underactivation 
in VLPFC and striatum during motor response inhibition, while boys with 
ASD showed enhanced IFC activation. Boys with ASD exhibited mPFC 
underactivation during reward reversal learning. These disorder-specific 
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dysfunctions, if replicated, may potentially be useful in the future to 
differentiate between the two disorders. However, more research needs to be 
conducted before the findings of this study can be extrapolated to a clinical 
setting. 
 
2) Under placebo, shared deficits were observed in DLPFC during WM, in left 
inferior parietal lobe during inhibition and in precuneus during reward reversal 
learning. This suggests that significant underactivation in dorsolateral fronto-
parietal attention areas may be a common underlying dysfunction in ADHD 
and ASD, potentially leading to the attention difficulties reported in both 
disorders.  
 
3) Under Fluoxetine the disorder-specific abnormalities in each disorder, relative 
to controls, were normalised. This was due to the fact that Fluoxetine relative 
to placebo increased (underactivated) VLPFC activation in ADHD, but 
decreased it in ASD, during motor response inhibition and increased 
(underactivated) mPFC activation in ASD, but decreased it in ADHD, during 
reward reversal learning. This suggests that the disorder-specific dysfunctions 
in these tasks have a serotonergic basis and this may be due to the different, 
potentially inverse, serotonergic abnormalities present in each disorder. These 
inverse effects of Fluoxetine may be mediated via an increase in 5-HT directly 
or the effect of this increase on other neurotransmitters. These findings suggest 
that Fluoxetine has an ameliorative effect on disorder-specific abnormalities 
and this may potentially underlie the clinically positive results that have been 
reported in small number of studies investigating Fluoxetine treatment in these 
disorders. However, studies investigating the long-term, chronic effects of 
Fluoxetine need to be conducted in order to directly relate the neurofunctional 
effect of Fluoxetine to clinically significant changes in behaviour. 
 
4) Under Fluoxetine the shared underactivation in DLPFC and precuneus was 
increased in both disorders. However, Fluoxetine had an inverse effect in left 
inferior parietal lobe which was an area of shared dysfunction. This suggests 
that different biochemical abnormalities in each disorder, potentially 
serotonergic in ASD and dopaminergic in ADHD, underlie the dysfunction 
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present in left inferior parietal lobe under placebo. It would be of great interest 
if the biochemical profile of this area was elucidated in both ADHD, ASD and 
comorbid groups, as this would provide evidence for or against this 
hypothesis.  
 
This study makes a highly novel contribution to the field as it shows shared and 
disorder-specific abnormalities in a homogenous group of boys with ADHD and boys 
with ASD during three cognitive tasks. Most importantly, this thesis shows for the 
first time that Fluoxetine has shared effects in DLPFC during WM, as well as inverse, 
disorder-specific modulatory effects on VLPFC during inhibition and mPFC during 
reward reversal learning, in boys with ADHD and boys with ASD. Due to the 
subjective measures that are currently used to diagnose ADHD and ASD, there is a 
wide margin for error and in persistent, debilitating disorders such as these, 
misdiagnosis can have severe ramifications on a young child’s life. Therefore, the 
development of objective, neurobiological biomarkers that are specific for each 
disorder will potentially lead to improved diagnoses. Similarly, as DSM-V is now 
allowing co-diagnosis of ADHD and ASD, an objective measure that could identify 
shared abnormalities in these disorders, such as brain activation, is much needed. 
Furthermore, as brain function is mediated by neurotransmitters, a greater 
understanding of the abnormalities present in these neurochemical systems will enable 
one to better comprehend the basis of the brain dysfunction present in ADHD and 
ASD, and potentially lead to more tailored, effective treatment. Although further 
research is needed to corroborate these findings and elucidate any potential clinical 
applications they may have. This thesis shows that fMRI may be a useful tool for 
differentiating between these two disorders and that Fluoxetine may exert its 
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